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Abstract
ABSTRACT OF THE DISSERTATION
Post-Lysosomal Cholesterol Trafficking: Novel Tools and Insights
by
McKenna Rae Feltes
Doctor of Philosophy in Biology and Biomedical Sciences
Biochemistry, Biophysics, and Structural Biology
Washington University in St. Louis, 2020
Professor Daniel Ory, advisor
Professor Douglas Covey, co-advisor
Cholesterol is an essential mammalian lipid. It is a major component of cellular membranes, a
precursor molecule for the synthesis of hormones and bile acids, and a regulator of protein
function. Although cholesterol is synthesized, de novo, in the endoplasmic reticulum, cells
principally meet cholesterol requirements through uptake of lipoprotein particles. Lipoproteinderived cholesterol is transported to the lysosome where it is transferred from the soluble
lysosomal protein, NPC2, to limiting-lysosomal membrane protein NPC1. Cholesterol is then redistributed to other cellular membranes in order to fulfill organellar cholesterol requirements;
however, the cellular machineries involved in coordinating this distribution are poorly
characterized. In the absence of NPC proteins, cholesterol is inefficiently redistributed beyond the
lysosome, and instead accumulates, leading to lysosomal dysfunction and eventual cell death. NPC
protein deficiency underlies Niemann-Pick Type C disease, a fatal neurodegenerative condition
for which there is no FDA-approved treatment. While some potential therapeutics have been
identified, their mechanisms remain unknown. NPC1-dependent and independent post-lysosomal
xiv

cholesterol trafficking has been difficult to study, in part, because existing cholesterol probes either
fail to mimic authentic cholesterol trafficking or cannot be efficiently used to identify candidate
trafficking proteins. In this thesis, I describe new tools and methodologies for the study of postlysosomal cholesterol trafficking and demonstrate their utility in NPC1-dependent and independent cell models. First, through rigorous biochemical characterization, I evaluate a series
of cholesterol probes that are functionalized to enable tagging and enrichment of protein binding
partners for identification by mass spectrometry. By screening many probes, I identify permissible
and non-permissible sites for functional modification. Next, I develop a strategy for delivering
cholesterol probe to the lysosome in order to identify the post-lysosomal trafficking interactome.
Finally, I use isotopically labeled cholesterol to investigate drug-induced cholesterol trafficking in
NPC1-deficient cell models. The new tools developed in these studies will advance our
understanding of post-lysosomal cholesterol trafficking and may provide mechanistic insight into
therapeutics for NPC disease.

xv

Chapter 1 – Introduction
1.1 Cellular Cholesterol Metabolism
1.1.1 Role of cholesterol in regulating membrane function
The vast majority of cholesterol is associated with cellular membranes. Cholesterol orients
in membranes with the hydrophilic 3’OH positioned in proximity with phospholipid head groups
while the body and side-chain of cholesterol pack amongst the acyl phospholipid tails. Cholesterol
increases acyl chain order in a concentration dependent manner. This effect, termed “membrane
condensation,” has important effects on membrane dynamics. As membrane cholesterol increases,
the bilayer thickens and the membrane becomes less fluid and permeable (1, 2). Biophysical
membrane effects are further tuned by acyl chain saturation and length as well as by lipid head
groups. Membrane condensation is also observed for the enantiomer of cholesterol, entcholesterol. Ent-cholesterol is a useful tool for deciphering whether a cholesterol-dependent
phenomenon is due to membrane biophysical or stereospecific binding effects.
The differential roles of cellular membranes require different fluidity and permeability
features, which are modulated, in part, by membrane cholesterol content. The plasma membrane
(PM) is the most cholesterol-rich of the cellular membranes. It contains 60-70% of the total cellular
pool and is ~ 40 mol % cholesterol (3, 4). The PM is highly impermeable, except for where protein
channels selectively admit specific nutrients. Signal transduction across the PM is accomplished
through transmembrane proteins. Specialized cholesterol-rich membrane regions, termed “lipid
rafts,” are thought to play an important role in signal transduction by sequestering membrane
signaling components into microdomains for increased transduction efficiency (5). Myelin, a
1

highly specialized PM that enables efficient transmission of electrical signals by insulating
neuronal axons, achieves tight membrane packing thanks to a high concentration of cholesterol
(6). Over 20% of total body cholesterol is in the brain; 70-80 % of which makes up the cholesterolrich myelin sheath that surrounds axons (7).
The membrane cholesterol content of endosomes is highly similar to the PM from which
they are derived. In contrast, the molar contribution of cholesterol in the endoplasmic reticulum
(ER) membrane is quite small (<5%) and harbors just 1% of the total cholesterol pool (3, 8, 9).
The mitochondria contain even less cholesterol. This is perhaps due to the increased need for rapid
diffusion of membrane-bound proteins and substrates for efficient respiration (9, 10). The Golgi
contains moderate amounts of cholesterol, reflecting its role in delivering newly synthesized
cholesterol from the ER to the PM (9). Mismatches in the local leaflet cholesterol content promote
membrane curvature, a feature hypothesized to play a critical role in stabilizing membrane fusion
intermediates (11).

1.1.2 Regulation of cholesterol homeostasis
Cholesterol synthesis, uptake, and efflux must be carefully balanced in order to maintain
cellular cholesterol homeostasis. The ER is a critical organelle for controlling cellular cholesterol
levels. The ER is the site of de novo cholesterol synthesis and receives excess cholesterol from the
PM. Yet, the ER maintains reduced membrane cholesterol content. Thus, the ER is primed to be
acutely sensitive to changes in cellular cholesterol levels. When ER cholesterol levels are low, the
sterol regulatory element-binding protein 2 (SREBP-2) transcription factor is activated (12).
SREBP-2 is normally retained in the ER membrane bound in complex to SREBP cleavage
activating protein (SCAP) and insulin-induced gene protein (INSIG). When cholesterol levels
2

decrease, SCAP is no longer bound to cholesterol and undergoes a conformational change,
resulting in dissociation from INSIG. Free from INSIG, SCAP/SREBP-2 traffic to the Golgi where
SREBP-2 is cleaved sequentially by two proteases (S1P and S2P) to release a mature SREBP-2.
The activated transcription factor re-localizes to the nucleus where it promotes expression of
cholesterol synthesis (e.g., HMG-CoA reductase and synthase, HMGCR and HMGCS
respectively) and uptake (e.g., LDL receptor, LDLR) genes. When ER cholesterol levels are high,
SREBP-2/SCAP remains in complex with INSIG and is retained in the compartment. Excess ER
cholesterol is converted to cholesteryl ester by the resident ER protein acyl-CoA: cholesterol
acyltransferase (ACAT) and stored in lipid droplets.
Elevated cellular cholesterol leads to the formation of side-chain oxysterols. Side-chain
oxysterols are hydroxylated cholesterol derivatives generated by enzymes located in the ER
(CYP46A1, CH25H) or the mitochondria (P450scc, CYP27A1). Endogenously generated
oxysterols include 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, 25-hydroxychoelsterol
and 27-hydroxycholesterol (13). Side-chain oxysterols regulate cholesterol homeostasis in diverse
ways. Lipoprotein uptake and cholesterol synthesis are suppressed by side-chain oxysterol
activation of INSIG which promotes retention of SREBP-2 in the ER membrane, and side-chain
oxysterols promote proteasomal degradation of HMGCR (14-16). Side-chain oxysterols are
agonists for the liver-X-receptor (LXR) which promotes expression of cholesterol efflux genes
(e.g., ABCA1, ABCG1). Cholesterol storage is increased due to side-chain oxysterols by
allosterically activating ACAT and increasing cholesterol activity through membrane disruption
(17-19).

3

1.1.3 Cholesterol metabolism into bioactive metabolites
Cholesterol is a precursor molecule for the formation of oxysterols, bile acids, and steroid
hormones. Oxysterols are formed either through enzymatic synthesis or by non-enzymatic
autoxidation. At very low concentrations, side-chain oxysterols are potent regulators of cellular
cholesterol homeostasis. Oxysterols also play a role as metabolic precursors. In the ER and
mitochondria, some oxysterols are further oxidized and modified to form water-soluble bile acids.
Bile acids are produced in the liver and secreted in the small intestine where they act as surfactants,
dissolving fats and oils. A majority (95%) of secreted bile acids are reabsorbed while the remaining
are excreted in stool (20). Bile acid secretion serves as the major pathway for whole body sterol
elimination.
Steroid hormones play diverse roles in human physiology ranging from the regulation of
metabolism to the development of sex characteristics. Steroid hormone synthesis begins with the
conversion of cholesterol to pregnenolone, which is catalyzed in the mitochondria of steroidogenic
cells by CYP11A1. Various downstream synthesis pathways result in the formation of
progestogen, androgen, estrogen, and glucocorticoid hormone classes.

1.1.4 Post-translational regulation of proteins by cholesterol
Membrane-mediated post-translational regulation of proteins is achieved through both
membrane biophysical and direct protein-binding interactions. Beyond its non-specific role in lipid
rafts and signal transduction (discussed above), cholesterol can interact with membrane proteins
through specific binding motifs. A well-studied example is the interaction of cholesterol with
membrane proteins, such as SCAP, HMGGR, Patched and NPC1, which contain a pentahelical
region referred to as the sterol-sensing domain. Cholesterol also binds to membrane proteins
4

through Cholesterol Recognition/Interaction Amino acid Consensus (CRAC) and related CARC
motifs embedded within transmembrane regions of proteins. These include a cholesterol sensing
regulator of the mTOR complex, SLC38A9, which partners with the NPC1 protein to sense
lysosomal cholesterol (21). Transmembrane binding regions, such as CRAC/CARC domains and
sterol sensing domains, are common features of proteins regulated by transient binding to
cholesterol.
Covalent modification of proteins with cholesterol, termed cholesterylation, has also been
observed. Sonic hedgehog and smoothened proteins are involved in the hedgehog signaling
pathway. These proteins play an important role in development and are aberrantly expressed in
many cancers. Cholesterylation of sonic hedgehog is well established and helps to anchor the
protein to the membrane, is important for protein-protein interactions, and enhances sonic
hedgehog stability (22). Cholesterylation of smoothened has been reported but its significance has
yet to be determined (23). By contrast, regulation of smoothened by free cholesterol and oxysterols
is well supported.

1.2 Intracellular cholesterol trafficking
1.2.1 Mechanism of lipoprotein cholesterol uptake
Cells acquire exogenous cholesterol through the uptake of cholesterol and cholesteryl ester
rich lipoproteins. Low-density lipoprotein (LDL) is synthesized in the liver and is approximately
8 wt % cholesterol and 37 wt % cholesteryl ester (24). The receptor for LDL, LDLR, is
ubiquitously expressed. LDL binds to LDLR and is endocytosed. As the endosome matures LDL
and LDLR dissociate and LDLR recycles back to the cell surface. Continued maturation of
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endosome to lysosome is accompanied by lowering pH which activates lysosomal acid lipase
(LAL), the enzyme responsible for hydrolyzing cholesteryl ester to cholesterol (25). LDLR and
LAL are essential for normal cholesterol trafficking. High levels of circulating cholesterol are
observed in familial hypercholesterolemia (OMIM *606945), a genetic disorder caused by
mutations in LDLR. Mutations in LAL result in accumulation of esterified cholesterol in the
lysosome and are the underlying genetic cause of Wolman disease (OMIM #278000).
Some cell types also express a class of receptors called scavenger receptors. Scavenger
receptors bind to damaged forms of LDL for uptake in a manner similar to unmodified LDL.
Macrophages express several scavenger receptors, among which scavenger receptor A (SRA) is
responsible for the majority of damaged LDL uptake. The SRA receptor recognizes both oxidized
LDL (oxLDL) and acetylated LDL (acLDL). Unlike LDLR, SRA expression is not regulated by
cellular cholesterol levels. In this way, SRA expression allows for the unregulated uptake of
cholesterol (26).

1.2.2 Intra-lysosomal cholesterol trafficking
Niemann-Pick Type C protein 1 (NPC1) and 2 (NPC2) are critical for lysosomal release of
LDL-derived cholesterol. The soluble lysosomal protein, NPC2, interacts with cholesterol from
the side-chain-end, housing the molecule in a deep hydrophobic pocket while LAL binds the fatty
acid portion of the cholesteryl ester (27). Upon ester cleavage, NPC2 transfers liberated
cholesterol, 3’OH group first, to the luminal N-terminal domain of NPC1 (28). NPC1 is a polytopic
transmembrane membrane protein with three large, lumen-facing, and glycosylated soluble
domains. NPC1 is anchored in the limiting lysosomal membrane by 13 membrane-spanning
helices. Five of the helices comprise the sterol-sensing domain which likely binds to cholesterol
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(29, 30). The heavily glycosylated decoration on the luminal side of the lysosomal membrane
presents a significant barrier to cholesterol insertion. NPC1, perhaps, provides a channel through
the glycocalyx through which cholesterol can pass to reach the limiting membrane (31). The
precise role that NPC1 plays in mobilizing LDL-derived cholesterol remains to be clarified.

1.2.3 Post-lysosomal cholesterol trafficking
From the lysosome, LDL-derived cholesterol is re-distributed to many cellular
compartments including the PM, ER, and mitochondria. Cholesterol trafficking must be
coordinated in order to serve the diverse needs of various cellular membranes. Because of the
aqueous insolubility of cholesterol, this trafficking occurs primarily through membrane fusion
events, by dedicated cholesterol transfer proteins, and is likely, at least partially, dependent on
membrane tethering proteins.
Members of the steroidogenic acute regulatory (StAR) protein and oxysterol binding
protein (OSBP) families have been implicated in redistributing cholesterol. STARD1 is well
established as a cholesterol transporter between mitochondrial membranes for hormone synthesis
(32). Cytosolic, soluble StAR proteins, STARD4 and 5, may play a role in PM trafficking (33, 34).
Lysosome-anchored member, STARD3, has been implicated in lysosome-ER and lysosomemitochondria trafficking (35, 36). OSBP related proteins (ORPs) are thought to facilitate
bidirectional lipid transfer by tethering membranes and shuttling lipids, particularly cholesterol
and phosphatidylinositols, via an OSBP-related domain. ORP1L and Orp5 may play a role in
lysosome-ER cholesterol trafficking (37, 38) while Orp2 has been implicated in lysosome-PM
trafficking (39). Several SNARE proteins have also been implicated in vesicular trafficking

7

pathways (40). The precise trafficking pathway, trafficking itinerary, NPC1-dependence, and
relative contribution of each of these proteins has yet to be clarified.

1.2.4 Cholesterol efflux
Cholesterol is transported from the periphery to the liver for recycling and bile acid
synthesis. This reverse cholesterol transport is facilitated by apolipoprotein A1(ApoA1)containing high-density lipoprotein (HDL) particles. Lipidation of ApoA-1 and cholesterol
transfer to HDL for cellular removal is mediated by the cell surface efflux proteins ABCA1 and
ABCG1, respectively (3). Scavenger Receptor B1 (SR-B1) has differential effects on cholesterol
transport depending on the tissue in which it is being expressed. In the liver, SR-B1 facilitates the
uptake of HDL particles. In the periphery, SR-B1 participates in cholesterol efflux to HDL (41).

1.3 NPC Disease
1.3.1 Molecular basis of disease
Loss-of-function mutations in the genes encoding NPC1 and NPC2 are the underlying
genetic cause of NPC disease (NPC, OMIM #257220 and #607625). NPC patients exhibit
hepatosplenomegaly, progressive neurodegeneration, and shortened life span. Disease severity and
onset varies depending on the specific mutation. At the cellular level, accumulation of cholesterol
and glycosphingolipids in the lysosomal compartment is observed. Lipid accumulation is
accompanied by lysosomal dysfunction, impaired autophagy, abnormal cholesterol homeostasis
and eventual cell death (42, 43).
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Mutations to the NPC2 gene account for ~5% of NPC cases while mutations in NPC1
account for ~95% (44), with the most common being the NPC1I1061T missense mutation (45).
NPC1I1061T protein is translated but is improperly folded in the ER leading to proteasomal
degradation. NPC1I1061T that escapes degradation (~2.5-5%) is glycosylated in the Golgi and
trafficked to the lysosome where it is fully functional (46). 2-fold overexpression of NPC1I1061T
results in increased mature, properly localized protein and a partial rescue of the lysosomal
cholesterol accumulation suggesting the primary defect of NPC1I1061T protein is not function, but
improper trafficking. In contrast, NPC1P691S, a sterol sensing domain mutant is expressed and
correctly localized, but does not support post-lysosomal cholesterol distribution (47). Several other
NPC1 mutations have been described (48).

1.3.2 Disorder of cholesterol homeostasis
NPC-deficient cells exhibit lysosomal cholesterol accumulation and abnormal cholesterol
homeostasis. LDL-derived cholesterol is normally trafficked to the ER where it promotes ERretention of SREBP-2 and is esterified for storage in lipid droplets. NPC-deficient cells are unable
to esterify cholesterol and do not suppress SREBP-2 expression after LDL challenge (49). The
sequestered lysosomal pool is inaccessible to sensing by the cholesterol homeostatic machinery
and is also unable to properly regulate many other cholesterol-dependent cellular responses.
NPC1-deficient cells exhibit impaired autophagy (42) as well as sterol-insensitive constitutively
active mTORC1 (21). Dysregulated sonic hedgehog signaling (50), impaired neurosteroid
synthesis (51) and hypomyelination (6) are also observed.

9

1.3.3 Emerging therapeutics
There is currently no FDA approved therapy for the treatment of NPC disease.
Experimental therapeutics for NPC disease can be broadly characterized into drugs that address
secondary phenotypes, drugs that regulate proteostasis, and drugs that target cholesterol synthesis,
uptake, and efflux. Miglustat, an inhibitor of glycosphingolipid synthesis, resolves the secondary
accumulation of lysosomal glycosphingolipids observed in NPC-deficiency. Miglustat has shown
mild efficacy for the treatment of NPC disease, and is approved for treatment in some countries
(52, 53). Curcumin and Imatinib, which address secondary dysregulation of calcium homeostasis
and c-Abl, respectively, were also investigated, but yielded only slight improvements in life span
(54, 55). In vitro, the HDAC inhibitor Vorinostat, increases expression of NPC1I1061T which
resolves cholesterol accumulation. However, the cholesterol-lowering effects of HDAC inhibitors
have not translated to in vivo models (56), suggesting limited applicability in the clinic.
Arimoclomol, which induces expression of chaperone protein HSP70, also shows promise and has
been evaluated in a late-stage clinical trial (57). Therapeutics that center on increasing protein
expression are unlikely to be beneficial for non-functional NPC1 mutations such as NPC1P691S.
Therapeutic intervention in cholesterol uptake, synthesis, and efflux have each been
explored as strategies for resolving cholesterol accumulation in NPC disease models. Strategies to
decrease cholesterol uptake, such as cholesterol-restricted diets and pharmacological inhibition of
cholesterol absorption, showed a benefit for LDL-dependent tissues, but had no effect on
neurological symptoms (58, 59); brain lipoproteins are not governed by dietary manipulation.
Statins reduce de novo cholesterol synthesis by inhibiting HMGCR but also upregulated LDLR,
statin administration was ultimately ineffective (58). In an effort to increase cholesterol efflux,
LXR agonists were tested as NPC therapeutics. A synthetic LXR agonist increased cholesterol
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efflux from the brain, but had only mild effects on improving life span (60, 61). A synthetic HDL
nanoparticle approach rescued cholesterol storage in Purkinje neurons when administered
ventricularly (62). However, HDL treatment increased expression of SREBP-2 targets which could
potentially have deleterious effects; survival studies are required to further evaluate the therapeutic
potential of this approach.
Hydroxypropyl-beta-cyclodextrin (CD) has emerged as the most promising therapeutic for
NPC disease and is currently in phase III clinical trials. In mouse models of the disease, CDtreatment increases lifespan and delays onset of neurological symptoms. CD penetrates the blood
brain barrier but is more effective when delivered intraventricularly (63, 64). On a cellular level,
CD-treatment decreases lysosomal cholesterol accumulation, normalizes expression of SREBP-2target genes, and increases cholesterol esterification (65, 66). However, the precise mechanism of
action of CD remains unclear.
Cyclodextrins are cyclic oligosaccharides that are water soluble but possess a hydrophobic
pocket. Cyclodextrins are frequently used as excipients in drug formulations. In fact, CD was
serendipitously discovered as a therapeutic for NPC disease when it was isolated as the active
component of the drug formulation for allopregnanolone, an ultimately ineffective drug (67). At
high concentrations, cyclodextrins are used to deplete cellular cholesterol (68). While welldescribed as a cholesterol vehicle, CD does not appear to resolve lysosomal cholesterol
accumulation by removing cholesterol from the cell. CD treatment does not reduce total cellular
cholesterol, increase plasma cholesterol levels, or increase cholesterol excretion. A potent relative
of CD, methyl-β-CD has been reported to increase autophagic flux in NPC1 cells (69). Other
groups have suggested CD and methyl-β-CD may reduce cholesterol accumulation by stimulating
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the release of cholesterol-rich vesicles (70-72). Additional studies are required to clarify the role
of CD in resolving cholesterol accumulation in NPC disease.

1.4 Tools for the study of cholesterol trafficking
Many tools have been developed for the study of cholesterol trafficking. Their merits and
limitations are discussed in this section and summarized in Table 1.1.
Table 1.1: Current tools for studying cholesterol trafficking.
Perfringolysin O (PFO), anthrolysin O domain 4 (ALOD4), dehydroergosterol (DHE), cholestatrienol (CTL).
Class

Example(s)

Advantages

Limitations

Small molecule
sensor

Filipin

Good fluorophore

Indirect
Specificity not well characterized
For fixed cells – static
measurements only

Protein sensors

PFO
ALOD4

Good fluorophore
Threshold measurements
PM-specific

Insert into membrane potentially
modifying
Not available for other membranes

Intrinsic
fluorophores

DHE
CTL

Mimics biophysical properties

Poor quantum yield

Fluorophore
conjugates

BODIPY-cholesterol
NBD-cholesterol

Good fluorophore

Abnormal trafficking
Abnormal membrane orientation

Cholesterol
isotopes

2

Mimics biophysical properties
Sensitive detection

Specific assays required to
determine spatial localization

Minimally modified
Xlink to nearby proteins
“clickable” to fluorophores and
affinity probes

Cholesterol-authenticity unknown

Diazirine alkyne
probes

3

H-cholesterol
H-cholesterol

trans-sterol probe

1.4.1 Indirect approaches: filipin, ALOD4, PFO
Cholesterol trafficking can be indirectly monitored using the antibiotic, filipin, or the
cholesterol sensing proteins perfringolysin O (PFO) and anthrolysin O, domain 4 (ALOD4).
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Filipin is highly fluorescent and binds to cholesterol. Filipin is quite useful for labeling the large
lysosomal cholesterol accumulation in NPC cells and is used clinically to diagnose NPC disease
(73). However, the specificity of filipin is not well characterized, it is not sensitive or quantitative,
and cells must be fixed prior to staining. PFO is a pore-forming bacterial toxin that inserts into
cellular membranes when active cholesterol reaches a critical threshold (74). PFO sensing is
ultimately cytotoxic, making PFO an effective tool for screens, but useless for other applications.
ALOD4 is a fluorescent, non-dimerizing PFO relative that also inserts into the PM as cholesterol
levels increase (75). ALOD4 also inhibited PM-ER traffic, raising concerns about its utility as noninvasive cholesterol sensor. The use of both PFO and ALOD4 remain controversial, as the effects
of protein insertion on membrane properties and cholesterol trafficking have not been
independently assessed.

1.4.2 Isotopic cholesterol probes
Cholesterol isotopes are essentially identical to cholesterol, but contain heavy (deuterium,
carbon-13) or radioactive (tritium, carbon-14) atoms which can be detected by mass spectrometry
or scintillation counting, respectively. Radioactivity-based approaches are sensitive and
quantitative. However, in order to glean spatial information, the organelle of interest must be
isolated. Assays designed to measure organelle-specific cholesterol metabolites can also provide
spatial information, but must be combined with a lipid separation technique, such as thin-layer
chromatography, to isolate the desired product. For example, radiolabeled oleate has been used as
a reporter of cholesterol trafficking to the ER by measuring radiolabeled cholesteryl esters (66).
Both tritiated and carbon-14 cholesterol isotopes are commercially available.
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Deuterated (2H) and carbon-13 (13C) stable cholesterol isotopes are commercially available
and have become a useful alternative to their more harrying and dangerous radiolabeled
counterparts. This has been particularly true as liquid chromatography mass spectrometry (LCMS) has become more accessible and cost effective. LC-MS reports on a molecules retention time,
exact mass, and in some cases the molecular fragments (LC-MS/MS), all of which allow for a
precise identification of the species being analyzed. Further, differentially deuterated species can
be separated and quantified by this technique. We have leveraged this advantage to measure
cholesteryl ester products produced from different cholesterol pools (76, 77).

1.4.3 Fluorescent cholesterol probes
The subcellular localization of cholesterol can be determined visually using microscopy
and fluorescent cholesterol analogs. Dehydroergosterol (DHE) is a naturally occurring, fluorescent
yeast sterol that is structurally similar to cholesterol and exhibits cholesterol-like cellular
distribution. However, it is weakly fluorescent, rapidly photobleached, and exhibits environmentdependent fluorescence, limiting quantitative use (3). Cholestatrienol (CTL) is another structurally
similar, intrinsically fluorescent cholesterol analog; it is plagued by the same imaging
impracticalities.
In contrast to intrinsically fluorescent cholesterol analogues, fluorescent cholesterol
conjugates are designed to have optimal fluorescent properties. Cholesterol with a BODIPY
fluorophore attached at the 24-carbon (BODIPY-cholesterol) and cholesterol with an NBD
fluorophore at the 22-carbon (NBD-cholesterol) are commercially available. DHE and CTL are
structurally very similar to cholesterol and behave almost identically regarding biophysical
membrane effects and cellular distribution (3, 78). In contrast, the large bulky fluorogenic groups
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of BODIPY-cholesterol and NBD-cholesterol result in misorientation and abnormal membrane
condensation properties relative to cholesterol. These effects are likely responsible for the
abnormal cholesterol trafficking patterns observed for these sterols (79). Despite this, BODIPYand NBD- cholesterol are frequently used as they have excellent fluorogenic properties.

1.4.4 Diazirine alkyne cholesterol probes
Copper-catalyzed azide-alkyne cycloaddition (CuAAC or “click chemistry”) is a one-step
reaction enabling the addition of an azide reporter molecule to an alkynylated probe (or vice versa).
Using fluorescent microscopy, probe distribution can be visualized in fixed cells after click
addition of a fluorophore-azide to the alkyne probe. Using this approach, a C19 alkyne cholesterol
was observed to be appropriately associated with PM, ER, and mitochondrial membranes (80).
Alkyne addition is a minor structural modification. Unlike fluorophore conjugates, bulky
fluorophores can be added after the alkyne probe has trafficked. Many fluorophore-azides are
commercially available. Fluorophore-azides are interchangeable, allowing for flexibility in
experimental design and selection of fluorophores with optimal excitation and emission properties.
Alkyne modified probes represent a compromise between intrinsic and conjugated fluorescent
cholesterol analogs: minimal modification with optimal detection properties. In contrast to these
probes, however, cells must be fixed before fluorophore addition.
While click-addition of fluorophore-azide allows for probe visualization, addition of an
affinity handle, such as biotin-azide, enables probe capture. When paired with protein crosslinking
functionality, through addition of a diazirine group, crosslinkable-alkyne probes enable capture of
probe-interactomes for identification by mass spectrometry. Trans-sterol probe, a diazirine alkyne
cholesterol analog, was used to identify several established cholesterol binding proteins including
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caveolin and HMGCR (81). A similar approach, using a variety of fatty acid diazirine alkyne
analogs was used to identify lipid-binding proteomes (82). While diazirine alkyne probes show
great promise for addressing the limitations of other cholesterol trafficking tools, further
characterization is required in order to avoid the pitfalls of previous attempts to create cholesterol
probes.

1.5 Scope of thesis
As evidenced by the cellular defects observed in NPC disease, post-lysosomal cholesterol
trafficking is essential for the proper regulation of cholesterol homeostasis, cell health, and is
ultimately required for the appropriate function of essential organs such as the brain and liver.
However, the cellular machinery required, for both NPC1-dependent and NPC1-independent
cholesterol trafficking remain poorly characterized. While some proteins have been implicated in
post-lysosomal cholesterol redistribution, their precise route, itinerary, and relative contribution
remain unknown. This is due, in part, to the limitations of existing cholesterol-trafficking tools.
To address this gap, I have developed new cholesterol-trafficking probes and approaches and have
used them to investigate the mechanism of NPC therapeutics.
In Chapters 2 and 3, I introduce several novel diazirine alkyne cholesterol probes and
characterize them for their ability to mimic cholesterol. Chapter 2 details extensive
characterization of diazirine alkyne cholesterol probe LKM38. Not only does LKM38 sustain
cholesterol auxotrophic cell growth, it properly regulates cholesterol homeostatic gene expression,
and binds to bon fide cholesterol-binding proteins such as NPC1, NPC2, and caveolin. Further
characterization using biochemical trafficking assays shows that LKM38 traffics to the PM and to
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the ER. In Chapter 3, additional diazirine alkyne probes, as well as diazirine- and alkyne- only
probes are characterized. I identify additional diazirine alkyne cholesterol analogs that show
promise for use as cholesterol-trafficking probes. Further, I establish permissible and nonpermissible sites for diazirine and alkyne modification.
In Chapter 4, I describe the application of diazirine alkyne probes for the study of postlysosomal cholesterol trafficking using mass spectrometry-based proteomics. I first describe
optimization of a strategy for loading probe into the lysosomal compartment. I then describe the
optimization of experimental steps needed to yield quality protein for data analysis. This chapter
lays the ground work for use of this technique for the future collection of time-resolved proteomes.
In Chapters 5 and 6, I use an isotopic labeling approach to investigate the mechanism of NPC
therapeutics. In Chapter 5, I evaluate the effect of alexidine, a novel therapeutic identified by our
collaborators Anne Bang and Emily Pugach. I show that alexidine induces a robust increase in
esterification of lysosome-derived cholesterol. We further discover that alexidine increases
expression of mutant NPC1 resulting in increased mature NPC1 at the lysosome. In Chapter 6, I
evaluate the effects of CD on post-lysosomal cholesterol trafficking. CD redistributes lysosomederived cholesterol to ER for esterification and to the PM where it is exchanged with lipoproteins.
In addition, I find that cholesterol esterification, an indication of improved cholesterol
homeostasis, occurs in the absence of PM exchange. This data supports a mechanism by which
CD redistributes cholesterol intracellularly, resolving a current question in the field.
The new tools developed in these studies will advance our understanding of post-lysosomal
cholesterol trafficking and may provide mechanistic insight into therapeutics for NPC disease.
Chapter 7 highlights these findings and explores future directions of this work.
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Chapter 2 – Synthesis and
characterization of diazirine alkyne
probes for the study of intracellular
cholesterol trafficking
2.1 Preamble
This research was originally published in the Journal of Lipid Research. M Feltes, S
Moores, SE Gale, K Krishnan, L Mydock-Mcgrane, DF Covey, DS Ory, JE Schaffer. Synthesis
and characterization of diazirine alkyne probes for the study of intracellular cholesterol trafficking.
J. Lipid Res. 2019; 60:707-716. © the Authors.
I played the leading role in experimental design, data collection, analysis, and manuscript
preparation for this work. Probes were synthesized by the Covey Laboratory (K Kirshnan, L
Mydock-Mcgrane, DF Covey). SE Gale helped in collecting data used in figures 4A and B. S
Moores collected data for Figure 6D and E. I performed all other data collection, all data analysis
and experimental design with mentorship by JE Schaffer and DS Ory. The original manuscript was
written by me and edited collaboratively with JE Schaffer and DS Ory with additional final editing
by the other authors.

2.2 Introduction
Cholesterol is an essential structural component of cellular membranes that regulates
membrane fluidity and permeability of phospholipid bilayers and the functions of integral
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membrane proteins. In addition, cholesterol serves as a precursor molecule for bile acid and
hormone synthesis. Distribution of cholesterol amongst cellular membranes is heterogeneous. The
PM contains 60-70% of total cellular cholesterol at a concentration of ~40 mol% (3, 4). In contrast,
the ER and mitochondria are cholesterol poor, with approximately 1% of total cellular cholesterol
in the ER where its concentration is <5 mol% (3, 8). The low cholesterol content of the ER and its
proximity to the cholesterol synthesis machinery facilitate sensitive monitoring of cellular
cholesterol levels and tight regulation of uptake and synthesis. The ER-resident SREBP-2
transcription factor serves as the primary regulatory axis for cholesterol homeostasis. When ER is
cholesterol depleted, membrane-bound SREBP-2 traffics from the ER to the Golgi where
proteolytic processing liberates the soluble, mature transcription factor which then translocates to
the nucleus to upregulate genes involved in cholesterol synthesis and uptake. When the ER is
cholesterol replete, SREBP-2 is retained in the ER. The ER-resident protein, ACAT, converts
excess sterol to cholesteryl esters for storage in lipid droplets (12). Excess cholesterol also
promotes conversion of cholesterol to oxysterols in the mitochondria, activating LXR that
upregulates expression of genes involved in cholesterol efflux (83). The asymmetric distribution
of cholesterol within and across different cellular membranes is critical in these regulatory
mechanisms and persists despite rapid flux of cholesterol between surface and internal pools (84).
Mammalian cells acquire cholesterol through uptake of cholesterol and cholesteryl-ester
laden lipoprotein particles by receptor-mediated endocytosis, or through de novo synthesis in the
ER (25). Bulk distribution of endocytosed, LDL-derived cholesterol and cholesteryl esters depends
on lysosomal proteins NPC1 and NPC2, as well as LAL. LDL-derived cholesterol and cholesterylesters are delivered to late endosomes/lysosomes. Under acidic conditions, LAL cleaves
cholesteryl esters, liberating free cholesterol (25). Sequential “hydrophobic hand-offs” are
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proposed to facilitate the transfer of cholesterol to the limiting lysosomal membrane, the first
between LAL and NPC2, and the second between NPC2 and NPC1. NPC2, a small soluble protein
localized to the lysosomal lumen, binds cholesterol with the iso-octyl side chain buried deep within
its binding pocket (27). By contrast, NPC1 is a large multi-domain protein located in the limiting
membrane of late endosome/lysosomes. Its luminal, N-terminal domain binds the 3-hydroxyl
group of cholesterol and is hypothesized to accept cholesterol from NPC2 (28, 85, 86). Mutations
in either NPC1 or NPC2 result in dysregulated cholesterol homeostasis with accumulation of
unesterified cholesterol in the lysosomal compartment and impaired cholesterol re-esterification
(73).
The study of intracellular cholesterol trafficking pathways is central to understanding
homeostatic pathways as well as disease pathogenesis. However, past approaches have been
limited in part due to a lack of suitable cholesterol probes. Intrinsically fluorescent cholesterol
analogs (DHE and CTL) have weak fluorogenic properties. Bulky fluorophore-conjugates
(BODIPY- and NBD-cholesterol) fail to faithfully mimic cholesterol trafficking and membrane
behavior (87, 88). Minimally modified diazirine alkyne cholesterol probes provide a new approach
for the study of cholesterol trafficking. The alkyne functional group enables copper-catalyzed
azide-alkyne cycloaddition of azide reporter molecules (e.g., fluorophores or biotin) after
trafficking has taken place, while the diazirine group enables UV-activated cross-linking of probe
to nearby biomolecules. A diazirine alkyne probe, trans-sterol probe, was recently used to identify
the static cholesterol proteome (81). Several known cholesterol binding proteins such as SCAP
and HMGCR were identified, highlighting the utility of this approach. Protein binding for two
other diazirine alkyne cholesterol probes, LKM38 and KK174, has been shown to be sensitive to
cholesterol competition (21, 89). Nonetheless, the extent to which this cholesterol probe mimics
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the trafficking characteristics of native cholesterol and its behavior with respect to regulation of
sterol homeostatic responses, has yet to be determined.
Herein, we studied diazirine alkyne cholesterol probes LKM38, KK174, and trans-sterol
probe, as well as a novel probe, KK175, for their fidelity as cholesterol mimics and use as dynamic
cholesterol probes. Through detailed characterization of the cellular behavior of these diazirine
alkyne probes, we identify new tools for the study of intracellular cholesterol trafficking.

Figure 2.1: Diazirine alkyne cholesterol probes.
Cholesterol (A), LKM38 (B), KK174 (C), KK175 (D), trans-sterol probe (E), LKM38 oleate (F).
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Figure 2.2: Growth of cholesterol auxotrophic cells in presence of diazirine alkyne probes.
U2OS-SRA cells were pulsed for 15 minutes with 0.5% methyl-β-cyclodextrin in LPDM and treated for 72 h in
starvation media containing 10 µM cholesterol, diazirine alkyne probe (A) or alkyne probe without diazirine (B) in
ethanol. Cell viability was assessed using the CellTiter-Glo assay. Values are normalized to cholesterol treated cells.
Bars: mean + SEM. Each experiment was performed in quadruplicate, n= 3 experiments, ****, P<0.0001; ***,
P<0.001; **, P<0.01; *, P<0.05 for compound vs. vehicle and $, P<0.001 for compound or vehicle vs. cholesterol,
using one-way ANOVA followed by Dunnett’s test. Alternative names for LKM38, KK174, and KK175 compounds
w/o diazirine groups are LKM37, KK170, and KK176 respectively.

2.3 Results
2.3.1 Characterization of diazirine alkyne probes
To develop tools for the study of cholesterol-protein interactions, we synthesized several,
novel, cholesterol analogs. Each analog contains a diazirine and alkyne group to enable UVcrosslinking and CuAAC, respectively. Probes were generated with diazirine and alkyne groups at
different positions in an effort to survey the effect of these modifications on the behavior of the
molecule (Figure 2.1). We also evaluated a previously described diazirine alkyne cholesterol
analog, trans-sterol probe (81). In a stringent test of cholesterol mimicry, we examined the ability
of diazirine alkyne probes to support growth of cholesterol auxotrophic cells (Figure 2.2A).
Compounds trans-sterol probe and KK174 were cytotoxic, while KK175 was cytostatic. By
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contrast, LKM38 partially supported auxotrophic cell growth, though not as robustly as
cholesterol. Interestingly, alkyne-only probes supported growth at levels nearly equivalent to
cholesterol, suggesting the diazirine group is the modification that limits the ability of the probes
to support growth in the absence of cholesterol (Figure 2.2B).

Figure 2.3: Diazirine alkyne probes regulate cholesterol homeostasis.
U2OS-SRA cells (A, B) or Cyp27A1-deficient human skin fibroblasts (C, D) were treated for 14 h in starvation media
containing 10 µM probe or cholesterol in ethanol. HMGCS (A, C) and ABCA1 (B, D) mRNA expression were
determined by qPCR relative to Rplp0. LXR agonist T0901317 (T-cmpd) is shown as a positive control. Values are
normalized to vehicle. Bars: mean + SEM, n= 5 (A, B) or n=3 (C, D) experiments/condition, ****, P<0.0001; ***,
P<0.001; **, P<0.01; *P, <0.05 for comparisons indicated using one-way ANOVA followed by Dunnett’s test.
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2.3.2 Effects of diazirine alkyne probes on regulation of sterol homeostatic
responses
To assess the ability of diazirine alkyne probes to serve as authentic cholesterol mimics,
we tested their capacity to regulate SREBP-2-target gene expression, an important sterol
homeostatic response that governs de novo cholesterol synthesis. Transcript levels of HMGCS, an
SREBP-2 target, were monitored after 14 h in the presence of cholesterol or diazirine alkyne probe
as the only provided sterol. All diazirine alkyne probes suppressed HMGCS expression to a similar
degree as cholesterol (Figure 2.3A). To monitor for possible off-target oxysterol effects,
expression of ABCA1, an LXR target, was determined. Neither cholesterol, LKM38, nor transsterol probe significantly increased ABCA1 expression (Figure 2.3B). In contrast, diazirine alkyne
probes KK174 and KK175 increased ABCA1 expression. When this experiment was performed
in cells deficient in CYP27A1, a mitochondrial enzyme responsible for synthesis of the
endogenous LXR ligand 27- hydroxycholesterol, similar suppression of HMGCS expression was
observed (Figure 2.3C). ABCA1 expression was significantly increased after KK174 treatment,
and a trend was observed for KK175 (Figure 2.3D). Although neither compound increased ABCA1
expression as robustly as LXR agonist T0901317, these results indicate that these probes, in
contrast to LKM38 and trans-sterol probe, directly activate LXR.

2.3.3 Localization of lipoprotein-derived diazirine alkyne probe
Based on the results in cholesterol auxotrophy and SREBP-2 target gene expression assays,
LKM38 was selected for further characterization. Cholesterol and cholesteryl ester-laden
lipoprotein particles enter the cell through receptor-mediated endocytosis, and then transit through
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the endocytic pathway to reach the lysosomal compartment. To assess whether diazirine alkyne
probes trafficked in a similar manner, acLDL reconstituted with LKM38 oleate was delivered to
U2OS cells expressing human SRA (U2OS-SRA). Click addition of azide-fluorophore allowed for
visualization of the cellular distribution of probe. In the presence of a LAL inhibitor (LALi), which
prevents the cleavage of cholesteryl esters to free cholesterol, punctate probe staining was
observed (Figure 2.4A). Probe signal colocalized with LysoTracker Red DND-99, a selective
marker for acidic organelles, with a Pearson’s coefficient of 0.6788 (Figure 2.4B). In the absence
of LALi, both punctate and reticular staining patterns were observed, and LysoTracker
colocalization was attenuated (Pearson’s coefficient: 0.4780). Thus, when provided as an ester in
lipoprotein particles, LKM38 accumulates in lysosomes and the action of LAL is required for
trafficking to other cellular compartments, similar to native cholesterol.

Figure 2.4: LKM38 oleate localizes to the lysosomal compartment.
U2OS-SRA cells were incubated in LPDM containing 50 µg/mL acLDL reconstituted with LKM38 oleate, labeled
with lysotracker, and fluorescently labeled using copper-catalyzed azide alkyne cycloaddition of Alexa-488. Images
were collected by laser scan confocal microscopy (A). Colocalization quantification (B). Pearson coefficients were
calculated for 6-10 fields/condition/per experiment using ImageJ. Each data point represents the average Pearson
coefficient for a biologically independent sample (n=3). Bars: mean + SEM. *, P<0.05, using t test.
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Figure 2.5: LKM38 traffics to the PM and ER compartments.
A: U2OS-SRA cells were treated with LPDM containing 50 µg/mL acLDL reconstituted with d7-cholesteryl oleate
or LKM38 oleate in the presence of LALi to load the lysosomal compartment and chased in LALi-free media for 012 h to allow sterol trafficking. B: chase media contained d9- oleate/BSA to label newly synthesized esters. C: cells
were fixed then treated with cholesterol oxidase before cellular lipids were extracted. d7-cholesteryl oleate or LKM38
oleate (B), d16-cholesteryl oleate or d9-LKM38 oleate (C) and cholestenone or LKM38-one (D) were quantified by
LC-MS/MS. Bars: mean + SEM, n=3 independent experiments. *, P<0.01 using multiple t tests with FDR, Q = 1%.

2.3.4 Post-lysosomal distribution of diazirine alkyne probe
From the lysosome, cholesterol is distributed to other cellular compartments, including the
ER and PM. To evaluate the fidelity of trafficking of the diazirine alkyne probe, the kinetics of
probe arrival at these compartments was compared to deuterated cholesterol using LC-MS/MSbased biochemical trafficking assays. LKM38 oleate or d7- cholesteryl oleate was reconstituted in
acLDL particles and delivered to U2OS-SRA cells in the presence of LALi (Figure 2.5A).
Cholesterol or probe metabolites were collected at several points after LALi washout. By
supplying d9-oleate, formation of a differentially deuterated re-esterification product (d9-LKM38
oleate or d16-cholesteryl oleate) was used to monitor probe arrival at the ER. Arrival at the PM
was determined using a cholesterol oxidase assay and quantification of oxidized derivatives
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(LKM38-one or d7-cholestenone). The difference in the amount of LKM38 oleate and d7cholesteryl oleate loaded to cells was not statistically significant (Figure 2.5B). After inhibitor
washout, LAL cleaved LKM38 oleate and d7-cholesteryl oleate with similar kinetics. Reesterification products were detected for both LKM38 and d7-cholesterol (Figure 2.5C).
Significantly more LKM38 was re-esterified relative to d7-cholesterol. At early timepoints,
LKM38 and d7-cholesterol arrival at the PM were nearly identical; however, LKM38, in contrast
to cholesterol, failed to continue to accumulate in the PM past 6 h (Figure 2.5D). Together, these
data suggest structural modifications present in the LKM38 diazirine alkyne probe do not affect
sterol trafficking to the PM at short time points, but do increase re-esterification.

2.3.5 Protein labeling by diazirine alkyne probe
The diazirine modification to the sterol structure of LKM38 permits the cholesterol probe
to be UV-crosslinked to molecules in close proximity. To test this functionality and to assay the
probe interactome, we evaluated LKM38 labeling of structurally diverse, established cholesterol
binding proteins, NPC1, NPC2, and caveolin. Following labeling, incubation with probe, and UVcrosslinking, target proteins were immunoprecipitated from labeled lysates using the respective
antibody, subjected to click addition of a fluoro-azide, separated by SDS-PAGE and then imaged.
LKM38 labeled endogenously expressed NPC1 and caveolin (Figure 2.6A, C) and epitope tagged
NPC2 (Figure 2.6B) as evidenced by the fluorescent signal at the appropriate molecular weight in
the immunoprecipitates. When labeling was performed in the presence of increasing amounts of
excess free cholesterol or in the presence of acLDL as competitor, probe binding was diminished.
Specific binding of LKM38 has previously been reported for CRAC/CARC domain-containing
protein SLC38A9 (21). Importantly, LKM38 failed to label VAMP7, an abundant transmembrane
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endo-lysosomal protein that has not been previously identified as interacting with cholesterol
(Figure 2.6D) (30).

Figure 2.6: LKM38 specifically labels established cholesterol binding proteins.
Normal human skin fibroblasts (A), NPC2-HA (B) or U2OS-SRA (C-E) cells were treated with 2.5 (A) or 10 µM (B,
C, D) probe complexed to mβCD without (1:0) or with 10X (1:10) or 100X (1:100) cholesterol or acLDL as competitor
and crosslinked. Immunoprecipitated protein was clicked to ROX- azide before elution in sample buffer and separation
by SDS-PAGE. Gels were imaged at 610 nm then transferred to nitrocellulose for western blotting (WB) for NPC1
(160 kDa), NPC2 (23 and 20 kDa), caveolin (20 kDa), and VAMP7 (25 kDa). Bars: mean + SEM, n= 3 independent
experiments. ****, P<0.0001; ***, P<0.001; **, P<0.01; *, P<0.05 for comparisons indicated using paired two-tailed
t test.
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In order to obtain a broader view of the LKM38 interactome, total protein lysate was
visualized after labeling with LKM38 probe. Many fluorescent bands were identified, indicating
the LKM38 probe has a large interactome (Figure 2.7A). To test specificity, excess cholesterol, in
the form of acLDL, was included after probe incubation. AcLDL incubation led to reduced labeling
of many of these species, suggesting these interactions are specific (Figure 2.7B).

Figure 2.7: Fluorescent gel profiling reveals specific labeling of proteins.
Fluorescent gel profiling reveals specific labeling of proteins. Following treatment of U2OS-SRA cells with 10 µM
probe in complete media, cells were incubated with to complete media (FBS), LPDM, or LPDM containing 100 µg/mL
acLDL. After 18 h, cells were crosslinked, lysed, and clicked to ROX-azide before separation by SDS-PAGE. A:
Representative gel imaged at 610 nm, with parallel immunoblot for GAPDH. B: Gel profile quantified using ImageJ
software. Graph quantifies the difference in gray value between LPDM with and without acLDL as a measure of
competition due to excess cholesterol.

2.4 Discussion
Intracellular cholesterol trafficking is widely studied, but remains poorly understood.
Diazirine alkyne probes provide a new approach for the study of intracellular cholesterol
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distribution using a variety of techniques including immunofluorescence microscopy, mass
spectrometry-based biochemical trafficking, and proteomics. In this study, we synthesized and
characterized novel diazirine alkyne probes and investigated their fidelity as cholesterol mimics.
Probes were designed with diazirine alkyne functional modifications located at different points on
the sterol backbone in order to identify the least perturbing set of modifications. Novel probes
were compared to the commercially available diazirine alkyne probe, trans- sterol probe. Prior
characterization of trans-sterol probe, LKM38, and KK174 has been limited to protein binding
studies with non-physiological probe delivery (21, 89). The results presented here are the first
assessment of the ability of diazirine alkyne probes to support cell growth in the absence of
cholesterol and to report on the interactions and trafficking itinerary of probe that is presented to
cells in the context of lipoprotein particles.
Multiple readouts of cholesterol’s function were used to compare the ability of the different
probes to mimic cellular functions of cholesterol. SREBP-regulated responses rely primarily on
the behavior of the sterol in the ER membrane and can serve as sensitive readouts of cholesterol
function in this organelle. LKM38 and trans-sterol probe similarly suppressed transcription of an
SREBP-2 target gene, in the absence of off-target oxysterol transcriptional effects. We also tested
for the ability of probes to support growth of cholesterol auxotrophic cells, a more rigorous test of
cholesterol mimicry that relies on the ability of the probe to serve as the sole sterol source in the
cell and assume all of the cellular functions of cholesterol. Of the diazirine alkyne probes
evaluated, only LKM38 was able to sustain growth of cholesterol-auxotrophic cells, and transsterol probe was cytotoxic in this assay. We hypothesize that the position of the diazirine on the
trans-sterol probe and/or side chain modifications may have prevented sterol-protein interactions
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required for cellular functions beyond the SREBP system. Based on these findings, LKM38 was
selected for further evaluation as a cholesterol trafficking mimic.
Biochemical trafficking experiments allowed for characterization of the post-lysosomal
trafficking of probe. Esterification of the LKM38 probe was more robust than for d7-cholesterol.
Increased esterification of LKM38 could be an indication of increased delivery to the ER
compartment or increased ACAT activity, possibly due to increased membrane availability (18,
90). Trafficking of LKM38 to the PM was essentially identical to native cholesterol trafficking to
this compartment at early time points. Divergence at longer time points could be due to increased
availability in the PM or an inability of LKM38 to recycle back to this compartment. Together,
these data indicate that LKM38 is a useful probe for studying the post-lysosomal cholesterol
trafficking to the PM, but a bias of LKM38 toward lipid droplets should be considered when using
this probe as a post-lysosomal cholesterol trafficking tool. Increased association of a commonly
used fluorescent cholesterol conjugate, BODIPY-cholesterol, with lipid droplets has also been
observed (79).
Alkyne modification to the backbone structure of diazirine alkyne probes provides a highly
flexible approach for the study of molecular distribution by fluorescence microscopy. The alkynegroup is a minor modification which does not greatly influence the character of the molecule, as
evidenced by the ability of a variety of alkyne cholesterol probes to support growth of cholesterol
auxotrophic cells to nearly the same degree as cholesterol. Unlike the intrinsic fluorescent
cholesterol probes, like DHE and CTL, which have low quantum yields, the click-chemistry
compatible alkyne group of diazirine alkyne probes allows for addition of a strong, photostable
fluorescent azide (of which there are many commercially available) to be added after trafficking
has taken place. This approach is compatible with fixed cell imaging to visualize static cholesterol
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distribution, similar to prior use of a C19 alkyne cholesterol (80). By using a targeted lipoprotein
delivery system and the alkyne functionality of diazirine alkyne probes, in this study we were able
to monitor the dynamic re-distribution of cholesterol from the lysosome to the rest of the cell using
confocal microscopy.
The crosslinking functionality of diazirine alkyne probes enables the study of probe-protein
interactions, which are not possible with BODIPY-cholesterol and DHE. We demonstrated binding
for LKM38 to NPC1, NPC2, caveolin, and have previously reported binding to the CRAC/CARC
domain containing protein SLC38A9 (21). These interactions are specific, as each was sensitive
to cholesterol competition. These proteins represent four structurally distinct cholesterol- binding
motifs. The ability of LKM38 to bind specifically to structurally diverse proteins with distinct
cholesterol binding motifs has the potential to expand the interactome accessible for study using
this technique. While these experiments were based on fluorescent detection of labeled targets,
click addition of different azide-handles allow for enrichment of labeled proteins for mass
spectrometry-based protein identification. Such an approach was used for trans-sterol probe, a
commercially available diazirine alkyne cholesterol probe (81); however, trans-sterol probe did
not identify NPC2, and did not label NPC1 in a cholesterol-specific manner. Our data suggest that
the structure of LKM38 has the potential to serve as a more sensitive and biologically relevant
cholesterol probe.
In summary, we have characterized the authenticity of diazirine alkyne probes as
cholesterol mimics using a variety of cell biological approaches. LKM38 emerged as a highfidelity cholesterol mimic through its ability to sustain growth in auxotrophic cells and
appropriately regulate cholesterol homeostasis. Moreover, through biochemical trafficking assays
and immunofluorescence microscopy, we show that lysosomally-derived LKM38 is distributed to
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the PM and ER, providing evidence that this probe is suitable for trafficking studies. Finally, we
demonstrate specific cholesterol-protein interactions between LKM38 and known cholesterol
binding proteins. Taken together, these findings validate LKM38 as a flexible tool for the study of
intracellular cholesterol trafficking.

2.5 Methods and Materials
2.5.1 Reagents
All

cell

culture

reagents

as

well

as

methyl-β-cyclodextrin,

CuSO4,

tris-

hydroxypropyltriazolylmethylamine (THPTA), ascorbic acid, BSA, SDS, glutaraldehyde,
cholesterol oxidase, sphingomyelinase, nicotinic acid, O-[2-(1-azepanyl)ethyl]hydroxylamine
dihydrocholoride, and PMSF were obtained from MilliporeSigma, with the exception of McCoy’s
medium (Gibco), sodium bicarbonate (Corning) and GlutaMAXTM (Promega). Lipoprotein
deficient serum was prepared from FBS in house using Cab-O-Sil (Supelco Analytical) (91).
Lalistat (LALi) was a gift from the Maxfield Laboratory (compound 13) (92). Cholesterol was
from Steraloids. AcLDL was from Alfa Aesar. Commercially available deuterated compounds
used in this study include d7-cholesteryl oleate (Avanti Polar Lipids), d5- cholesterol (Medical
Isotopes, Inc.) and d5-cholestenone (CDN Isotopes). D17-oleic acid (Cayman Chemical) and d4cholesterol (Cambridge Isotope Laboratories) were used for the synthesis for d17-LKM38 oleate
and d4-cholesteryl oleate standards, respectively. Additional reagents included methanol (JT
Baker), chloroform (BDH VWR Analytical), and formic acid (Acros Organics).
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2.5.2 Diazirine Alkyne Probes
Trans-sterol probe was made in house using the published synthesis(81). The synthesis of
LKM38 and KK174 have previously been reported (21, 89). The synthesis of KK175 and LKM38
oleate as well as LKM38-one, d17-LKM38 oleate and d4-cholesteryl oleate standards are detailed
in the Supplemental Methods. Diazirine alkyne probe stocks were prepared at 10 µM in ethanol
unless otherwise stated.

2.5.3 Cell Culture
U2OS-SRA cells, which express the human SRA, were obtained from the Maxfield
Laboratory (93). Chinese Hamster Ovary (CHO) cells expressing human influenza hemagglutinin
(HA) epitope tagged NPC2 (NPC2-HA) were generated by transduction of CHO cells with a
retroviral construct expressing NPC2-HA (94, 95). Human skin fibroblasts were obtained from
ATCC, and CYP27A1-deficient CTX-205-5 fibroblasts were a gift from Eran Leitersdorf (96).
U2OS-SRA cells were cultured in McCoy’s medium containing 10% FBS, 1.2 g/L sodium
bicarbonate, and 1 mg/mL G418. CHO cells were cultured in DMEM/F12 (1:1) containing 5%
FBS, 0.5 mM sodium pyruvate, and 2 mM L-glutamine. Human fibroblasts were cultured in
DMEM containing 10% FBS and 1X GlutaMAXTM. Lipoprotein-deficient medium (LPDM)
contained lipoprotein-depleted FBS instead of regular serum. Starvation media was prepared by
the addition of 20 µM lovastatin and 50 µM mevalonate to LPDM.
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2.5.4 Cell Viability
U2OS-SRA cells were seeded at 3000 cells/well in 96-well plates overnight before being
subjected to a 15-minute pulse of 0.5% methyl-β-cyclodextrin in LPDM to deplete cellular
cholesterol. Cells were then treated with starvation media containing 10 µM cholesterol, LKM38,
KK174, KK175, trans-sterol probe or vehicle. After 72 h, cell viability was assayed using
CellTiter-Glo Luminescent Cell Viability Assay (Promega).

2.5.5 Microscopy
U2OS-SRA cells grown on coverslips at 1.8x105 cells/ well in 6-well dishes. Cells were
incubated in LPDM containing LKM38 oleate reconstituted acLDL (97) with or without 10 µM
LALi overnight. Media was spiked with 1 µM LysoTracker Red DND-99 (Molecular Probes, Life
Technologies) 2 h before fixation for 10 minutes in 4% paraformaldehyde (Electron Microcopy
Sciences). Coverslips were washed, then subjected to CuAAC. Cells were placed in 0.5 mL tris
buffered saline; 20 µL 50 mM CuSO4, 20 µL 10 mM THPTA, 5 µL 10 mM FAM-azide
(Lumiprobe), and 20 µL 250 mM ascorbic acid were added sequentially to each well, then
incubated for 30 minutes rocking in the dark. This was immediately followed by a second, identical
click reaction in order to maximize click efficiency. Coverslips were washed for 5 minutes each
with PBS containing 40 mg/mL BSA, 0.5 M NaCl, and PBS before mounting on slides. Images
were collected on a Nikon A1plus confocal microscope at 100X magnification (pixel size=0.1 µm,
Z-step size = 0.13 µm, optical resolution=0.23 µm, optical sectioning=0.42 µm). Colocalization
quantification was performed using ImageJ.
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2.5.6 Gene Expression
U2OS-SRA cells or CTX-205-5 (CYP27-A1 deficient) cells were plated at 4x105 or 2x105,
respectively, in 6 cm dishes and grown overnight before incubation with starvation media
containing 10 µM cholesterol, LKM38, KK174, KK175, trans-sterol probe or vehicle (ethanol)
for 14 h. After washing, RNA was collected in Trizol (Ambion) and prepared for quantitative PCR
(qPCR) using SuperScriptTM III First Strand Kit (Invitrogen). Relative RNA amount was
determined by qPCR using PerfeCTa® SYBR® green FastMix® (QuantaBio) and primers (IDT)
to HMGCS (FWD: GAT GTG GGA ATT GTT GCC CTT; REV: ATT GTC TCT GTT CCA ACT
TCC AG), ABCA1 (FWD: TTC CCG CAT TAT CTG GAA AGC; REV: CAA GGT CCA TTT
CTT GGC TGT), and Rplp0 (FWD: GGA GAC GGA TTA CAC CTT CCC; REV: CAG CCA
CAA AGG CAG ATG G). Relative quantification of target transcript abundance was calculated
using the ddCT method using Rplp0 as an endogenous control on an ABI 7500 Fast Real-time
PCR system.

2.5.7 Biochemical Trafficking Assays
For esterification and cholestenone assays, cells were plated at 6x104 cells/well in 12-well
dishes. After overnight incubation, media was changed to LPDM supplemented with acLDL
reconstituted with either LKM38 oleate or d7- cholesteryl oleate overnight in the presence of 10
µM LALi. Cells were chased in LALi-free media for 0-12 h before harvest. For esterification
experiments, d9-oleate/BSA (98) was included during the chase period. For ester quantification,
cellular lipids were extracted in 9:1 methanol/chloroform at -20°C. d17-LKM38 oleate or d4cholesteryl oleate was added as an internal standard for LKM38 oleate or d7-cholesteryl oleate
experiments, respectively. Cell lysate was collected by scraping. Supernatant was collected after
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centrifugation, dried under nitrogen, and resuspended in 9:1 methanol/chloroform. For For
quantification of PM cholesterol, we used a cholesterol oxidase assay (99). In brief, cells were
fixed in 1% glutaraldehyde then exposed to 0.1 U/mL sphingomyelinase and 2 U/mL cholesterol
oxidase to convert surface- accessible cholesterol or LKM38 to cholestenone or LKM38-one,
respectively. Cellular lipids were extracted in 9:1 methanol/chloroform with d5-cholestenone
added as an internal standard. Extracts were dried under nitrogen, then resuspended in 20 µL 0.05
M O-[2-(1-azepanyl)ethyl]hydroxylamine dihydrocholoride and 10 µL formic acid and heated for
1 h at 50°C to derivatize cholestenones. LC-MS/MS was monitored in positive mode for the ion
transitions of interest (Supplemental Table S1).

2.5.8 Immunoprecipitation
Following incubation in LPDM overnight, cells were pulse labeled for 1 h with 2.5 µM
(for NPC1) or 10 µM (for NPC2, caveolin, and VAMP7) LKM38/methyl-β-cyclodextrin
complexes diluted in McCoy’s medium with 0, 10, or 100X cholesterol/methyl-β-cyclodextrin as
a competitor. LKM38 and cholesterol methyl-β-cyclodextrin complexes were prepared in a ratio
of 2.5 mM methyl-β-cyclodextrin:250 µM sterol then sterile filtered. The amount of cholesterol
recovered in the cyclodextrin solution was determined by mass spectrometry. Cells were washed
with PBS before being subjected to UV-crosslinking (366 nm) by UV StratalinkerTM 1800
(Stratagene) for 5 minutes on ice. Cells were collected by scraping in RIPA lysis buffer (50 mM
Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate) containing 1 mM PMSF and EDTAfree Protease Complete (Roche), sonicated, and incubated for 1 h rotating at 4°C. Lysates were
spun at 16,000g for 10 minutes at 4°C, and supernatants were collected and analyzed for protein
content by BCA (ThermoFisher). Equal amounts of protein were added to Protein A Dynabeads
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(Novex) loaded with the appropriate antibody. After immunoprecipitation, beads were washed and
subjected to click reaction. Beads were resuspended in 50 µL RIPA lysis buffer, before sequential
addition of 1 µL 50 mM CuSO4, 1 µL 5 mM THPTA, 0.5 µL 10 mM ROX-azide (Lumiprobe),
and 1 µL 250 mM ascorbic acid. The mixture was incubated for 30 minutes at 37°C shaking at
1,100 rpm in the dark. Beads were washed in lysis buffer, then suspended in 1X Laemmli sample
buffer (LSB), and incubated for 10 minutes at 37°C before loading on 4-12% pre-cast bis- tris tris
gels (Invitrogen) for SDS-PAGE. Fluorescent images of gels were collected by Typhoon scanner
at 100 µm resolution. After imaging, gels were transferred to nitrocellulose then probed for the
appropriate target by western blot. Immunoprecipitation and western blotting antibody conditions
are provided in Supplemental Table S2.

2.5.9 Fluorescent Gel Profiling
U2OS-SRA cells were treated with 10 µM probe (in ethanol) in culture media for 24 h.
Media was changed to normal culture media, LPDM, or LPDM containing 100 µg/mL acLDL for
18 h. Crosslinking, click reaction, SDS-PAGE, and imaging were performed as described above,
except gels were methanol fixed before imaging. Parallel samples were prepared for western blot
analysis.
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Chapter 3 – Characterization of other
diazirine alkyne probes
3.1 Introduction
The pathways and proteins required for cellular distribution of cholesterol are poorly
characterized, in part, because cholesterol probes are difficult to design. The highly hydrophobic
nature of the molecule and stringent structural demands required for cholesterol-like function
present high barriers for the generation of experimental cholesterol probes. Bulky fluorescent
conjugates of cholesterol (BODIPY-or NBD- cholesterol) have been useful for imaging studies
but exhibit altered intracellular trafficking and/or misorientation in the membrane (87).
Intrinsically fluorescent probes are minimally modified and robustly mimic cholesterol-like
membrane behavior; however, the low quantum yields of these probes limit their utility.
Isotopically-labeled cholesterols have been useful for studying cholesterol trafficking to the PM,
ER, and mitochondria, as specific biochemical assays exist for measuring cholesterol products
produced in these compartments, but these assays are not easily scaled for high-throughput genetic
and pharmacologic screens (76, 100, 101). Study of trafficking to other compartments has relied
on low through-put, targeted loss-of-function assays for proteins implicated in these pathways.
Diazirine alkyne probes offer a new approach for the study of cholesterol trafficking and
cholesterol-binding proteins. These cholesterol-like probes contain a diazirine group for in situ
crosslinking to nearby proteins. An alkyne group allows for addition of fluorescent or affinity
handles after trafficking has occurred. Using this approach, minimally-modified cholesterol probes
can be used to visualize cholesterol trafficking using imaging techniques or to “fish-out”
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interacting proteins for identification by proteomics (76, 81). Characteristics of the most promising
probes are the ability to support growth of auxotrophic cells similar to cholesterol, ability to label
established cholesterol binding proteins, and demonstration of trafficking itineraries similar to
cholesterol (76).
We previously characterized diazirine alkyne probes LKM38, KK174, KK175, and transsterol probe (76). Of these, only LKM38 sustained growth of auxotrophic cells, appropriately
regulated SREBP2-gene expression, and labeled established cholesterol binding proteins. While
LKM38 shows great promise for use as a cholesterol probe, in trafficking studies, LKM38 exhibits
increased trafficking to the ER, a limitation of the probe. Further, complete characterization of the
cholesterol interactome is likely to require multiple probes since the position of the cross-linkable
diazirine group on the probe determines the amino acids of the protein available as crosslinking
partners. This feature was recently leveraged to map the cholesterol binding pocket of VDAC1, a
mitochondrial ion channel (89). In addition, aliphatic diazirines, like those contained in LKM38,
exhibit a preference for nucleophilic amino acids for crosslinking (102). Trifluoromethylphenyl
diazirine (TPD) groups are less discriminatory, labeling any nearby residue and have been used to
expand the number of map-able sites (103). Canonical cholesterol binding sites are highly enriched
with hydrophobic, non-nucleophilic residues, so the ability to label any amino acid is particularly
important for diazirine alkyne cholesterol probes.
In order to expand and diversify the number of diazirine alkyne probes available, as well
as to determine structure-activity-relationships between functional modifications and probe
fidelity, I characterized a panel of diazirine, alkyne, and diazirine alkyne probes synthesized by
the Covey laboratory with respect to cholesterol auxotrophy, regulation of cholesterol homeostatic
gene expression, and protein binding assays.
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Figure 3.1: Cholesterol, cholesterol-related molecules, and probes.
A) cholesterol like molecules; B) alkyne-modified cholesterol probes; C) side-chain diazirine compounds and their
diazirine alkyne derivatives; D) sterol-body diazirine compounds and their diazirine alkyne derivatives; E) other
diazirine alkyne probes. Alternative names for LKM37, KK170, and KK176 are LKM38 w/o diazirine, KK174 w/o
diazirine, and KK175 w/o diazirine, respectively (76).

3.2 Results
3.2.1 Cholesterol, cholesterol-related molecules, and probes
In the process of generating the diazirine alkyne probes described in Chapter 2, and in order
to study the structure activity relationship of diazirine and alkyne modifications to the sterol rings,
the probes in Figure 3.1 were generated and evaluated in auxotrophy, gene expression, and protein
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binding assays. The panel of compounds included cholesterol with alkyne addition (KK177, Figure
3.1B), compounds with side-chain addition of aliphatic diazirine or TPD and their alkynylated
derivatives (KK173, KK226, KK237, KK231, Figure 3.1C), a sterol-body diazirine (6azicholesterol, Figure 3.1D), and diazirine alkyne probes MQ182 and MQ238 (Figure 3.1E).
Structures for previously characterized probes KK176, KK170, LKM37, KK174, KK175, transsterol probe, and LKM38 are also shown (Figure 3.1B, C, D). Cholesterol-like molecules
epicholesterol, ent-cholesterol, coprostanol, and hydroxycholesterols were included in some
assays in order to further probe structural requirements for cholesterol mimicry (Figure 3.1A).

3.2.2 Location of diazirine and alkyne modifications differentially affect ability
of probes to support growth of cholesterol auxotrophic cells
Some cholesterol-like molecules do not support growth
In the first and most stringent test of cholesterol mimicry, the panel of compounds were
introduced to U2OS-SRA cells made auxotrophic for cholesterol through inclusion of statin in the
growth media. Cells were grown in LPDM with cholesterol, vehicle (ethanol), or probe as the sole
sterol source. When cholesterol was present in the growth medium, cell number grew 3-fold
compared to vehicle (Figure 3.2, gray background). Similar growth was observed for a
diastereomer (epicholesterol) and the enantiomer (ent-cholesterol) of cholesterol (Figure 3.2,
yellow background). Conversely, coprostanol, which is the 5b-reduced analog of cholesterol, was
cytotoxic. 24S-hydroxycholesterol and 25-hydroxycholesterol were cytotoxic even at 3 µM
concentrations. Together these data suggest that while some alterations in stereochemistry are
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tolerated, 5b-reduction of the C5-C6 bond or side-chain oxysterol modifications render cholesterol
cytotoxic in the auxotrophy assay.

Figure 3.2: Location of diazirine and alkyne modifications differentially affect ability of probes to support
growth of cholesterol auxotrophic cells.
U2OS-SRA cells were treated with 10 µM sterol or 3 µM oxysterol (24S-OHC, 25-OHC) for 72 h in starvation media.
Viability was measured by Cell Titer Glo assay. Values are normalized to vehicle. Bars: mean + SE, n = 3-4 or n=2
(KK177). $, P<0.05 vs cholesterol, * P<0.05 vs vehicle by one-way ANOVA. #, P<0.05 vs vehicle, paired t-test; for
25-OHC P = 0.07, for KK177 P = 0.06.

Alkyne addition at C19 compromises cholesterol-auxotrophic growth
We previously characterized cholesterol probes with alkyne addition at C26 (LKM37,
a.k.a. LKM38 w/o diazirine), C21 (KK170, a.k.a. KK174 w/o diazirine) and C19 (KK176, a.k.a.
KK175 w/o diazirine) (76). Compounds with alkyne addition at C26 and C21 supported
auxotrophic cell growth to a similar degree as cholesterol, while addition at C19 resulted in a
compound that partially supported auxotrophic cell growth to ~60% of cholesterol treated cells. In
this study we evaluated KK177, which also contained alkyne modification at C19 but differed
from KK176 due to a spacer carbon between C19 and alkyne. In contrast to KK176, LKM37 and
KK170, alkyne probe KK177 was cytotoxic (Figure 3.2, blue background). Together with our
previous findings, this data suggests that manipulation at C19 is detrimental to the ability of probe
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to support auxotrophic cell growth and is more severely affected when additional carbons are
added. Side chain alkyne additions appear to be relatively inert.
Side chain diazirines are well tolerated
Of the diazirine modified probes, KK173 and KK226 supported auxotrophic cell growth
to a level similar to unmodified cholesterol (Figure 3.2, purple background). These probes are
similar in that they both contain diazirine groups in the side chain. As compared to KK173 that
contains an aliphatic diazirine, KK226 contains a diazirine as a TPD group that is bound to the
sterol C17 carbon by an ether linkage. By contrast, diazirine addition to the 6-position resulted in
cytotoxicity (6-azicholesterol).
Diazirine alkyne probes
Using these data, we hypothesized that probes that incorporate a C19 alkyne, C6 diazirine,
or C5-C6 bond reduction would be cytotoxic, while probes with other modifications would be
better tolerated. Indeed, we previously observed that KK175 (C19 alkyne, C25 diazirine) was
cytostatic (76). Further, KK231 (C19+CH2 alkyne, TMD) was cytotoxic (Figure 3.2, green
background). Trans-sterol probe, which contains a side-chain alkyne, C6 diazirine, and 5areduced bond was cytotoxic as anticipated (76). LKM38, a 5a-reduced analogue that contains a
C7 diazirine and C26 alkyne was still able to support cell growth at ~ 40% the level of cholesterol
(76). While C19 alkyne and C6 diazirine modifications appear to be dominant in causing
cytotoxicity, evaluation of LKM38 demonstrates that C7 diazirine and 5a-reduction does not. C7diazirine cholesterol and 5a-reduced cholesterol (cholestanol) could be evaluated to confirm this
finding.
KK237 (C7+CH2 alkyne, TPD) was cytotoxic while the diazirine modification on its own
was not, suggesting alkyne modification at that position is detrimental. MQ182, which contained
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all modifications in the side chain, supported growth to ~70% that of cholesterol, and MQ238 (C21
alkyne, TPD) appeared identically to cholesterol in this assay. Another C21 alkyne probe KK174
(C25 diazirine), was cytotoxic (76). In isolation, C21 alkyne, KK170 (76), and C25 diazirine
(KK173) modifications had minimal effects on probe activity in this assay; the reason why
combining both modifications becomes cytotoxic, as in KK174, is unclear.

Figure 3.3: Diazirine alkyne probes suppress SREBP-2 target gene expression without activating oxysterolmediated LXR-target gene expression.
U2OS-SRA cells were treated with 10 µM sterol or 3 µM oxysterol (24S-OHC, 25-OHC) in starvation media for 14
h before harvesting cells for quantification of RNA by qPCR. HMGCS (A) or ABCA1 (B) RNA was quantified
relative to RPLP0. Values are normalized to cholesterol. Bars: mean + SE, n = 3. $, P<0.05 vs cholesterol, * P<0.05
vs vehicle by one-way ANOVA.

3.2.3 Diazirine alkyne probes suppress SREBP-2 target gene expression without
activating oxysterol-mediated LXR-target gene expression
Cholesterol homeostasis is tightly regulated by the SREBP-2 transcription factor which is
activated when ER cholesterol levels are low. Addition of cholesterol to the cell suppresses
SREBP-2 activity as demonstrated by decreased mRNA abundance of HMGCS, an SREBP-2
target (Figure 3.3, left) (12). Cholesterol probes were evaluated for their ability to suppress
HMGCS as a measure of their cholesterol mimicry. All of the probes evaluated suppressed
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HMGCS expression to a similar degree as cholesterol (Figure 3.3, left). Previously evaluated
probes (LKM38, KK174, KK175, trans-sterol probe) behaved similarly in this assay (76). Since
oxysterols similarly suppress SREBP-2-target gene expression it is possible that the probes act like
oxysterols to modulate this pathway (Figure 3.3, left) (104). 24S- and 25-hydroxysterol, but not
cholesterol, activate LXR to promote expression of genes involved in cholesterol efflux. To test if
probes exhibited oxysterol-like activity, expression of LXR-target ABCA1 was evaluated after
probe administration. While 24S- and 25-hydroxycholesterol increased ABCA1-expression 4 to
8-fold, none of the probes exhibited a significant increase relative to cholesterol (Figure 3.3, right).
A similar response was observed for LKM38 and trans-sterol probe (76).

Figure 3.4: Diazirine alkyne probes differentially bind NPC1.
U2OS-SRA cells were labeled with 10 µM probe before click addition of ROX azide. Proteins were separated by
SDS-PAGE before scanning for fluorescent signal (top) or probing for NPC1 by western blot (bottom).

3.2.4 Diazirine alkyne probes differentially bind NPC1
Based on auxotrophy and gene expression assays, MQ182 and MQ238 emerged as the most
promising candidates for further evaluation as cholesterol probes. Previously characterized
diazirine alkyne probes LKM38 and trans-sterol probe were shown to interact with cholesterol
binding protein NPC1 (76, 81). MQ182 and MQ238 were likewise tested for their ability to interact
with NPC1. While it was clear that MQ182 bound to NPC1, little to no signal was observed for
MQ238 (Figure 3.4).
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3.3 Discussion
In an effort to determine the effects of diazirine and alkyne modification to cholesterol, we
have evaluated a panel of cholesterol probes for their ability to mimic cholesterol. Support of
growth in cells auxotrophic for cholesterol is a stringent test of cholesterol mimicry and thus was
chosen as an initial screening assay. MQ182 and MQ238, fully functionalized diazirine alkyne
probes, supported auxotrophic cell growth. Both MQ182 and MQ238 appropriately suppressed
SREBP-2 target gene expression without activating oxysterol-mediated pathways. However, only
MQ182 was detected as labeling NPC1, an established cholesterol binding protein. While the
previously characterized LKM38 contains an alkyl diazirine at C7, MQ182 contains an alkyl
diazirine in the side chain of the cholesterol structure. By using MQ182 and LKM38 in parallel, a
wider proteome is likely to be accessible for study using the crosslink-and-click technique. These
findings support MQ182 as a candidate cholesterol probe; however, further biochemical
trafficking studies will be required to fully evaluate the fidelity of the probe as a cholesterol mimic.
NPC1 binds to cholesterol at the luminal N-terminal domain and at the transmembrane
sterol-sensing domain, both of which are highly hydrophobic (28, 30). Given the added ability of
the TPD group to crosslink to non-nucleophilic residues, we hypothesized that MQ238 interacting
with NPC1 would potentially have a higher labeling efficiency relative to the aliphatic diazirine
probes that were assayed (LKM38, MQ182, trans-sterol probe). However, MQ238 binding to
NPC1 could not be detected. A negative result in this assay could indicate that probe does not
interact, interacts transiently or too weakly to be detected, or interacts but is unable to crosslink
because of the orientation of the diazirine ring. Our assays are unable to differentiate between these
cases. However, as the TPD group is much bulkier than its alkyl diazirine counterpart, this could
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prevent protein interaction particularly when the interaction occurs via the side chain (i.e., NPC2).
Additional protein targets will have to be assayed in order to explore the utility of MQ238 as a
diazirine alkyne cholesterol probe. If MQ238 does label other established cholesterol binding
proteins, it could be a useful complement to the alkyl diazirine probes that have been identified
thus far.
Diazirine-only and alkyne-only compounds assayed in this study allowed for the
identification of permissive locations for functionalized modifications to the sterol body and
provide a framework for the rational design of new diazirine alkyne probes. Probes with alkyne
addition at the C19 position do not perform well in the auxotrophy assay regardless of diazirine
modification, and alkyne addition at the C7 position was also unfavorable (KK237). Compounds
with alkyne addition in the side chain included MQ182 and MQ238 in this study, and KK170,
LKM37, KK174, LKM38, and trans-sterol probe in our previous study (76). Except for KK174
and trans-sterol probe, all side-chain alkyne probes supported auxotrophic cell growth. Toxicity
for trans-sterol probe was anticipated, as it contains a 6-diazirine which in isolation is cytotoxic
(6-azicholesterol). On the other hand, cytotoxicity for KK174 was surprising, because its C21
alkyne-only (KK170) and C25 diazirine-only (KK173) counterparts supported auxotrophic growth
to cholesterol-like levels and the TPD probe MQ238, which contains a C21 alkyne, also sustains
robust growth. C25-diazirine probes KK174 and KK175 do exhibit oxysterol-like activity, so it is
possible that this activity acts cooperatively with the alkyne modification to render these probes
cytotoxic (76). With KK174 as an exception, side-chain alkyne and diazirine modifications appear
to be the least perturbing.
Multiple characterization parameters must be examined in order to identify high-fidelity
cholesterol probes. While SREBP-2-target gene expression assays are frequently used as the
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principal measure of cholesterol mimicry, reliance on this assay alone would have resulted in
selection of several probes that by other measures are poor candidates. Although all of the probes
tested in this study appropriately regulated SREBP-2 and LXR gene expression, KK237 and
KK231 were clearly cytotoxic in the auxotrophy assay indicating that they cannot substitute for
cholesterol. Stereoisomers of cholesterol (epi- and ent-cholesterol) supported growth of
cholesterol-auxotrophic cells. However, due to their altered 3D structure, these stereoisomers are
unlikely to bind with specificity to cholesterol-binding proteins due to their inability to fit into
stereospecific binding pockets. Indeed, epicholesterol has been shown to have lower binding
affinities for NPC1 relative to cholesterol (105), and while ent-cholesterol appropriately
suppresses SREBP-2, it is inefficiently esterified by ACAT (19, 106). Accordingly, proteinbinding and biochemical trafficking assays can provide additional tools for the characterization of
novel cholesterol probes.
This study identified MQ182 as a promising diazirine alkyne probe. MQ238 also shows
great promise but will need to be further investigated for its ability to bind NPC1. Both probes
should be further tested for their ability to bind other cholesterol-interacting proteins, particularly
those which use other cholesterol-binding strategies (e.g., hydrophobic pocket, CRAC/CARC
domains). Biochemical assays to monitor trafficking to the PM and ER provide additional
strategies for assaying cholesterol mimicry. Should these probes perform well in these assays, they
could complement the use of LKM38 for the study of the cholesterol interactome.
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3.4 Methods
Cell culture, auxotrophy assay, gene expression assay, and NPC1 binding assay were
performed as described (76).
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Chapter 4 – Post-lysosomal cholesterol
trafficking: a mass spectrometry-based
proteomics method
4.1 Introduction
The distribution of cholesterol among cellular organelles is non-uniform. Some membranes
are cholesterol-rich (PM, Golgi, lysosome) and others are cholesterol-poor (ER, mitochondria).
The cholesterol content of cellular membranes is largely determined by biophysical interactions
with other lipid components and by rates of cholesterol trafficking among membranes. Within
membrane leaflets cholesterol is situated with the 3´OH group oriented toward the aqueous phase
while the sterol ring system and isooctyl side chain reside amongst hydrophobic phospholipid tails
and transmembrane protein domains. Cholesterol engages proteins through diverse structural
motifs. CRAC and CARC sequences are found in the transmembrane region of several cholesterol
binding proteins (107). Polytopic proteins such as NPC1 and HMGCR bind cholesterol through
“sterol sensing domains,” ill-defined transmembrane regions required for cholesterol-regulated
function. Soluble proteins with cholesterol-binding capability have also been identified. These
include NPC2, the ORPs and members of the StAR protein family. These proteins contain
hydrophobic cholesterol binding pockets and are thought to play a role in the inter-membrane
transfer of cholesterol in order to maintain membrane and cholesterol homeostasis (3).
Cells acquire cholesterol through de novo synthesis or uptake of exogenous cholesterol. De
novo synthesis is an energetically expensive, multi-step process that largely takes place in the ER.
Exogenous cholesterol is principally acquired by the cell through receptor-mediated endocytosis
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of LDL that contain cholesterol and a cholesteryl ester-rich hydrophobic core. The endocytosed
particles and their cargo are trafficked to the lysosome where acidification activates LAL, which
cleaves cholesteryl esters, enabling release of free cholesterol. Cholesterol is bound by the soluble,
luminal cholesterol binding protein, NPC2, which transfers the cholesterol to NPC1 which resides
in the limiting lysosomal membrane. Post-lysosome, cholesterol is rapidly redistributed to the PM,
ER and other cellular compartments by poorly understood mechanisms.
The hydrophobic core of LDL has been reconstituted with a variety of molecules including
radiolabeled cholesteryl esters, therapeutics, and fluorescent lipids as a strategy for cellular
administration of hydrophobic cargo (25, 108, 109). Cyclodextrins, a family of water-soluble,
cyclic oligosaccharides with hydrophobic cores, have also been used to deliver water insoluble
lipids and drugs. In contrast to the specific nature of lipoprotein endocytosis, cyclodextrin-based
cargo delivery is highly efficient but is much less specific. Cyclodextrins interact with the PM, can
be endocytosed, and have been observed in the cytosol (68, 69, 110).
Methyl-beta-cyclodextrin delivery of trans-sterol, a diazirine alkyne cholesterol probe,
enabled the identification of over 250 binding proteins (81). Proteins in the data set were
associated with many cellular compartments (cytosol, mitochondria, ER, PM, Golgi) and included
several established cholesterol-interacting proteins (e.g., caveolin and HMGCR), of which >80%
contained either a known or predicted transmembrane domain. This work provided a proof-ofconcept for the utility of diazirine alkyne cholesterol probes. We hypothesized that this technique
could be adapted in order to specifically probe the post-lysosomal cholesterol trafficking network.
The development of a lysosomal loading strategy, as well as optimization of labeling, enrichment,
and detection protocols are described in the following.

52

A lysosome loading

B inhibitor washout and UV-crosslink
PM

acLDL
+lalistat

intracellular

extracellular

PM

C CuAAC

extracellular
O
HN NH

Labeled
Target

Biotin Azide Linker

LYS

S
O

intracellular
LAL

LYS

+ CuSO4
+ TBTA
+ TCEP

Time 1

Labeled
Target
Biotin Azide Linker

S
O

Time 2

LAL

O
HN NH

Time 3

F elution

D preparation for enrichment
1. Protein precipitation for excess biotin removal
2. Re-solubilization
3. Reduction and alkylation

UV (PC-biotin only)
handheld UV lamp

ditionite (MQ112 only)

on-bead digestion

Na2S2O4
T
T

E enrichment
streptavidin
agarose
beads

Labeled
Target

O
HN NH

Biotin Azide Linker

S
O

Labeled
Target

Key:

diazirine alkyne probe
diazirine alkyne
probe ester
UV exposure

Labeled
Target

streptavidin
T

trypsin

1. clean-up
2. trypsin digest

peptide

clean-up

Figure 4.1: Experimental approach for proteomic analysis of post-lysosomal cholesterol trafficking.
A) Lysosome-loading: probe is loaded to the lysosome (LYS) by introducing acLDL reconstituted with probe-ester to
SRA-expressing cells. In the presence of lalistat, probe-ester is not cleaved and is retained in the compartment. B)
Inhibitor washout and UV-crosslink: when lalistat is removed, un-esterified probe is released from LYS. In situ UV
exposure covalently binds probe to proximal proteins. UV exposure at different time points after lalistat washout
allows for the capture of temporal interactomes. C) CuAAC: an azide-containing biotinylated handle is added to the
probe-alkyne using click chemistry. D) Preparation for enrichment: excess biotin is removed using
methanol/chloroform precipitation. Protein is resolubilized in a ~2% SDS buffer then exposed to DTT (for disulfide
reduction) and iodoacetamide (to alkylate free cysteines). E) Enrichment: labeled lysate is diluted to lower SDS
concentration, then added to streptavidin agarose beads to capture biotinylated proteins. After incubation, beads are
washed to minimize non-specific interactions. F) Elution: enriched proteins are released from beads using UV,
dithionite, or on-bead digestion. UV exposure cleaves PC-biotin, resulting in release of PC-biotin-modified proteins.
Incubation with dithionite cleaves MQ112, resulting in release of MQ112-modified proteins. Both of these methods
require SDS removal and trypsin digestion to produce peptides for mass spectrometry. For on-bead digestion, beads
are incubated with trypsin, releasing peptides from bound proteins and streptavidin.
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4.2 Results
4.2.1 Experimental approach for proteomic analysis of post-lysosomal
cholesterol trafficking
Initial studies with trans-sterol probe (81) provided a framework for the identification of
cholesterol interactomes using diazirine alkyne probes. In brief, UV exposure crosslinks probe to
protein. Click addition of a biotin-linker adds an affinity handle for bead-based immunoisolation
of labeled proteins. Proteins are eluted from beads and prepared for analysis by mass spectrometry.
Adaptations made to this protocol in order to specifically monitor post-lysosomal cholesterol
trafficking are outlined in Figure 4.1 and discussed in section 4.2.2. Optimization to labeling and
immunoisolation steps for increased enrichment efficiency are discussed in sections 4.2.3-4.2.5.
Finally, data acquisition and analysis approaches are addressed in section 4.2.6.

4.2.2 Development of a lysosomal loading strategy
In order to specifically monitor post-lysosomal cholesterol trafficking, we developed an
approach to selectively load cholesterol cargo to the lysosomal compartment (Figure 4.1A).
Cholesterol and CE-rich LDL enters the cell by receptor-mediated endocytosis, with the cargo
eventually reaching the lysosomal compartment. Some cell types express SRA for the uptake of
oxLDL and acLDL. Cell types primarily expressing LDLR or LDLR and SRA were tested for their
ability to take up LDL or acLDL (Figure 4.2A). Uptake of oxidized LDL could not be tested as it
could not be efficiently reconstituted with cholesteryl ester cargo. LDLR-expressing cell types
behaved as anticipated: NSF fibroblasts and U2OS took up more LDL-cholesteryl ester relative to
acLDL-cholesteryl ester. RAW cells (endogenously express SRA) and U2OS cells with ectopic
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SRA expression (U2OS-SRA) took up more acLDL-cholesteryl ester than LDL-cholesteryl ester.
Most impressively, U2OS-SRA cells were the most efficient with respect to acLDL-cholesteryl
ester uptake, taking up at least 2-fold more cholesteryl ester/µg protein than any other cell type.
Based on this data, acLDL-cholesteryl ester delivery to U2OS-SRA cells was selected as the
lysosomal loading strategy.

Figure 4.2: Optimization of lysosomal loading.
A) cholesteryl ester (CE) uptake by NSF fibroblasts (NSF), RAW macrophages (RAW), U2OS, and U2OS-SRA cells
when presented LDL or acLDL reconstituted with CE. B) d7-cholestenone detected in cells loaded with d7 CE 18:1
acLDL (d7-acLDL) in the presence of 10 µg/mL progesterone at 0 or 2 h after progesterone washout (P, 0 h and P, 2
h respectively) or at 0 h in cells loaded in the presence of 10 µM lalistat-2 (L-2, 0 h). C) cellular d7 CE 18:1
accumulation after overnight loading of d7-acLDL in the presence of 10 µM lalistat-2 or various concentrations of
lalistat-1. D) Immunoprecipitation of HA-NPC2 from LKM38 or trans-sterol labeled lysates. Left, top: fluorescence
signal for clicked azide-reporter; left, bottom: western blot (WB) for HA tagged NPC2 using anti-HA antibody; right:
fluorescence quantification, normalized to protein signal. A, n=2, bars = mean + SD; B-C and E, n=1; D, n=4, bars =
mean + SE, *P<0.05, unpaired t-test.
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In order to synchronize probe release from the lysosome, several blocking approaches were
investigated. Progesterone has been shown to suppress esterification of lysosome-derived
cholesterol, though the mechanism is poorly understood (111). While progesterone prevented
esterification of acLDL-derived cargo (not shown), substantial leak of lysosomal cholesterol to the
PM was observed (Figure 4.2B). Cellular incubation at temperatures below 20ºC inhibits endocytic
trafficking and cholesteryl ester hydrolysis, thereby disrupting lysosomal cholesterol trafficking
(47, 112). However, due to restrictions on loading time, in order to prevent cell death, temperaturebased approaches did not allow for robust loading of cholesteryl ester to the compartment (data
not shown). Pharmacological inhibition of cholesteryl ester hydrolysis was also investigated. LAL
cleaves cholesteryl ester to liberate free cholesterol and LAL deficiency leads to cholesteryl ester
accumulation (113). Lalistats are potent, small molecule inhibitors of LAL (92). When compared
to progesterone, lalistat-2 was more efficient at blocking PM trafficking (Figure 4.2B). Lalistat-1,
a related LAL inhibitor, was equally as effective in promoting accumulation of acLDL-derived
cholesteryl ester during overnight incubation (Figure 4.2C). Lalistat-1 also prevented trafficking
of acLDL-derived cholesteryl ester to the PM (76). Relative to lalistat-2, however, lalistat-1
exhibits faster washout kinetics (92), so lalistat-1 was selected to block post-lysosomal cholesterol
trafficking.
Extensive effort was invested in selecting an appropriate diazirine alkyne probe cargo for
the post-lysosomal cholesterol trafficking application. Unlike trans-sterol probe, novel diazirine
alkyne probe, LKM38, was able to label intra-lysosomal cholesterol trafficking protein, NPC2
(Figure 4.2D). Further characterization of LKM38 and trans-sterol probe (in addition to two
others: KK174, KK175) using gene expression, auxotrophy, and biochemical trafficking assays
further confirmed that LKM38 was the most suitable for post-lysosomal cholesterol trafficking
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studies (76). MQ182 and MQ238, described in Chapter 3, may also be potentially useful in parallel
to LKM38.

Figure 4.3: Statistical enrichment cellular component GO term analysis for proteins identified in LKM38labeled proteomes.
U2OS-SRA cells incubated with LKM38 oleate in acLDL overnight with (block) or without (no-block) lalistat-2.
After clicking to PC-biotin, bead-enrichment, and on-bead trypsin digestion, peptides were analyzed by mass
spectrometry. Of the 406 proteins identified, 74 were found under block only (block/unique), 248 were found with
no-block only (no-block/unique) and 88 were found under both conditions. Of the shared proteins, 11 were enriched
under block (block/enriched), 43 were enriched with no-block (no-block/enriched), and 30 were enriched in neither
(shared). Protein ID requirements: ≥ 2 unique peptides, ratio to no-click condition > 2. Enrichment = no-block : block
ratio between 0.5 and 2. The top 10 GO terms, p-value for enrichment relative to Homo sapiens reference data set (P),
and fraction of the data set represented by the term (%) are displayed for each subset.
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Using LKM38 oleate, we have demonstrated that cholesteryl ester cargo introduced in
acLDL particles under 10 µM lalistat-1 block is efficiently loaded to the lysosome and released
after block washout (76). Based on these observations, we hypothesized that under block, the probe
interactome would be enriched in lysosomal proteins, and block-release or no-block conditions
would contain proteins belonging to organelles to which cholesterol is known to traffic, such as
the PM and ER. To test this, cells were loaded with LKM38 oleate in acLDL in the presence
(block) or absence of lalistat-block (no-block), and the labeled proteomes were collected and
evaluated by mass spectrometry. 115 proteins were identified in the blocked condition and 321
were identified in the no-block condition (Figure 4.3). 74 of the block, and 248 of the no-block
proteins were found under only one condition. 88 proteins were found under both conditions; 11
were enriched under block while 43 were enriched with no-block.
Table 4.1: Selected Cellular Component GO terms for proteins identified in LKM38-labeled proteomes under
block or no-block conditions.
The number of ID’s associated with the specified term for the human reference (REF), block, and no block data sets
are displayed (#). The proportion of the block or no block data set associated with the specified term (%) and p-value
for enrichment relative to REF (P) are calculated. Results with P > 0.05 are shaded in grey.
GO cellular component complete

REF
#

membrane (GO:0016020)
lysosome (GO:0005764)
lysosomal lumen (GO:0043202)
lysosomal membrane (GO:0005765)
primary lysosome (GO:0005766)
endosome (GO:0005768)
autophagosome membrane (GO:0000421)
Golgi apparatus (GO:0005794)
plasma membrane (GO:0005886)
endoplasmic reticulum (GO:0005783)
mitochondrial membrane (GO:0031966)
lipid droplet (GO:0005811)

9898
702
96
372
154
950
38
1602
5757
1447
726
82

#

block
P

%

53
18
8
10
3
11
0
16
25
17
5
3

5.53E-05
2.77E-09
2.92E-07
3.75E-05
2.78E-01
1.23E-02
1.00E+00
2.77E-03
1.00E+00
2.26E-04
1.00E+00
7.74E-02

77%
26%
12%
14%
4%
16%
0%
23%
36%
25%
7%
4%
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#

no-block
P

%

231
21
2
18
8
28
4
62
77
85
24
6

4.50E-62
1.65E-03
1.00E+00
1.77E-05
9.23E-03
1.54E-04
2.06E-02
1.50E-15
7.41E-01
6.65E-35
1.27E-04
8.95E-03

97%
9%
1%
8%
3%
12%
2%
26%
32%
36%
10%
3%

Cellular Component GO analysis was used to evaluate the data sets. The top 10 cellular
component GO terms associated with each data set are in Figure 4.3, a complete list is included in
Appendix A. The block, unique data set was associated with extracellular and lysosome-related
terms and included established cholesterol binding protein NPC1. The no-block/unique data set
included many non-lysosomal, cellular membrane terms including several ER and Golgi
associated terms (Figure 4.3, Appendix A). This data set included neutral cholesterol ester
hydrolase and ACAT. NPC2 and LAL were identified in the block/enriched data set, while
caveolin-1 was identified in the no-block/enriched data set.
Cellular component GO terms associated with organelles to which cholesterol is known to
traffic were extracted in order to further characterize the data sets (Table 4.1). Under the blocked
condition, 26% of the data set was classified as “lysosome;” 8 proteins were associated with the
lysosomal lumen. In contrast, in the no-block set, “lysosome” represented just 9% of the ID’s.
While “lysosomal lumen” was not a significant term, “lysosomal membrane” was, and represented
8% of the data set. In the no-block set, “endoplasmic reticulum” was well represented (36%), while
“lipid droplet” and “mitochondrial membrane” were less so (3 and 10% respectively). Both data
sets were well-represented by the GO “membrane” term, with 97% associated for the no-block set,
and 77% associated for the block set.
Finally, GO protein class analysis revealed “membrane traffic protein” and “transporter”
best described the most proteins in the no-block condition (Table 4.2). “SNARE protein” was also
identified in the no-block condition which is particularly interesting because SNARES have
previously been implicated in post-lysosomal cholesterol trafficking (40). However, the majority
of proteins did not have an identified protein class term which is a limitation to this analysis. No
significant protein class terms were identified in the block data set.
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Combined with biochemical trafficking data and microscopy-based visualization of probe
distribution, these proteomic data provide proof-of-concept for LKM38 as a cholesterol probe and
for the lysosomal loading strategy.
Table 4.2: Protein class GO terms for proteins identified in LKM38-labeled proteomes under no-block
condition.
The number of ID’s associated with the specified term in the human reference list (REF) and input list (no-block) are
displayed (ref and input #, respectively). P-value (P) for enrichment relative to REF, and fraction of the input data set
associated with the term (%) were calculated.
REF
#
280
638
32
127

GO protein class
membrane traffic protein (PC00150)
transporter (PC00227)
SNARE protein (PC00034)
glycosyltransferase (PC00111)

#
14
22
6
8

no-block
P
3.42E-04
4.07E-04
4.09E-04
6.21E-03

%
6%
9%
3%
3%

4.2.3 Optimized UV-crosslinking approach for time course analysis
UV exposure promotes the decomposition of probe diazirine to a highly reactive carbene
which can then covalently attach to nearby biomolecules. In contrast to previous use of diazirine
alkyne probes, the collection of a time course of interactomes under multiple conditions requires
repeated use of UV bulbs (Figure 4.1B). In order to ensure equal labeling across time points and
experiments, UV bulbs were evaluated for their output over repeated use using a UV A/B meter
(detects UV from 290-370nm). Bulbs exhibited a decrease in UV output after consecutive 5minute UV exposures (Figure 4.4A). UV output was also measure at 1, 3, and 6 h after initial use
in order to mimic a time course experiment (Figure 4.4B). UV output decreased at 1 h, remained
low at 3 h and began to recover by 6 h. These data indicated repeated use of a single set of UV
bulbs would result in decreased UV output, potentially leading to decreased labeling over the time
course.
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Figure 4.4: Optimization of UV bulb sets for time course exposures.
A: UV A/B output for the E-16 bulbs over consecutive 5-minute exposures; a: first use, b: use immediately following
a, c: use immediately following b. B) UV A/B output for E-16 bulbs over 6 h time course. C) UV A/B output for
individual bulbs from several bulb sets. bulb sets are defined in Table A.3. D) Optimized bulb sets: arrangement of
NuncTM dishes in the Stratalinker (D, left). Grey and white rectangles represent different conditions. This arrangement
ensures each condition receives UV irradiation from the same UV bulbs. UV bulb positions are defined (D, y-axis).
UV bulb output is plotted for each bulb set (D, right). Average and total UV A/B output is quantified (D, bottom)
using individual bulb values. E) UV A/B output measured for optimized bulb sets. Output for individual bulb sets are
shown in black; numbers denote bulb set. Data in red represents the average UV output for bulb sets 2 and 3 for the
specified time point. In A-D, UV meter was placed on 5 cm riser. In E, UV meter was placed on the Stratalinker
bottom. Bars = mean + SD.

In order to label multiple time points over a single time course, additional bulbs were
acquired. UV output for individual bulbs was determined (Figure 4.4C). No UV A/B was detected
for germicidal bulbs which emit light at 253.7 nm (www.eiko.com). EIKO brand (labeled E-“date
acquired”) obtained before 2016 exhibited consistent UV output at ~2.4 mW/cm2 per bulb.
Additional EIKO bulb sets contained either high (≥3 mW/cm2) or low (<2 mW/cm2) output bulbs.
Hitachi brand bulbs (H-19) had poor UV output.
Using only bulbs with emission > 2 mW/cm2, 3 bulb sets were designed such that each set
had similar average bulb output and summative output (Figure 4.4D, right), and were arranged
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such that exposed culture plates would receive equal UV irradiation whether placed on the left or
right side of the Stratalinker chamber (Figure 4.4D, left). The bulbs were then tested for their UV
output over a 0, 1, 3, 6 h time course for an experiment with 2 conditions, where each timepoint
would require 2 rounds of UV exposure to crosslink all plates (Figure 4.4E). Bulb set 1 was used
for the 0 h exposure. Bulb set 2 and 3 were used for consecutive exposures at the 1 h time point.
Sets 2 and 3 were also used for time 3, and time 6. Because output was higher, the UV meter was
placed 5 cm below where it was positioned for panels A-D; consequently, the apparent UV output
values are lower. Whereas bulb set 2 increased in output over the time course, bulb set 3 decreased.
However, the average UV exposure at each time point remained relatively consistent (Figure 4.4E,
red line). Using this approach, equal UV exposure was achieved over a time course.

4.2.4 Click-chemistry: selecting a biotin-azide linker
After crosslinking, protein is clicked to a biotin-azide handle (Figure 4.1C) to enable
downstream streptavidin-based enrichment. Several biotin-azide linkers are commercially
available. To determine if labeling efficiency could be increased by optimizing the biotin-azide
linker, three different biotin-azides were tested: Pegylated biotin azide (PBA), biotin azide (BA),
and a photocleavable biotin azide (PC) (Figure 4.5A). Analysis of biotinylation profile by
streptavidin western blot revealed stark differences in proteome complexity (Figure 4.5B). A nonclicked sample was included as a control for endogenously biotinylated proteins. The BA-clicked
sample had a few unique bands and more were visible in the PBA-clicked sample. The PC-clicked
sample exhibited the highest intensity and largest number of bands. Proteomic analysis of the
enriched fraction for PC and BA conditions paralleled the western blotting data. The number of
protein IDs in elution from PC-clicked was 660, of which 291 were identified in the BA-clicked
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sample (Figure 4.5C). Proteins with less than 2 peptide IDs are not considered bona fide hits; this
category constituted ~30% of the BA-click data set (Figure 4.5C, yellow). When compared to a
parallel non-clicked control, more than 60% of the BA-click ID’s were not enriched over the
negative control (Figure 4.5C, red). In contrast, the PC-clicked set contained more hits that were
enriched over the negative control (Figure 4.5C, blue), or were unique to the clicked condition
(Figure 4.5C, green), indicating higher data quality. The increased hydrophobicity and length of
the PC linker may explain the improved click-efficiency for this linker.

Figure 4.5: differential efficiency of click linkers.
A) chemical structure and calculated LogP (cLogP) values for (PEG)3 biotin azide (PBA), biotin azide (BA), and
photocleavable biotin azide (PC). B) streptavidin-HRP western blot analysis of trans-sterol-labeled proteomes after
click reaction to PBA, BA, or PC azides. L=ladder. C) mass spectrometry analysis of enriched trans-sterol-labeled
proteomes after click reaction to PC or BA azides. Protein ID categories: ≥ 2 peptides, <2-fold enrichment over noclick condition (red); 1 peptide, unique to click condition (yellow); ≥ 2 peptides, unique to click condition (green); ≥2
peptides, ≥ 2-fold enrichment over no-click condition (blue).
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4.2.5 Optimization of enrichment and elution conditions
Biotinylated protein is isolated from non-biotinylated protein through incubation of lysates
with streptavidin agarose beads (Figure 4.1E). In order to maximize enrichment-efficiency,
enrichment volume/vessel, enrichment duration, and bead volume were optimized using
biotinylated-BSA. Enrichment volume/vessel did not have a large impact on binding of
biotinylated BSA to beads (Figure 4.6A). Increasing the duration of protein and bead incubation
increased binding efficiency from ~40% at 2 h to ~50% at 4 h (Figure 4.6B). Despite designing
these experiments such that the biotinylated BSA concentration was below the bead binding
capacity, doubling the bead volume dramatically increased binding; only 10% remained unbound
after 4 h incubation. This bead volume and duration was selected as optimal.
Several elution methods were tested for their efficiency and included UV, dithionite, and
on-bead trypsin digestion (Figure 4.1F). The eluate from LKM38-labled enrichment fractions was
monitored for NPC1 by western blot in order to evaluate elution efficiency for UV and dithionite
methods (Figure 4.6C, D). Dithionite elution relies on biotin-azide linker MQ112 which is cleaved
when exposed to dithionite. Short incubations with dithionite did not efficiently release NPC1;
however, after 10 minutes of dithionite exposure, nearly all NPC1 had eluted from the beads and
little remaining NPC1 was detected when beads were heated in denaturing LSB buffer. UV elution
relies on biotin-azide linker PC-biotin which is cleaved when exposed to 345-368 nm light. UV
exposure to beads for 30 minutes in H2O yielded no NPC1 protein. However, strong NPC1 signal
was detected in the 1% SDS bead wash suggesting the initial UV exposure was effective, but NPC1
was not soluble in the water buffer. Subsequent UV exposures in 1% SDS buffer enabled recovery
of additional NPC1. Very little NPC1 remained associated with the agarose beads after 1.5 h total
UV exposure.
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Figure 4.6: optimization of bead enrichment and elution.
Biotinylated BSA was used in A and B to optimize enrichment conditions. A) equal amounts of protein and bead were
incubated in 1.5 mL Eppendorf tubes (1.5 total volume) or 15 mL conical tubes (6 mL total volume) for 2 h at room
temperature. B) equal amounts of protein and bead were incubated in 15 mL conical tubes at room temperature for
the time specified. * indicates bead amount was doubled. C) MQ112-clicked lysate was enriched to streptavidin beads
then eluted using dithionite (DT) cleavage. Whole lysate (input), or elution fractions from beads after consecutive DT
exposure for the specified times, were probed for NPC1 by western blot. D) PC-biotin-clicked lysate was enriched to
streptavidin beads then eluted using UV exposure. Whole lysate (input) and eluate from after consecutive UV exposure
under the specified conditions, were probed for NPC1 by western blot. E) Total protein (left) and biotinylated protein
(right) in whole lysate (input), pre-enrichment lysate (rcvd), UV-eluted, or LSB-eluted fractions using two different
UV-elution protocols (see methods). F) total protein recovered in elution fractions for methods A and B. G) total
protein recovered in elution fractions using method B when the standard or 1.5X amount of pre-enrichment lysate was
loaded to the beads.

UV elution was further optimized by measuring total protein in eluate and monitoring
protein and biotinylation using gel-based assays (Figure 4.6E-G). UV elution was performed as in
Figure 4.6D for “Protocol A” in Figure 4.6E. UV elution for “Protocol B” was performed in 1%
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SDS in PBS for 1 h at room temperature, followed by 1 h shaking at 37°C. UV elution by protocol
B increased the amount of protein in the eluate (Figure 4.6F). Identification of biotinylated proteins
in the UV-eluted fractions would be indicative of non-specific elution (no-cleavage required); this
was not observed for either condition (Figure 4.6E, right). The presence of biotinylated protein in
the LSB eluted fraction indicated some biotinylated proteins were still bound to the beads after
UV exposure. This proteome likely includes both endogenously biotinylated proteins (Figure 4.6E,
right, input) and probe-labeled proteins as many species were detectable. However, this was
minimized under “Protocol B.” Additional protein could be eluted (~2X more) if the amount of
labeled-lysate added to beads was increased 1.5-fold (Figure 4.6F), suggesting beads were not
saturated.

Figure 4.7: comparison of on-bead trypsin digestion (OB) and UV elution methods.
A: number of unique protein IDs in elution fractions from probe-labeled cells. After enrichment, samples were eluted
by on-bead trypsin digestion (OB) or UV exposure (UV). B: number of peptide spectral matches (PSMs) in OB or UV
samples. Peptides belonging to streptavidin (black) and trypsin (red) are indicted, the remaining are in grey. Both
U2OS-SRA (WT) and U2OS-SRAshNPC1 (shNPC1) cells were analyzed. Cells were labeled with LKM38 oleate loaded
in acLDL + lalistat-1, or with LKM38.

To assess the efficiency of on-bead trypsin digestion, proteins labeled with LKM38 were
isolated on bead then subjected to tryptic digestion before analysis by LC-MS/MS; UV-eluted
samples were prepared in parallel for comparison. Compared to UV-eluted samples, on-bead
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trypsin digested samples (OB) had fewer unique protein IDs (Figure 4.7A). Streptavidin accounted
for ~80% of the peptide spectral matches (PSMs) in OB samples, while in UV-samples,
streptavidin made up an average of 4% (Figure 4.7B). The high abundance of streptavidin peptides
in the OB is likely responsible for the decreased quality of the OB proteomes. UV elution is
recommended to minimize this effect.

4.2.6 Data acquisition
Due to efficiency and analysis benefits, multiplexed relative quantification approaches are
an attractive strategy for analysis of the multipoint time courses described in this chapter. Tandemmass-tag (TMT) and isotopic tags for relative and absolute quantification (ITRAQ) reagents allow
parallel samples to be multiplexed, enabling relative quantification between multiplexed samples,
and minimizing instrument run time. These protocols are designed for 100’s of µg of protein.
Using our approach, maximal yields reach no more than 50 µg. Scaling down the ITRAQ kit for
10’s of µg of protein was unsuccessful; very little peptide could be recovered for mass
spectrometry analysis (data not shown). Isotopic labeling is unlikely to be a useful quantification
strategy for these time course experiments. Spike-in of a non-human protein (such as GFP or
bacterial alcohol dehydrogenase) could serve as an alternative approach for quantification;
however, samples cannot be multiplexed using this method. Label-free quantitation approaches
are additional, non-multiplexable options.
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4.3 Discussion
Crosslink and click proteomics is a powerful tool for the analysis of probe interactomes. In
order to use this approach to specifically target the post-lysosomal cholesterol interactome, we
developed a probe-loading strategy that utilized reconstituted lipoprotein particles and a LALblocking approach. The labeled proteome under block and no-block conditions fits well with other
biochemical evidence that the cellular localization of probe can be controlled and used to study
post-lysosomal cholesterol trafficking using this approach.
Cholesterol is a hydrophobic substrate that is known to interact with transmembrane
protein regions (CRAC and sterol sensing domain motifs) and hydrophobic binding pockets in
soluble proteins (StAR and ORP families). Accordingly, nearly all proteins identified in the
LKM38 data set were associated with the “membrane” cellular component GO term. While several
established cholesterol binding proteins (i.e., NPC1, NPC2, caveolin) were identified in the data
set, others, such as ORP and StAR family members were not. It is possible that LKM38 does not
bind these proteins, binds but does not label, or that the interaction is too transient to label enough
protein to be detectable. The nature of the absence of these proteins from the labeled proteome
warrants further investigation, as some of these issues can be resolved by using additional diazirine
alkyne probes (i.e., MQ182, MQ238) or by increasing elution yield by increasing input or further
optimizing the enrichment protocol.
Acknowledging the hydrophobic nature of the labeled proteome was essential for designing
this protocol and may be an important consideration for further optimization. We observed that
azides with low cLogP values and short-linkers had poor click efficiency and efficient UV elution
of multi-pass transmembrane protein, NPC1, required SDS. Trypsin digestion was performed
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under denaturing conditions (urea/SDS) so that hydrophobic regions could be accessed during
digestion. Interestingly, sodium deoxycholate has been used to enhance hydrophobic protein
digestion by denaturing proteins and increasing trypsin activity (114). Alternative detergents could
also improve the accessibility of the biotin linker for binding to the streptavidin beads during the
enrichment step. These additional parameters could be investigated for increasing the quality and
coverage of labeled proteomes but must be carefully adjusted and considered so as to minimize
sampling bias.
Despite efforts to maximize recovery of probe-bound material, low yields precluded use of
isobaric labeling strategies. However, increased efficiency at several steps was achieved.
Decreased UV output for crosslinking after repeated UV exposure (required for time-course
experiments) was resolved by acquiring additional UV bulb sets. Increasing bead volume and
enrichment duration increased enrichment efficiency. Switching PC biotin azide for biotin-azide
(BA) allowed for the identification of more proteins, generated a higher quality interactome
library, and enabled UV elution, which was found to be superior to on-bead digestion as an elution
strategy. Of note, MQ112 paired with dithionite elution, may also be effective but requires
additional characterization. In order to maximize probe uptake, ectopic SRA-based uptake was
utilized instead of a native LDLR-based method which would be downregulated in response to
sterol loading. While not directly compared, it is still unlikely that acLDL-based delivery is a more
efficient than cyclodextrin-based probe delivery. In contrast to a cyclodextrin-based delivery
method, the amount of probe deliverable to cells is limited by the uptake capacity. This factor, in
addition to purposeful spatial restriction of probe, likely limits the amount of probe-bound
material.
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In summary, I have described a method for the study of post-lysosomal cholesterol
trafficking using diazirine alkyne probes. While partially optimized, parts of the protocol could
still be modified in order to maximize yield and data quality and have been outlined. By following
a lysosome-derived pool of probe, this approach could be a powerful tool for identifying the postlysosomal cholesterol trafficking network.

4.4 Methods
4.4.1 Cell culture
NSF fibroblasts, U2OS-SRA, and U2OS-SRAshNPC1 cells were cultured as described (76,
77). U2OS cells were cultured identically to U2OS-SRA cells except that G418 was omitted from
the media. RAW 264.7 macrophages were cultured in 10% FBS in DMEM; 2mM L-glutamine
was added to the medium. Cholesterol starvation media was previously described (76).

4.4.2 LDL reconstitution
LDL or acLDL was reconstituted with cholesteryl linoleate (CE 18:2) or d7-cholesteryl
oleate (d7 CE 18:1) as specified. A step-wise protocol for LDL reconstitution is in Appendix B.

4.4.3 Biochemical trafficking assays
Cells were loaded overnight with LDL or acLDL reconstituted with cholesteryl ester. For
cell type comparisons, cells were cholesterol starved by statin-incubation to deplete native
cholesteryl linoleate prior to lipoprotein cholesteryl ester loading. Cholesteryl linoleate was
administered in LDL or acLDL in the presence of 10 µg/mL progesterone. For progesterone vs.
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lalistat and lalistat titration experiments, cells were loaded with d7-cholesteryl oleate in acLDL.
Cholesterol oxidase assay and cholesteryl ester quantification were performed as described (77).

4.4.4 HA-NPC2 binding assays
HA-NPC2 binding assays were performed as described previously (76).

4.4.5 GO enrichment analysis
The Panther GO analysis tool was used to evaluate GO-term association for probe-enriched
data sets (http://www.pantherdb.org/). Protein ID’s were included in the analysis if they had >1
unique peptide and were enriched > 2-fold (based on intensity) over a parallel non-clicked sample.
The IDs were further sorted according to their enrichment over the opposing condition: an ID was
considered enriched in the blocked condition if the intensity was > 2-fold that of the unblocked
condition and vice versa. A statistical overrepresentation test (Fisher’s Exact) for “GO cellular
component complete” was performed using the Homo sapiens gene list as a reference. P-values
displayed are FDR corrected. Complete GO term lists, sorted by p-value, are available in Appendix
A.

4.4.6 Measuring UV output
UVA/B output was measured using a Sper Scientific UVA/B Light Meter. To test
individual bulbs, the bulb was inserted in the rear-most position with the meter was placed atop a
5 cm riser beneath it. UV bulbs were turned on for 3 minutes before UV output value was recorded
in order to allow bulbs to equilibrate. To test complete bulb sets, the meter was placed in the middle
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of the Stratalinker atop a 5 cm riser or directly on the bottom surface of the Stratalinker as specified.
Average UV output was measured every 30 seconds for 5 minutes; the middle 6 data points are
displayed (1.5-4 minutes).

4.4.7 IP optimization with biotinylated BSA
A 600 µg/mL solution of biotinylated-BSA was prepared in 0.2% SDS. 900 µg protein was
added to each washed bead set. This protein amount was selected because it is below the binding
capacity of the beads (10 mg/mL resin) and within range for BCA assay. If IP was performed in
15mL conical, the volume was adjusted to 6 mL using 0.2% SDS. BSA and bead mixture was
rotated end-over-end for specified time. Remaining BSA in the flow-through was determined by
BCA assay.

4.4.8 Bead elution
For all elution protocols, protein-loaded beads were transferred to PierceTM spin columns
(ThermoFisher, 69705), columns were plugged during elution incubations. To separate eluate from
beads, spin columns were centrifuged; eluate was collected in a clean Eppendorf tube. For
dithionite elution, protein-loaded beads were incubated in a 25 mM dithionite, 0.1% triton, 150
mM NaCl, 50 mM tris pH 7.4 for the amount of time specified. For PC elution, protein-loaded
beads were resuspended in H2O, TNS (50 mM tris, 150 mM NaCl, 1% SDS, pH 8), or 1% SDS in
PBS, shaking at 1100 rpm for the time specified. Protocol A: beads in H2O with 30-minute UV
irradiation followed by TNS wash. Protocol B: beads in 1% SDS in PBS for 60-minute UV
irradiation followed by 60-minutes shaking at 37°C. Although LSB elution is incompatible with
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down-stream proteomic analysis, it was used to determine how much protein was still bound to
beads.

4.4.9 Gel-based analyses of LKM38 interactomes
Protein input, flow-through, or elution fractions were incubated in LSB for 10 minutes at
37°C. Lysate was separated by SDS-PAGE. For western blotting, proteins were transferred to
nitrocellulose, and membrane was probed for the epitope of interest. To detect NPC1, an in-house
antibody was used at 1:2000 in 5% milk/TBS-T (99). To detect biotinylation, streptavidin-HRP
was diluted 1:10,000 in 1% BSA/TBS-T (Abcam, Ab7403). To detect total protein, a parallel gel
was fixed and stained with SYPROTM Ruby Protein Gel Stain (ThermoFisher, S12000) according
to the manufacturers protocol.

4.4.10 Post-lysosomal cholesterol trafficking proteomics
A step-wise protocol for labeling, enrichment, and elution of proteins is in Appendix C.

4.4.11 Trypsin digestion
Beads, in a plugged spin-column, were resuspended in 200 µL buffer containing 25 mM
TEAB (ITRAQ dissolution buffer) or NH4HCO3, with 2 M urea and 1 mM CaCl2. 2 µg sequencing
grade trypsin was added to each bead set and incubated at 37ºC overnight. The spin-column was
unplugged and placed in a fresh Eppendorf tube then spun by microfuge to collect peptides. 100
µL PBS was added to the beads to release remaining peptides from the beads.
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4.4.12 Data acquisition
Proteomic data was collected by the laboratories of Jason Held (Jessica Behring) at
Washington University in St. Louis, and Stephanie Cologna (Melissa Pergande) at University of
Illinois-Chicago.
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Chapter 5 – High-content screen for
modifiers of Niemann-Pick type C
disease in patient cells
5.1 Preamble
This research was originally published in Human and Molecular Genetics. E Pugach, M
Feltes, Randal Kaufman, DS Ory, AG Bang. High-content screen for modifiers of Niemann-Pick
type C disease in patient cells. Human Molecular Genetics. 2018; 27(12):2101-2112. © the
Authors.
This project was initiated by AG Bang and E Pugach. The Bang laboratory developed the
imaging platform and identified alexidine as cholesterol-reducing agent in NPC1-deficient cells.
Our expertise was sought in order to further characterize the cellular biology affected by drug
treatment. Under the mentorship of DS Ory, I designed experiments and collected and analyzed
data for Figures 3C,D and Figure 5A-E. These critical experiments provide evidence that alexidine
increases NPC1 expression and consequently the amount of mature NPC1 and that alexidine
treatment causes increased cholesterol esterification. For Figure 4, I grew and treated cells which
were analyzed by E Pugach, in order to evaluate the dependence of alexidine cholesterol-reduction
on NPC1 and NPC2 proteins. In writing the manuscript, I prepared text (results, legends, methods)
for the figures I contributed and provided additional support as an editor for the rest of the
manuscript.
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5.2 Introduction
NPC disease (OMIM #257220 and #607625) is a rare [incidence ranging from ~1: 89 000
based on projections (115), to 1:120,000 live births based on clinical observations (44)] fatal
neurodegenerative lysosomal storage disease that can manifest from infancy to adulthood
depending on the genetic lesion (44, 116). There are no FDA-approved treatments for NPC, though
limited efficacy has been shown for miglustat, a glycosphingolipid synthesis inhibitor, which is
approved for use outside the United States. The majority of NPC cases are caused by mutations in
NPC1, the gene encoding the transmembrane lysosomal protein NPC1, while a small subset (<5%)
are caused by mutations in the NPC2 gene that encodes a luminal lysosomal protein (44). Both
genes encode proteins that are critical for cholesterol egress from lysosomes, though the exact role
for each protein in cholesterol transport is not completely understood (117). While the hallmark of
NPC is lysosomal cholesterol accumulation, disease severity depends on the type and position of
the mutations in NPC1, as well as the genetic background of the individual (118-120). Most NPC
patients have compound heterozygous NPC1 mutations, and the most common mutation,
I1061T

NPC1

, typically leads to a juvenile disease onset and results in a misfolded protein that is

rapidly degraded by the proteostasis machinery (45, 46, 118).
Previous studies identified HDAC inhibitors (HDACi) as negative modulators of
lysosomal cholesterol storage (121), possibly through modulation of the proteostasis machinery
(121). Early-stage clinical investigation of the HDACi, vorinostat (SAHA) is currently underway.
Another drug proposed to modulate proteostasis, arimoclomol, is being tested in a phase III clinical
trial for treatment of NPC1 patients (57). Finally, the cholesterol-reducing agent, CD, has shown
efficacy in treatment of NPC1 patients a phase 1/2a trial (122), and is now in a pivotal phase 3
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trial. Though promising, each therapy is associated with distinct off-target or adverse side effects,
or limited blood–brain barrier permeability (123-125), the latter requiring direct delivery into the
central nervous system (63, 122). Further, although HDACi and arimoclomol are hypothesized to
modulate the general chaperone machinery (121), neither of these drugs nor CD directly addresses
the protein misfolding defect present in the majority of NPC patients harboring missense mutations
(93). Thus, there remains an unmet clinical need for more specific therapies that target the
underlying molecular defect.
A number of large-scale compound screens designed to identify an effective NPC
therapeutic have been reported. Screening strategies have varied. Early attempts utilized automated
microscopy of NPC1 mutant CHO cells stained with the fluorescent cholesterol dye, filipin (126,
127), while more recent screens have used fluorescent plate reader-based assays on patient-derived
fibroblasts in conjunction with the acidophilic dye, lysotracker, to label acidic organelles such as
late endosomes and lysosomes (128). Lysotracker staining is increased in both NPC patient
fibroblasts and fibroblasts from other lysosomal storage disease patients relative to fibroblasts
from healthy individuals, making it a useful screening reagent (128). Still others have utilized
mutant cells from an Npc1 knockout mouse model (129). However, none of the previously
described screens has considered lysosomal cholesterol content in NPC patient cells as a first-tier
screen in a high-content fluorescent microscopy assay.
By examining both cholesterol content and lysosomes in patient cells using the dual
markers filipin and anti-LAMP1, a lysosome/late endosome-specific marker, increased specificity
is achieved. Moreover, a high-content phenotypic assay in patient-derived cells improves clinical
relevance and reveals information about cell health and viability in response to test compounds,
and has increased sensitivity and power compared to plate reader-based assays. In this report, we
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describe a high-content screen, based on filipin and LAMP1 readouts, of NPC patient fibroblasts.
NPC patient fibroblasts homozygous for the most common NPC1 mutation, NPC1I1061T (45, 118)
were selected as a cell source given the prevalence of the mutation, the moderate degree of
lysosomal cholesterol accumulation, and the potential to correct the protein misfolding phenotype
with a proteostasis modulator (46). Using this assay, we screened 3532 small molecules, primarily
FDA-approved drugs and well-characterized tool compounds that modulate known targets,
affording opportunities for drug repurposing, and identification of specific molecular pathways
and targets that impact the cellular phenotype. Among the hits identified were previously described
modulators of NPC cholesterol accumulation as well as novel modulators.

5.3 Results
5.3.1 Development of a high-content image-based assay for lysosomal
cholesterol accumulation in NPC patient cells
To develop a miniaturized high-content image-based assay in 384-well plates for
monitoring lysosomal cholesterol accumulation, a panel of control and NPC patient cells
representing a range of NPC1 genotypes was assembled (Table 5.1). These included fibroblasts
from two patients homozygous for the most common NPC mutation, NPC1I1061T (45, 118) and a
severely affected patient with a compound heterozygous mutation (NPC1E612D/542fsX) (116). We
first sought to validate the sensitivity and relevance of our assays by confirming the cellular
phenotypes of the control and NPC patient cells. In addition, we aimed to determine the extent to
which genotype and clinical phenotype correlate with cellular phenotype in our proposed system
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and the dynamic range of our assay. To that end, NPC patient lines, and two control fibroblast
lines from unaffected individuals, were cultured in 384-well imaging plates, and characterized in
parallel for cholesterol content, with the naturally fluorescent polyene antibiotic, filipin (127) and
for lysosomes with lysotracker dye or by LAMP1 immunofluorescence as described in
Supplementary Material, Figure S1.
Table 5.1: Genotype of patient cells included in the study
(NPC1 RefSeq cDNA NM_000271.4, NPC2 RefSeq cDNA NM_006432.3, genomic DNA NG_007117.1)
Patient Cells

NPC1 Allele 1

NPC1 Allele 2

GM18453 (NPC1I1061T/I1061T)

c.3182 T>C (p.I1061T)

c.3182 T>C (p.I1061T)

GM18417 (NPC1I1061T/I1061T)

c.3182 T>C (p.I1061T)

c.3182 T>C (p.I1061T)

c.1836A>C (p.E612D)

c.1628delC (p.F542fsX)

NPC1 Null (NPC1-/-)

c.1628delC (p.F542fsX)

c.1628delC (p.F542fsX)

Patient Cells

NPC2 Allele 1

NPC2 Allele 2

NPC2 Null (NPC2-/-)

c.IVS2+5G→A (c.190+5G>A) (p.0)

c.IVS2+5G→A (c.190+5G>A) (p.0)

E612D/542fsX

GM18436 (NPC1

)

We observed a clear phenotypic spectrum for cholesterol content and lysosomal staining
(Figure 5.1). As observed in the literature (128), NPC1 patient cells had increased lysosomal
signal, as inferred from LAMP1 staining, and cholesterol accumulation, based on filipin, compared
with control cells, with GM18436 NPC1E612D/542fsX patient cells exhibiting higher levels than
NPC1I1061T cells (Figure 5.1). Notably, of the two fibroblast lines, GM18453 and GM18417, which
harbor identical NPC1 mutations (NPC1I1061T/I1061T), GM18453 had a more pronounced phenotype
(Figure 5.1). Likewise, we observed variations in both filipin and lysotracker for control lines
(Figure 5.1), underscoring the importance of examining multiple patient and control lines, as
modifier genes and epigenetic factors can impact phenotypes (118-120). Of the two NPC1I1061T
patient lines, GM18453, which exhibited a stronger lysosomal cholesterol phenotype, was selected
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for further assay development and screening with the expectation that it should be amenable to
rescue by proteostatic regulators as well as other molecular modulators.

Figure 5.1: (A, B) Cholesterol accumulation and (A, C) lysosomes in control and NPC patient fibroblasts.
Cholesterol content was assessed using the naturally fluorescent antibiotic, filipin [3]. Lysosomal morphology (size,
distribution) was assessed using lysotracker-red. 20× magnification. Scale bar = 50 µm. Error bars: Mean ± SD, n = 3
wells/condition.*P < 0.05 versus Control I, **P < 0.01 versus Control I, $P < 0.05 versus Control II, one-way ANOVA
followed by Tukey’s test.

HDACi are capable of ameliorating NPC patient cell lysosomal cholesterol storage,
possibly through regulation of the proteostasis machinery (121). We tested the potent HDACi,
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trichostatin A (TSA) and panobinostat (Pb, LBH589) in our assay and found a robust reduction in
lysosomal cholesterol content following 72 h treatment (Supplementary Material, Fig. S2A and
B). HDACi treatment led to a reduction in cell number compared to DMSO-treated cells, likely
due to both cytotoxicity and anti-proliferative effects of HDACi (130), but remaining cells
appeared healthy according to nuclear parameters (Supplementary Material, Fig. S2C and D and
data not shown). Taken together these data suggest that HDACi’s effects on lysosomal cholesterol
are separable from its cytotoxicity. SSMD (strictly standardized mean difference) and Z0 values
for screening were found to be acceptable for screening (131), with panobinostat exhibiting the
most robust and reproducible effect on both filipin and LAMP1 immunofluorescence staining
(Supplementary Material, Fig. S2A and B). Both SSMD and Z0 values provide information
regarding effect size in screens; however, SSMD is more suitable for assessing quality control for
strong or moderate effect differences compared to Z0, which is better suited to extremely strong
effect differences (132). Therefore, SSMD was employed going forward for quality control
assessment. Based on these results, GM18453 (NPC1I1061T/I101T) patient fibroblasts and the control
compound, panobinostat, were selected for a subsequent pilot screen.
To test the robustness of our assay on a smaller scale before screening a larger library, and
to determine optimal timing of compound exposure, we performed a pilot screen of a kinase
inhibitor library comprised of 327 well-annotated small molecule kinase inhibitors. The library
was screened in duplicate at 5 µM, with 32 positive control wells and 32 negative control wells
per plate (16 wells per side of plate). Parallel experiments were run at 48 and 72 h of exposure to
compound. Although statistically significant decreases in both filipin and LAMP1 were observed
at 48 h (Supplementary Material, Fig. S3), SSMD values were greater at 72 h (for filipin: 48 h,
SSMD 1⁄4 –1.45, 72 h SSMD 1⁄4 –3.04). Of 327 compounds tested, 13 (4.0%) were cytotoxic
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based on cell counts. A compound was considered cytotoxic at a Z-score ≤ – 5 for number of
nuclei. A Z-score of – 5 was chosen based on average Z-scores for the positive control,
panobinostat, since HDACi are known to exhibit cytotoxic and anti- proliferative effects (130).
Compounds were then filtered for hits that reduced filipin and LAMP1 without drastically
affecting nuclear roundness (duplicate Z-score ≤ 3.5), intensity (– 2.0 ≤ duplicate Z-score ≥ 2.0),
or size (duplicate Z-score ≥ – 2.0). A Z-score threshold of – 2.0 was initially selected in order to
identify compounds that fall outside of 95% of results in a normal distribution. This cut-off was
then adjusted (e.g. nuclear roundness) to increase the number of hits for further characterization.
Table 5.2: Summary of libraries screened and plate statistics
Library
SSMD SSMD CV CV
FLP
Compounds
Name
FLP LAMP1 FLP LAMP1 Hits
FDA
2,013
-3.29 -3.46
5.37 6.58
32
Repurposing
Kinase
320
-3.04 -1.61
5.43 7.23
50
Inhibitor
Human
Metabolite

LAMP1 Dual Cherry
Confirmed Hits
Hits
Hits Picked
SAHA (x2),
47
18 18
3
alexidine
10

3

2

1

TWS-119

761

-2.07 -3.45

14.92 4.77

35

47

3

3

0

n/a

Metabolism 117

-4.05 -3.55

3.35 6.65

1

5

1

1

1

ChoKα inhibitor

Epigenetic

261

-4.28 -5.25

4.58 3.80

53

44

29

29

16

Chaperone

45

-3.50 -2.49

3.95 4.45

2

2

2

2

2

14 HDACia,
JFD00244 ,
Danusertib
Thapsigargin,
SAHA

TOTAL
3,524
173 155
56 55
23
AVERAGE
-3.15 -3.39
7.11 5.89
SSMD, strictly standardized mean difference; CV, coefficient of variation.
a
HDACi: scriptaid, belinostat (PXD101), trichostatin A, HDACi III (M-344), oxamflatin, SAHA, BML-281, AR-42,
CUDC-101, pracinostat (SB939), 4-iodo-SAHA, HC toxin, coumarin-SAHA, pyroxamide.

Of the remaining non-toxic compounds, 50/327 (15.3%) decreased filipin (duplicate Zscore ≤ –2) at 72 h, and 10/327 (3.1%) decreased LAMP1 (Z-score < – 2.5 singleton as no
compounds decreased LAMP1 in duplicate) but only four (1.2%) decreased both LAMP1 and
filipin. These four represented three unique compounds: staurosporine (duplicate compounds were
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present in the library), the GSK3b inhibitor TWS-119, and MK-2 Inhibitor III (Table 5.2,
Supplementary Material, Fig. S4 and data not shown). Thus, having demonstrated in our pilot
screen that using filipin and LAMP1 as multiplexed readouts was an efficient approach that aided
in hit detection and classification, we extended our screening efforts to larger compound
collections described below.

Figure 5.2: Alexidine treatment reduces lysosomal cholesterol accumulation.
(A) Representative images of GM18453 NPC1I1061T/I1061T patient fibroblasts plated and treated 24 h later with DMSO
or alexidine at indicated concentrations. Cells were fixed and stained with filipin, LAMP1 and Draq5 72 h after
treatment. (B) Dose–response curves for alexidine-treated GM18453 patient fibroblasts. (C) Dose–response curves
for nuclear parameters for alexidine-treated GM18453 patient fibroblasts. (D) Dose–response curve for cell area
parameters for alexidine-treated GM18453 patient fibroblasts. Scale bar = 50 µm.
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5.3.2 High-content screen for modifiers of lysosomal cholesterol in NPC patient
cells
In an effort to identify a clinically tractable mediator of lysosomal cholesterol storage in
NPC patient cells, a library of 2013 FDA-approved compounds was screened in duplicate using
the dual LAMP1/filipin assay. In addition, we screened our assay against a collection of 260
compounds with epigenetic activity, 45 compounds with proteostatic activity, 760 human
metabolites (133) and 127 compounds that target metabolic pathways (Table 5.2). Due to
redundancy in the libraries, in total 3248 unique compounds were screened (Supplementary
Material, Table S1). Average SSMD between DMSO and panobinostat-treated groups were – 3.15
(filipin) and – 3.39 (LAMP1) (134). Average coefficient of variation (CV) for DMSO and
panobinostat-treated groups were 7.11% (filipin) and 5.89% (LAMP1) (Table 5.2).
Seventy-five (2.1%) compounds were cytotoxic based on number of nuclei. Our criterion
for hit selection was Z-score- ≤ – 2 in duplicate for both filipin and LAMP1 staining intensity. For
initial hit selection, we considered compounds with evidence of cytotoxicity (either by nuclei
number or morphology) given the high concentration at which compounds were screened and the
small number of hits. From the primary screen, 171 compounds decreased filipin and 160
compounds decreased LAMP1 (Table 5.2, Supplementary Material, Table S1). Only 47 filipin hits
(27%) were also LAMP1 hits (Table 5.2), an overall hit rate of 1.3%. The observed difference
between filipin and LAMP1 hits may be related to differential flux rates for LAMP1 protein and
cholesterol. Three of the 47 hits with decreases in both LAMP1 and filipin were cytotoxic based
on number of nuclei. However, decreased lysosomal cholesterol was not generally correlated with
cytotoxicity, as 68/75 (91%) of the cytotoxic compounds we identified did not exhibit decreases
in both LAMP1 and filipin. Dose–response studies identified one compound, alexidine
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dihydrochloride (alexidine) as having dose-dependent activity, with half-maximal inhibitory
concentrations (IC50) of 4.3 µM or 6.36 µM for LAMP1 and filipin readouts, respectively (Figure
5.2A and B). Although alexidine was cytotoxic at the original dose screened (5 µM), its effect on
lysosomal cholesterol storage was separable from cytotoxicity as indicated by nuclear measures
(Figure 5.2C) and cell area (Figure 5.2D). Consistent with other reports (135), we did not identify
any of the six statins included in our repurposing library as hits (Supplementary Material, Fig. S5).

5.3.3 Alexidine is a novel enhancer of lysosomal cholesterol release through
upregulation of NPC1- and NPC2-dependent and -independent pathways
Alexidine was then tested in secondary assays to determine whether the compound directly
affected NPC1 expression. Western blot analysis revealed a ~3-fold increase in NPC1 protein
expression following 72 h treatment in both control and NPC1 mutant cells (NPC1I1061T/I1061T)
(Figure 5.3A and B). We did not observe an increase in NPC1 protein expression following 72 h
HDACi (panobinostat) treatment (Figure 5.3A and B), although HDACi treatment was effective
as evidenced by robust induction of acetylated tubulin (Figure 5.3C).
NPC1I1061T missense mutation leads to rapid proteasomal degradation of immature NPC1
(46). Forced expression of NPC1-mutant protein allows some protein to escape the degradation
pathway, resulting in increased delivery of mature, fully glycosylated mutant protein to the
endosome/lysosome where NPC1 functions in lysosomal cholesterol trafficking (46). To assess
the maturity of the increased NPC1 protein following alexidine treatment (Figure 5.3A and B), we
performed Endoglycosidase H (EndoH) digestion to remove immature N-linked glycan residues.
Resistance to EndoH is indicative of protein trafficking beyond the ER in the secretory pathway.
EndoH digestion revealed a dose-dependent increase in both EndoH-sensitive (immature) and
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EndoH-resistant (mature) NPC1 populations in alexidine-treated NPC1I1061T/I1061T fibroblasts, as
well as an increase in EndoH-resistant NPC1 in alexidine-treated control fibroblasts (Figure 5.3C
and D).

Figure 5.3: Alexidine treatment induces NPC1 expression.
(A) Western blot following 72 h drug treatment in fibroblasts from indicated genotypes, Anti-acetylated tubulin
demonstrates appropriate HDACi activity. (B) Quantification of (A), n = 3 biological replicates, mean ± SD,
****P < 0.0001 one-way ANOVA followed by Tukey’s test. (C, D) EndoH digestion of NPC1 reveals an increase in
both mature and immature NPC1 following alexidine treatment. NPC1I1061T/I1061T (C) or normal human fibroblasts (D)
were plated and treated 24 h later with DMSO or alexidine. After 72 h, cells were harvested then subjected to Endo
Hf or vehicle treatment. Western blot and normalized quantification for NPC1 in mutant (C) and normal (D) cell
lysates. Open triangles mark Endo Hf resistant (Endo HR) species. Closed triangles mark Endo Hf sensitive (Endo
HS) species. ****P < 0.0001, ***P < 0.001, **P < 0.01 versus glycospecies matched DMSO, two-way ANOVA
followed by Dunnett’s test. (E) NPC1 expression by TaqMan qRT-PCR in indicated cell lines following 48 h drug
treatment. n = 3 biological replicates, mean ± SD, ****P < 0.0001 versus DMSO, $versus Control alexidine two-way
ANOVA followed by Dunnett’s test.
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qRT-PCR analysis of NPC1 transcript expression revealed that the alexidine-mediated
change in NPC1 protein expression was accompanied by NPC1 gene expression changes (Figure
5.3E). NPC1 transcript abundance was similar in vehicle-treated cells from control and mutant
NPC1 cell lines, a finding that is in agreement with previously published studies (46).

Figure 5.4: NPC1/2 expression correlates with degree of alexidine-induced lysosomal cholesterol reduction.
(A) Control, patient NPC1I1061T/I1061T, NPC1−/− and NPC2−/− fibroblasts were treated with DMSO (0.05%), 122 nm
alexidine, or 1.1 µm alexidine for 72 h and then fixed, stained with filipin and anti-LAMP1 and imaged. Quantification
of filipin (A) and LAMP1 (B) and representative images of treated cells (C). Scale bar = 50 µM. Bars: mean ± SD,
n = 4 wells/condition, ****P < 0.0001, ***P < 0.001, **P < 0.01 versus genotype-matched DMSO, alexidine two-way
ANOVA followed by Dunnett’s test.
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To determine whether alexidine acts in an NPC1- or NPC2- dependent manner, alexidinemediated reduction of lysosomal cholesterol was next tested in control cells, and null mutant
NPC1-/- and NPC2-/- cells (Table 5.1). Alexidine-reduced lysosomal cholesterol in control cells
to a similar extent to NPC1I1061T/I1061T patient cells, and to a lesser extent in NPC1-/- and NPC2-/cells (e.g. reduction in LAMP1 DMSO versus alexidine: control 40%, NPC1I1061T/I1061T 31%,
NPC1-/- 15%, NPC2-/- 20%) (Figure 5.4A–C). At the concentrations tested, alexidine was not
cytotoxic, based on cell number, providing further evidence that alexidine’s effects on lysosomal
cholesterol can be separated from its cytoxicity (Supplementary Material, Fig. S6). Thus, alexidine
enhances both NPC1- and NPC2-dependent and -independent cholesterol release.
Finally, in an effort to understand the functional consequences of the observed alexidinemediated NPC1 gene and protein expression changes, we performed LDL-stimulated cholesterol
esterification assessments in alexidine-treated control and patient cells. To directly analyze the fate
of lysosomal cholesterol, LDL was reconstituted with deuterated cholesteryl ester. We found an
increase in esterification of LDL-derived cholesterol in NPC1I1061T/I1061T patient cells treated with
alexidine (Figure 5.5A–E). Increased esterification of non-deuterated cholesterol was also
observed, suggesting trafficking of non-LDL-derived cholesterol to the ER was also enhanced.
These data provide direct evidence for improved lysosomal cholesterol export following alexidine
treatment. In support of this interpretation, we also found corresponding changes in gene
expression related to improved cholesterol trafficking (Figure 5.5F–H). We assayed by qRT-PCR
expression of several genes known to be modulated by cholesterol movement from the lysosome.
Alexidine reduced expression of SREBP-2-dependent targets like the cholesterol uptake
transporter, LDLR and the cholesterol biosynthetic gene, HMGCR (136), similar to HDACi
treatment in both control and patient cells (Figure 5.5F and G). In addition, expression of the LXR88

dependent cholesterol export gene, ABCA1 (137), was induced in alexidine-treated control and
patient cells (Figure 5.5H).

Figure 5.5: Alexidine treatment stimulates esterification of lysosomal cholesterol.
NPC1I1061T/I1061T fibroblasts were plated and treated 24 h later with lipoprotein-deficient media containing 50 µg/mL
LDL reconstituted with d7-cholesteryl oleate. After 72 h growth, cells were re-plated, then treated with alexidine or
vehicle in media containing d9-oleate for 24 h. Cells were harvested and prepared for LC-MS/MS. (A) Experimental
work flow. (B, C) Cholesteryl esterification paradigms and cholesteryl-ester deuteration status in cells during the
loading (B) and treatment (C) phase of the ER cholesterol trafficking assay. (D) Relative levels of d16-cholesteryl
oleate and (E) d9-cholesteryl oleate after 24 h in DMSO, or alexidine-containing media. Values are normalized to
total protein. Bars: mean ± SD, n = 3 wells/condition, ****P < 0.0001 versus DMSO, one-way ANOVA followed by
Dunnett’s test. (F–H) Alexidine treatment modifies expression of cholesterol flux genes. Gene expression by TaqMan
qRT-PCR in indicated cell lines following 48 h alexidine (3 µm) treatment. n = 3 biological replicates, mean ± SD,
****P < 0.0001, **P < 0.01, *P < 0.05 versus genotype-DMSO (two-way ANOVA followed by Dunnett’s test).
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5.4 Discussion
We developed a phenotypic NPC patient cell-based assay for inhibitors of lysosomal
cholesterol, employing tandem use of filipin and LAMP1 assays which aided in hit selection (Table
5.2) without substantially increasing assay time or labor input for this focused screen. We tested
this assay in multiple control and patient lines and demonstrated in a high-throughput screen its
utility for reproducibly identifying compounds that modulate levels of lysosomal cholesterol,
including a novel lysosomal cholesterol-reducing molecule, alexidine.
Alexidine is an antibacterial bisbiguanide found in antimicrobial mouthwashes and contact
lens solutions. Alexidine binds to bacterial lipopolysaccharides (LPS) and phospholipids and
disrupts membranes by producing lipid phase separation and domain formation (138, 139). In
addition, alexidine has been demonstrated to affect metabolism in hematopoietic stem cells
through activation of AMPK (140). Our data indicate that alexidine affects multiple cellular and
molecular processes in control and NPC patient fibroblasts to reduce lysosomal cholesterol.
Alexidine induces transcription of NPC1 (Figure 5.3E) and in turn increases total NPC1 protein
(Figure 5.3A and B) as well as mature, EndoH-resistant NPC1 protein glycoforms (Figure 5.3C
and D). Increased mature NPC1 likely helps facilitate lysosomal cholesterol export (Figure 5.5A–
E), especially in NPC1I1061T patient cells where misfolded NPC1I1061T is rapidly degraded in the
ER prior to processing in the Golgi and trafficking to the lysosome (46).
Not only does alexidine increase NPC1 expression, but it also affects expression of genes
critical for cholesterol flux. Alexidine inhibits expression of SREBP-2 targets that regulate
cholesterol uptake and biosynthesis (136) while inducing expression of a key LXR target that
regulates cholesterol export (137) (Figure 5.5F–H). Alexidine may directly affect expression of
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cholesterol flux genes. More likely, these gene expression changes may result from the alexidinemediated improvement in cholesterol trafficking in NPC patient cells, promoting increased
cholesterol trafficking to mitochondria and conversion of cholesterol to oxysterol LXR ligands.
The latter mechanism could explain the NPC1- and NPC2-independent reduction in lysosomal
cholesterol observed in NPC1-/- and NPC2-/- cells. It is also possible that the NPC1/2-independent
effect of alexidine on cholesterol storage may be mediated through activation of AMPK (69, 140).
Although alexidine demonstrated efficacy in NPC1-/- and NPC2-/- cells, the effect on lysosomal
cholesterol reduction was blunted compared with control or NPC1I1061T cells (Figure 5.4),
suggesting that both NPC1 and NPC2 are required for full alexidine efficacy.
Forced overexpression of NPC1 was reported to contribute to phenotypic improvement in
NPC1I1061T patient cells. It has been noted, for example, that transfection with an NPC1I1061T DNA
construct is sufficient to rescue NPC1-mutant cells by forcing an adequate amount of mutant NPC1
to bypass the ER proteostasis control machinery (46). Since we observed a similar effect on
lysosomal cholesterol accumulation in control cells and on NPC1 expression in patient cells, we
hypothesize that the activity of alexidine was unlikely specific to the stabilization of misfoldedmutant NPC1. EndoH studies support this hypothesis as both EndoH-sensitive and EndoHresistant pools of NPC1I1061T were increased in patient cells following alexidine treatment (Figure
5.3C and D). This is further supported by an earlier study demonstrating that ~50% of normal
NPC1 protein is degraded within the ER (46).
The utility of a compound like alexidine for inducing NPC1 expression and maturation has
been repeatedly explored using other approaches. HDACi have been shown to affect the proteostatic machinery in other lysosomal storage disease settings (141) and have demonstrated efficacy
in decreasing lysosomal cholesterol storage for multiple different NPC1 patient mutations (93).
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This supports the hypothesis that HDACi modulate ER-associated degradation factors to allow
more mutant NPC1 to reach the lysosome and improve cholesterol trafficking. Along similar lines
arimoclomol is thought to act as a co-inducer, along with cellular stress, to upregulate the
chaperone, HSP70 (57). Additional work by Ohgane et al. confirms the usefulness of a chaperonebased approach for improving the cholesterol storage defect of NPC patient cells (142). In this
case, oxysterol derivatives were capable of binding and stabilizing mutant NPC1, thereby
increasing expression and localization to the lysosome (142). Alternatively, the NPC1-binding
protein TMEM97 was shown to be a negative regulator of NPC1 expression, making inhibition of
TMEM97 an attractive, yet underexplored NPC therapeutic angle (143).
An alternate screening strategy, though technically challenging, might require assessment
of the ratio of glycosylated, mature NPC1 relative to total cellular NPC1. NPC1 expressioninducing compounds like alexidine should increase total NPC1 expression (Figure 5.3A) and
moderately increase glycosylated NPC1, but a true NPC1 chaperone would likely robustly increase
both, with the glycosylated fraction becoming the predominant species, as in control cells (Figure
5.3C and D). This outcome could be screened using NPC1 antibodies specific to immature and
mature NPC1. To our knowledge, such reagents are not currently available. Another possible
screening strategy raised by our findings is a transcription-based readout of endogenous NPC1.
Although this approach would not enrich for mutant NPC1 chaperones, transcriptional activators
for other protein misfolding diseases like Cystic Fibrosis have proved successful in preclinical
studies (144).
In summary, we developed a sensitive high-throughput phenotypic screening assay for
NPC patient fibroblasts sensitive to multiple genotypes and degrees of phenotypic severity. Based
on a dual readout of lysosomal cholesterol, we screened ~3500 com- pounds, including 2013 FDA92

approved drugs and an additional ~1500 bioactive compounds against NPC1I1061T patient cells. A
number of HDACi, a class of compounds identified previously as modulators of cholesterol levels
in NPC1 patient cells, were identified as hits. Of the non-HDACi hits, the strongest hit, alexidine,
was confirmed as an inducer of both total and mature NPC1 protein expression that also modulates
expression of genes critical for cholesterol flux, but is unlikely to act as a chaperone for misfolded
NPC1I1061T. Although unsuitable for systemic therapy, alexidine has utility as a tool compound for
further NPC studies and as a potent inducer of NPC1. Thus, our screen successfully identified
alexidine as a novel enhancer of lysosomal cholesterol release through upregulation of NPC1- and
NPC2-dependent and -independent pathways. These data demonstrate that this phenotypic assay
has the capability to identify hits representing diverse molecular mechanisms that modulate
cholesterol accumulation in NPC1-mutant cells, motivating extension to larger screens of more
diverse compound collections.

5.5 Materials and Methods
5.5.1 Cell culture
NPC patient fibroblasts were obtained from the Coriell Institute for Medical Research
(Camden, NJ) (Table 5.1). Control, normal human fibroblasts were obtained from Lonza
(Allendale, NJ). NPC1-null fibroblasts (NPC11628delC) (145) and NPC2-null fibro- blasts
(NPC2IVS2+5G à A, National Institutes of Health, 94.85) (146) were obtained from archives in the
Ory laboratory (Washington University, St. Louis, MO) (Table 5.1). Fibroblasts were cultured in
DMEM high glucose with 10% fetal bovine serum (Hyclone GE Life Sciences, SH30396, Logan,
UT), Penicillin-Streptomycin (Corning 30-002-CI, Manassas, VA), and 1x GlutaMAX (Gibco/
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Thermo Fisher, 35050-061, Waltham, MA). All experiments were performed on cells within five
passages.

5.5.2 Compounds
Panobinostat was purchased from LC Labs (P-3703, Woburn, MA), and alexidine
dihydrochloride from Cayman Chemical (13876, Ann Arbor, MI). The compound collections
screened include Sanford Burnham Prebys’ internal FDA-approved repurposing collection (La
Jolla, CA) which encompasses the Prestwick Chemical library (Prestwick Chemical, San Diego,
CA), the Library of Pharmacologically Active Compounds (LOPAC) collection (Sigma-Aldrich)
and 813 additional FDA-approved or ‘in clinical trial’ compounds assembled in-house. Additional
libraries screened include the EMD-Millipore kinase inhibitor library composed of InhibitorSelect
Libraries I, II, and III (San Diego, CA), an internally assembled epigenetic collection compiled
from multiple libraries (Enzo Life Sciences, SelleckChem, Sigma-Aldrich and Cayman Chemical),
a human metabolite library (133), metabolism collection (Focus Biomolecules, Plymouth Meeting,
PA) and custom-assembled chaperone library. A complete list of compounds screened is provided
in Supplementary Material, Table S1.

5.5.3 Filipin, LAMP1, Draq5 and lysotracker staining
Fibroblasts were plated (2500/well) for 72–96 h on a CellCarrier 384-well plate (Perkin
Elmer, 6007550, Waltham, MA). Fibroblasts were fixed in 4% formaldehyde for 15 minutes at
room temperature. Cells were then washed with PBS and permeabilized with 0.2% saponin in PBS
and incubated overnight at 4°C with 1:800 anti-LAMP1 (Abcam, 24170, San Francisco, CA)
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diluted in 5% normal donkey serum. Following PBS wash, cells were incubated with secondary
antibody and 50 µg/ml filipin (Sigma, F9765, St. Louis, MO) diluted in 5% normal donkey serum
for 1.5 h at room temperature. Fibroblasts were then washed with PBS and stained with 1:1000
Draq5 (Thermo Fisher, 62251, Waltham, MA).
Lysotracker (Life Technologies, L-7528, Carlsbad, CA) staining was performed on live
cells. Cells were incubated in 50 nM lysotracker in growth media for 30 minutes at 37°C and
washed and imaged in phenol red-free live-cell imaging media (Thermo Fisher, A14291DJ) with
2 µg/ml Hoechst (Thermo Fisher, H3570).

5.5.4 Image acquisition and analysis
Following filipin/LAMP1 staining, cells were immediately imaged with a Perkin-Elmer
Opera Phenix or QEHS (Waltham, MA) high-content automatic imaging system with a 20x air
objective in confocal mode. Due to field size differences, five fields per well were imaged for each
experiment analyzed with the QEHS and two fields per well were imaged for each experiment
analyzed on the Opera Phenix such that>200 cells were analyzed from each well. Images were
analyzed on a per cell basis and then values were averaged across all cells and all fields acquired
for each well. Images were analyzed and quantified using Perkin-Elmer HarmonyVR image
analysis software (Supplementary Material, Fig. S1). Using Perkin Elmer’s proprietary image
analysis tools, cells were segmented first by identifying nuclei (‘Find Nuclei’ building block)
(Supplementary Material, Fig. S1C), and then surrounding cytoplasmic area (‘Find Cytoplasm’
building block) (Supplementary Material, Fig. S1D). To determine cell health, cell number was
determined along with three nuclear parameters: nuclear round-ness, area, and staining intensity
(‘Calculate Morpholopgy Properties’) (Supplementary Material, Fig. S1E). Mean cytoplasmic
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LAMP1 and filipin intensities (‘Calculate Intensity Properties’ building block) were then measured
in the segmented cytoplasm (Supplementary Material, Fig. S1F and G) such that the intensity of
each was normalized to total cell area on a per cell basis. No background correction was performed,
however the cell segmentation algorithm was adjusted and validated for individual plates to
account for staining differences between experiments. Cell number was counted for each well and
compared with the average for control wells by Z-score to determine cytotoxicity.

5.5.5 Gene expression
Fibroblasts were plated on 60 mm dishes (250000 cells/dish) and treated with compounds
for 48 h. RNA was isolated from fibroblasts using the Qiagen RNeasy Kit (74104, Hilden,
Germany). A total 8.5 ng of RNA per target probe were added to the Taqman RNA to CT 1 step
kit (Applied Biosystems, 4392938, Foster City, CA) with the appropriate Taqman probe (Applied
Biosystems, 4331182) (GAPDH: _g1, NPC1: Hs00264835_m1, ABCA1: Hs01059137_m1,
LDLR: Hs01092524_m1, HMGCR: Hs00168352_m1). Gene expression analysis was performed
using a ViiATM 7 Real-Time PCR System (Thermo Fisher, Waltham, MA) using the 2-D(DCT)
method.

5.5.6 Western Blot
Fibroblasts (250000/plate) were plated and treated with com- pounds for 72 h. Cells were
lysed in 1x RIPA buffer (Cell Signaling Technologies, 9806S, Danvers, MA) with 1x protease
inhibitors (Roche, 11836170001, Basel, Switzerland) and protein was quantified using Bio-Rad
DC Protein Assay (5000112, Hercules, CA). A total of 20 µg of lysate were resolved on a 4–12%
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Bis/Tris NuPage protein gel (Thermo Fisher, NP0322PK2) and transferred to a nitrocellulose
membrane (Thermo Fisher, LC2006). Membranes were probed for b-Actin 1:10 000 (Sigma,
A5441), NPC1 1:1000 (in-house antibody, Ory Laboratory, St. Louis, MO) (99), and acetylated
Tubulin 1:5000 (Sigma, T7451) diluted in 5% non-fat milk.

5.5.7 Endo H assay
On day 0, NPC1I1061T/I1061T or normal human skin fibroblasts were plated in 2 ml culturing
media at 1 x 105 or 0.5 x 105 cells/ well in a 6-well dish, respectively. On day 1, 1 ml of media
was removed and replaced with 1 ml complete media containing Alexidine or DMSO vehicle. On
day 4, cells were harvested by adding 50 µl RIPA buffer to each well. After 30 min, cell lysate
was collected and centrifuged at 18,400g for 20 minutes at 4°C. The protein concentration of the
clarified lysate was determined by BCA assay. A total of 10–20 µg total protein/condition were
combined with 1x glycoprotein denaturing buffer (New England Biolabs) and 1x GlycoBuffer
(New England Biolabs) in water then incubated at 50°C for 30 min. To each tube, 10000 U/ml
Endo Hf (New England Biolabs) or an equal volume of water was added. Samples were incubated
overnight at 37°C. Proteins were separated on a 4–12% Bis/Tris gradient gel, transferred to
nitrocellulose, then probed for a-tubulin (Sigma, T6199) or NPC1 (40) diluted in 5% non-fat milk.

5.5.8 Esterification assay
I1061T/I1061T

On day 0, NPC1

fibroblasts were plated at 5.8 x 105 cells/10 cm dish. On day 1,

media was changed to lipoprotein-depleted media with 50 µg/ml LDL reconstituted with
deuterated-cholesteryl oleate (d7 CE 18: 1). On day 4, cells were replated at 1.2 x 105 cells/well
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in a 6-well dish in 2 ml complete media. Once adhered, 1 ml of media was removed and replaced
with 1 ml Alexidine treatment media spiked with 10 µL/mL deuterium-labeled oleate (d9 18: 1,
Avanti, 861809) complexed to BSA (prepared at 12% in 150 mM NaCl). After 24 h, cells were
washed, collected by scraping, pelleted and stored at –20°C. For analysis, cell pellets were needle
homogenized in PBS. Homogenate was combined with 2: 2: 1 chloroform/H2O/5M NaCl and 50
ng d7-cholesteryl linoleate as an internal standard. Samples were vortexed, then centrifuged 5
minutes 100g 4°C. The chloroform layer was collected, dried, then reconstituted in 9:1 methanol
chloroform. Ion transitions for d7-cholesteryl linoleate (666.619/369.400), d9-cholesteryl oleate
(677.619/369.400) and d16-cholesteryl oleate (684.619/369.400) were monitored in positive mode
by LC-MS/MS. Protein concentration was determined by BCA.

5.5.9 Data and statistical analysis
Data are presented as mean ± standard deviation (SD) unless otherwise stated. Data were
evaluated for statistical significance using methods described in figure legends.

5.5.10 Supplementary Material
Supplementary Material is available at HMG online.
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Chapter 6 – Monitoring the itinerary
of lysosomal cholesterol in NiemannPick Type C1-deficient cells after
cyclodextrin treatment
6.1 Preamble
This research was originally published in The Journal of Lipid Research. M Feltes, SE
Gale, S Moores, DS Ory, JE Schaffer. Monitoring the itinerary of lysosomal cholesterol in
Niemann-Pick Type C1-deficient cells after cyclodextrin treatment. J. Lipid Res. 2020. © the
Authors.
I played the leading role in experimental design, data collection, analysis, and manuscript
preparation for this work. SE Gale helped in preparing cell lines and data collection for Figure 4CD. S Moores collected data for Figure 4A-B. I performed all other data collection, all data analysis
and experimental design with mentorship by JE Schaffer and DS Ory. The original manuscript was
written by me and edited collaboratively with JE Schaffer and DS Ory with additional final editing
by the other authors.

6.2 Introduction
Cholesterol is an essential component of mammalian cell membranes that plays a major
role in tuning membrane fluidity, thickness, and permeability to regulate membrane function and
support the needs of specific organelles. Different cellular membranes vary widely in cholesterol
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content, ranging from the cholesterol-rich PM and endosomes to the cholesterol-poor ER and
mitochondria (3, 4, 70). Due to its hydrophobicity, cholesterol does not transit between membranes
through the aqueous phase. Rather, cholesterol transfer is facilitated by lipid-binding proteins or
through membrane fusion events (3). Although a number of proteins have been shown to function
in cholesterol movement, the precise time-resolved itinerary of cholesterol trafficking between
membranes and mechanisms of regulation of this trafficking remain to be determined. Moreover,
how cells maintain steep gradients of cholesterol concentration across different membranes in the
face of rapid and dynamic cholesterol trafficking is not well understood.
Mammalian cells acquire cholesterol through endogenous cholesterol synthesis at the ER
or through uptake of cholesterol and cholesteryl ester-laden lipoprotein particles into the
endosomal/lysosomal system. Receptor-mediated endocytosis of LDL by LDLR or acLDL by
SRA are responsible for cholesterol delivery into lysosomal compartment. Here, the concerted
actions of LAL, NPC1, and NPC2 are critical for the mobilization of LDL cargo. LAL cleaves
cholesteryl esters liberating free cholesterol, which is bound by NPC2, a soluble lysosomal protein.
NPC2 transfers cholesterol to NPC1, a transmembrane protein embedded in the limiting lysosomal
membrane (86). In the presence of functional LAL, NPC1, and NPC2, cholesterol is efficiently
trafficked to the PM and ER as well as other cellular membranes. At the PM, excess cholesterol is
effluxed through ABCA1, ABCG1, and SR-B1 to ApoA1/HDL particles (147). In the ER
membrane, cholesterol serves as a critical regulator of sterol homeostasis through the SREBP-2
transcription factor, and excess cholesterol is esterified by ER-resident protein ACAT for storage
in lipid droplets (12).
Interruption of the intra-lysosomal cholesterol trafficking network (NPC1, NPC2, or LAL)
results in abnormal cholesterol homeostasis and lysosomal dysfunction. Mutations in NPC1 or
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NPC2 cause NPC disease, a fatal neurodegenerative disorder. Both cholesterol trafficking and
homeostatic regulation are disrupted in NPC1-deficient cells, in which accumulation of free
cholesterol in the lysosome is accompanied by elevated expression of cholesterol uptake and
synthesis genes and decreased cholesterol esterification (65, 66). There is currently no FDAapproved therapy for NPC disease, but CD has shown great promise in animal models and in
human clinical trials (148). CD is a cyclic oligosaccharide frequently used as an excipient in drug
formulations because of its ability to solubilize hydrophobic molecules. At concentrations >1 mM,
CD can extract cholesterol from cultured cells (68). At lower concentrations, in the range of
effective doses in vivo, CD enhances cholesterol trafficking from lysosomes without changing total
cellular cholesterol, and neither increases in serum cholesterol nor cholesterol excretion are
observed (149). In fact, in cell and animal models, CD treatment reduces expression of SREBP-2
gene targets and stimulates cholesterol esterification, consistent with a model in which lysosomal
cholesterol is redistributed to the ER membranes (65, 66). While the mechanism of CD action
remains unknown, recent studies provide evidence that CD promotes lysosomal exocytosis (7072). However, if release from the cells of cholesterol-laden exosomes is responsible for the
beneficial effects of CD treatment, this would be predicted to lower cellular cholesterol, a change
inconsistent with the observed suppression of SREBP-2 gene targets or with enhanced reesterification by ACAT.
To address these disparate findings, we used stable isotope labeling to track the movement
of lipoprotein cholesterol cargo in response to CD in NPC1-deficient cells. Our data support a
model in which CD promotes redistribution of lysosomal cholesterol to the PM from where it is
exchanged with cholesterol carried by extracellular acceptors, and to the ER where it directs
cholesterol homeostatic responses.
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Figure 6.1: Tracing cholesterol cargo.
A: U2OS-SRA cells with shRNA knockdown for NPC1 (U2OS-SRAshNPC1) were incubated in medium containing
acLDL reconstituted with d7-cholesteryl oleate (d7-acLDL, red oval-chain) to load the lysosomal compartment (LYS).
Lalistat was included during loading to prevent cleavage of labeled esters by LAL and release from the lysosome. d9oleate (blue chain) was included during loading to provide cells with labeled oleate for detection of re-esterification
product. B: Following removal of acLDL and lalistat, cells were incubated with CD. Washout of lalistat enables
hydrolysis of cholesteryl esters at the lysosome. Upon arrival at the ER, d7-cholesterol was re-esterified with d9-oleate
to form d16-cholesteryl ester, which can be distinguished from loaded d7-cholesteryl ester. Arrival of cholesterol at
the PM was detected by sphingomyelinase and cholesterol oxidase treatment, which converts d7-cholesterol to d7cholestenone. Efflux of lysosomal cholesterol was monitored by appearance of d7-cholesterol in the media.

6.3 Results
6.3.1 Lysosomal cholesterol is differentially distributed to the media and the ER
after CD treatment
U2OS-SRA cells efficiently take up cholesteryl ester probe reconstituted in acLDL to
lysotracker positive compartments (76). In the presence of lalistat, which prevents LAL mediated
ester hydrolysis (92, 126), cargo is retained in the compartment; upon inhibitor washout, cargo is
released. We adapted this approach in order to specifically monitor the NPC1-independent
trafficking of lysosomal cholesterol after CD treatment. In NPC1-deficient mice, CD is rapidly
cleared from the plasma in 3 hours and from the whole body in 6 hours (149) and CD is estimated
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to reach concentrations of 0.1-1 mM in vivo (69, 122). Based on these studies we chose to analyze
the effects of CD after 6 hours of treatment with 0.5 mM CD. U2OS-SRA cells with shRNA
knockdown of NPC1 (U2OS-SRAshNPC1) were incubated with acLDL reconstituted with
deuterated cholesteryl oleate (d7-acLDL) in the presence of lalistat (Figure 6.1). After loading, d7acLDL and lalistat were removed and replaced with media containing CD. Trafficking of
deuterated cholesterol away from the lysosome or to the PM, ER, and culture media was monitored
using LC-MS/MS-based biochemical trafficking assays.
Although previous studies have used filipin staining to demonstrate that total lysosomal
cholesterol is decreased by CD treatment (65), these studies have not metabolically traced
lipoprotein-derived cholesterol. We used U2OS-SRAshNPC1 cells expressing TMEM192-RFP-HA,
a tagged lysosomal protein, to quantify changes in lysosomal cholesterol cargo derived from
endocytosed

lipoproteins.

Lysosomes from U2OS-SRAshNPC1-TMEM192-RFP-HA cells

contained LAMP1 and HEXA, membrane bound and soluble lysosomal proteins, respectively
(Figure 6.2A). The isolated lysosomal fraction was depleted of contaminating membranes from
the nucleus, and PM as indicated by histone H3 (HIS) and Na/K ATPase (NAK) markers
respectively. While substantially depleted, ER marker calreticulin (CAL), and mitochondria
marker, COXIV (COX) could still be detected in the isolated fractions. The lysosome-enriched
fraction isolated from cells treated with CD had less d7-cholesterol relative to vehicle treated
control (Figure 6.2B). D7-cholesteryl oleate associated with the enriched fraction did not differ
significantly between CD and vehicle treated cells (Figure 6.2C). Some LAMP1-containing
membranes were not immuno-isolated and were detected in the flow-through. These LAMP+
membranes could represent lysosome-related organelles that do not contain TMEM197 or HEXA
but may harbor cholesterol.
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Figure 6.2: Lysosomal cholesterol is differentially distributed to the media and the ER after CD treatment.
U2OS-SRAshNPC1 cells that express epitope-tagged lysosomal protein TMEM192 (A-C) or U2OS-SRAshNPC1 cells (DG) were incubated overnight with d7-acLDL in the presence of lalistat and then treated for 6 h in media with CD or
vehicle (V) before immunoisolation of intact lysosomes (A-C) or analysis of other compartments (D-G). A:
Immunoblots of post-nuclear supernatant (PNS), flow through (FT), and immunoisolated lysosomes (IP) for LAMP1
(LMP), hexaminidase (HEX), calreticulin (CAL), cytochrome c oxidase IV (COX), histone 3 (HIS), and NaK ATPase
(NAK). B, C: LC-MS/MS quantification of lysosomal d7-cholesterol (B) and d7-cholesteryl oleate (C), normalized
to lysosomal protein. D-G: d7-cholesterol species quantified by LC-MS/MS in treated cells that also received d9oleate. Remaining d7-cholesteryl ester cargo (D), PM d7-cholestenone (E), ER re-esterification product, d16cholesteryl oleate (F), and media-associated d7-cholesterol (G), each normalized to cellular protein. Means + SE for
n = 3-4. #, P < 0.05 by paired t-test (B and C); *, P < 0.05 by unpaired t-test (D-G); NS, not significant by paired and
unpaired t-test.

To trace the fate of lipoprotein cholesterol cargo to other cellular compartments, we
analyzed cholesterol movement in U2OS-SRAshNPC1 cells. Similar to our findings in the
lysosomes, total cellular d7-cholesteryl oleate was unchanged by CD treatment (Figure 6.2D),
suggesting LAL activity was not affected. To measure PM cholesterol, cells were fixed and treated
with cholesterol oxidase and sphingomyelinase to oxidize d7-cholesterol to d7-cholestenone.
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Under vehicle-treated conditions, d7-cholesterol trafficked to the PM (Figure 6.2E). There was a
trend for increased trafficking of lysosomal cholesterol to the PM following CD treatment, but this
did not reach significance. In order to assess re-esterification, d9-oleate was included during
loading to provide substrate for ACAT mediated re-esterification of d7-cholesterol to d16cholesteryl ester. CD administration resulted in a 2-fold increase in the formation of d16cholesteryl esters from cholesterol cargo originating in the lysosome (Figure 6.2F). We also
analyzed d7-cholesterol content of conditioned media to assess efflux. Most strikingly, compared
to vehicle treatment, CD treatment increased the efflux of d7-cholesterol to the culture medium
28-fold (Figure 6.2G). Overall, the magnitude of d7-cholesterol arriving at the ER was small when
compared with the d7-cholesterol arriving at the PM and into the media.

6.3.2 Released d7-cholesterol is not detected in isolated extracellular vesicles
(EVs)
To further characterize the mechanism of release of d7-cholesterol into the culture medium,
we performed a time course. D7-cholesterol was detectable in the culture medium as early as 3
hours after lalistat washout and CD treatment. Between 3 hours and 6 hours, d7-cholesterol in the
media increased ~5 fold (Figure 6.3A). Appearance of lysosomal cholesterol in the PM preceded
appearance in the media (Figure 6.3B). Similar levels of PM d7-cholesterol were measured after
ionomycin or DMSO vehicle treatment. In contrast to CD, ionomycin did not promote release of
the cholesterol into the media over 6 h. These data show that distribution of d7-cholesterol from
the lysosome to the PM is an order of magnitude greater and occurs more rapidly than distribution
into the media.
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Figure 6.3: Released cholesterol is not detected in isolated extracellular vesicles (EVs)
U2OS-SRAshNPC1 cells were loaded overnight with d7-acLDL in the presence of lalistat and then treated for 6 h in
media with 500µM CD, 5µM ionomycin or vehicle (H2O for CD, DMSO for ionomycin). A: LC-MS/MS
quantification of d7-cholesterol associated with the media over time, normalized to cellular protein. B: PM d7cholestenone over time, normalized to cellular protein. C-E: EVs were isolated from conditioned media at 6 h by
differential centrifugation. Immunoblot analysis of total cell lysate (cell), and EVs for exosomal marker CD63 and
nuclear marker lamin-B (LMB, C). Total d7-cholesterol in 27 ml conditioned media (input), 27 ml EV-depleted media,
and EVs (from 27 ml conditioned media) at 6 h (D). Total EV cholesterol, normalized to EV protein (E). Means + SE
for n = 3. *, P < 0.05 by unpaired t-test; NS, not significant by two-way ANOVA; ND, not detected.

A recent report that CD induces lysosomal exocytosis in HeLa cells (72) provides a
potential mechanism for the appearance of lysosomal cholesterol in the culture medium. To test
whether d7-cholesterol arriving in the media was contained within membrane-bound structures
released from the cells, we used differential centrifugation to isolate extracellular vesicles (EVs)
from conditioned media from U2OS-SRAshNPC1 cells loaded with deuterated cholesterol and then
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treated with CD. The EV fraction was positive for the exosome marker CD63 but negative for
nuclear marker lamin B (LMB) by western blot (Figure 6.3C, top). Similar results were seen with
EVs isolated from conditioned media from cells treated with ionomycin (Figure 6.3C, bottom).
While d7-cholesterol was readily detected in whole media and EV-depleted media from CDtreated cells, d7-cholesterol was not detected in EVs. Although EVs contained d0-cholesterol, the
amount did not differ significantly between EVs isolated from the media of vehicle- and CDtreated cells (Figure 6.3E). Together, these data indicate that EV release does not significantly
contribute to the d7-cholesterol pool detected in the culture media.

6.3.3 CD-induced accumulation of cholesterol in the media is largely
independent of canonical cell surface cholesterol transporters
We next considered alternate mechanisms for release of lysosomal cholesterol following
CD treatment. SR-B1, ABCA1, and ABCG1 are cell surface sterol transport proteins. In order to
test their contributions to CD-mediated accumulation of cholesterol in the media, we knocked
down these proteins by si or shRNA and quantified delivery of d7 lysosome-derived cholesterol
into the media. Two independent SR-B1 siRNAs (siSR-B1-1, siSR-B1-2) robustly suppressed SRB1 protein expression (>95%) as shown by western blot (Figure 6.4A). Despite this, CD-induced
cholesterol accumulation in the media was not significantly different between siSR-B1 and control
siRNA (siCON)-treated cells (Figure 6.4B). To test the effects of ABCA1 and ABCG1 protein
depletion, stable shRNA knockdown cells were generated using target-specific (shABCA1-1 or
shABCA1-2 and shABCG1-1 or shABCG1-2) or control (shCON) shRNAs. Using two different
shRNAs for ABCA1, we isolated cell populations with 31 and 53% knockdown (Figure 6.4C); for
shABCG1, cell populations with 33 and 39% knockdown were isolated (Figure 6.4D). Neither
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knockdown of ABCA1 nor knockdown of ABCG1 impaired d7-cholesterol accumulation in the
media (Figure 6.4E). Thus, CD-induced release of lysosomal cholesterol into the media is
independent of SR-B1 and occurs even with substantial ABCA1 or ABCG1 knockdown.

Figure 6.4: CD-induced accumulation of cholesterol in the media is largely independent of canonical cell surface
cholesterol transporters.
U2OS-SRAshNPC1 cells were treated with control (CON) or SR-B1-targeting siRNAs (A, B), or with CON or ABCA1or ABCG1-targeting shRNAs (C-E). Following loading with d7-acLDL in the presence of lalistat, cells were treated
for 6 h with CD or vehicle (V), and effluxed d7-cholesterol quantified by LC-MS/MS. A: Representative immunoblot
for SR-B1 with GAPDH loading control (above) and quantification for n = 3 (below). B: Moles released d7 cholesterol
relative to moles d7-cholesteryl ester loaded expressed as efflux (relative units, RU). C, D: Representative
immunoblots for ABCA1 (C) and ABCG1 (D) with GAPDH loading control (above) and quantification for n = 3
(below). E: Relative efflux. Means + SE for n = 3. *, P < 0.05 for siRNA or shRNA vs. CON by unpaired t-test. siRNA
or shRNA vs. CON by two-way ANOVA was not significant for V and CD conditions.
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6.3.4 CD-induced cholesterol accumulation in the media depends on serum
lipoproteins
The majority of cholesterol found in serum is associated with serum lipoproteins. In order
to test whether extracellular lipoproteins play a role in CD-induced release of lysosomal
cholesterol into the media, the lipoprotein fraction was isolated from conditioned medium after
CD treatment. LDL and HDL are the major lipoproteins present in FBS (150). In line with this,
lipoprotein fractions 1 and 2 from conditioned culture medium of cells treated with CD or V
contained two dominant species that co-migrated with either human LDL (Figure 6.5A, lanes 1-4,
upper band) or human HDL (Figure 6.5A, lanes 1-4, lower band) on a native PAGE gel. Following
CD treatment, the lipoprotein fractions contained >50% of the d7-cholesterol found in the medium
(Figure 6.5A, graph, right). When cells were treated with CD in lipoprotein-deficient medium
(LPDM), d7-cholesterol was no longer detected in the medium (Figure 6.5B). Supplementation of
LPDM with 25 µg/mL HDL or LDL restored d7-cholesterol release. Equivalent concentrations of
ApoA1 or BSA did not support cholesterol release, suggesting that CD-mediated accumulation in
the media requires lipidated lipoproteins. Although the proportion of lysosomal cholesterol in the
PM was not significantly different between vehicle and CD treated cells when delivered in medium
containing FBS (Figure 6.2E), lysosome-derived cholesterol accumulated in the PM when
lipoproteins were absent in the media (Figure 6.5C). Re-esterification of lysosome-derived
cholesterol, detected as d16-cholesteryl ester, was enhanced in the absence of lipoproteins (Figure
6.5D). This is likely due to increased delivery of d7-cholesterol to the ER for esterification, and
not due to increased overall esterification, as the d9-oleate pool (esterification product of nonlabeled cholesterol) was not-significantly different between FBS and LPDM conditions (Figure
6.5E). Together these findings support a model in which CD enhances the trafficking of lysosomal
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cholesterol to the PM where it is released into the media if lipoproteins are present, or further
trafficked to the ER where it is esterified.

Figure 6.5: CD-induced cholesterol accumulation in the media depends on serum lipoproteins.
U2OS-SRAshNPC1 cells were loaded overnight with d7-acLDL in the presence of lalistat and then treated with CD or
vehicle (V) for 6 h in media of differing composition. A: Following treatment in media containing FBS, lipoproteins
were isolated from conditioned media and assayed for d7-cholesterol content. Sypro Ruby stained native PAGE gel
analysis (left) and d7-cholesterol content (right) of conditioned media and its lipoprotein fractions (F1 and F2) and
remaining material (F3) after lipoprotein isolation. Pure human LDL (hLDL) and HDL (hHDL) shown as markers. B:
Media-associated d7-cholesterol quantified following 6 h treatment in FBS, lipoprotein-deficient media (LPDM), or
LPDM supplemented with 25µg/mL ApoA1, HDL, LDL, or BSA. Efflux reported relative to efflux with FBS. C:
PM-localized lysosomal cholesterol after 6 h CD treatment in FBS or LPDM reported as percent of total cholestenone
pool that was deuterated. D: Re-esterification of lysosomal cholesterol after 6 h CD treatment in FBS or LPDM. E:
esterification of non-deuterated cholesterol (d9 CE 18:1) after 6 h CD treatment in FBS or LPDM. Means + SE for n
= 3-5. *, P<0.05 by unpaired t-test or two-way ANOVA for comparisons indicated; NS, not significant.

6.3.5 Bi-directional cholesterol exchange occurs at the PM
Despite release of lysosomal cholesterol from the cell, CD treatment in complete media
did not alter total cellular cholesterol (Figure 6.6A). Thus, we incubated cells with diI-labeled
lipoproteins in order to test whether lysosome-derived cholesterol release was matched by re110

uptake of lipoprotein cholesterol from the media during CD treatment. Only 1% per mg protein of
the diI-LDL was taken up under both vehicle and CD conditions (Figure 6.6B). This was blunted
by the dynamin inhibitor, dynasore (DYN), consistent with a mechanism of receptor-mediated
endocytosis. Uptake of HDL was negligible. Based on these observations, we hypothesized that in
the presence of CD, release of cholesterol from the PM to lipoproteins in the media occurs as an
exchange with lipoprotein cholesterol. To test this, we treated cells with CD in media containing
lipoproteins carrying deuterated cholesterol. CD treatment increased cell-associated deuterated
cholesterol in the presence of LDL or HDL donors (Figure 6.6C, left). Suppression of cellular
uptake of lipoproteins with DYN did not inhibit CD-dependent transfer of LDL or HDL-derived
cholesterol (Figure 6.6C, left). CD increased transfer of cholesterol from LDL to cells 2.8-fold
more than vehicle (Figure 6.6C, right). Transfer of cholesterol from HDL to cells was less efficient.
Together, our data support a model in which CD facilitates exchange of lysosome-derived d7 with
lipoprotein acceptors in the media, with LDL providing the more efficient exchange.
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Figure 6.6: Bi-directional cholesterol exchange occurs at the PM.
A: Total cellular cholesterol in U2OS-SRAshNPC1 cells treated for 6 h with CD or vehicle (V) quantified by LC-MS/MS.
B: Cellular uptake of diI-labeled LDL or HDL after 6 h with CD or V and in the presence or absence of dynasore
(DYN) to inhibit dynamin activity. Data expressed by the ratio of cell associated fluorescence relative to fluorescence
in media at baseline per mg of total protein. C: Cells were incubated with d7-cholesterol loaded LDL or HDL for 6 h
in the presence or absence of CD and in the presence or absence of DYN. Graph on left reports ratio of cell-associated
d7-cholesterol relative to d7-cholesterol in media at baseline. Graph on right reports cell-associated cholesterol for
each lipoprotein incubation in the presence of CD relative to V (no DYN). Means + SE for n = 3-5. *, P < 0.05 by
unpaired t-test or two-way ANOVA for comparisons indicated; ns, not significant.
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Figure 6.7: Model for CD-mediated cholesterol trafficking.
CD promotes redistribution of the lysosomal cholesterol pool. A: In the presence of lipoproteins, lysosomal cholesterol
is trafficked to the PM where CD promotes exchange with serum lipoproteins (acceptors). Lysosomal cholesterol is
also trafficked to the ER, directly or indirectly by way of the PM, and is re-esterified. B: In the absence of suitable
acceptors in the media, lysosomal cholesterol is not effluxed, but rather accumulates in the PM. Arrival of the
cholesterol at the ER and re-esterification is enhanced under lipoprotein-deficient conditions.

6.4 Discussion
The mechanism by which CD redistributes cholesterol from the lysosomal compartment in
the setting of NPC1 deficiency is not well understood. In order to specifically investigate the
lysosomal cholesterol pool, we loaded lysosomes with isotopically labeled cholesteryl esters in
reconstituted lipoproteins prior to CD treatment and tracked the itinerary of the labeled cholesterol
pool. We observed increased esterification and release of lysosome-derived cholesterol into the
media. The cholesterol released into the media was largely associated with lipoprotein particles,
but release was independent of SR-B1 and did not decrease with ABCA1 and ABCG1 knockdown.
In the absence of lipidated lipoproteins, release did not occur, and lysosome-derived cholesterol
accumulated in the PM. In the presence of lipoproteins, total cellular cholesterol was maintained
through the bidirectional movement of cholesterol between lipoproteins and the cell surface.
Together these data support a model by which CD enhances trafficking of lysosomal cholesterol
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to the PM where it is available for exchange with extracellular lipoproteins or is routed internally
for esterification (Figure 6.7).
There is evidence that CD exerts its effects on cholesterol homeostasis through stimulation
of lysosomal exocytosis, a hypothesis supported by localization of lysosomal markers with the PM
and release of a lysosomal lipid, lysobisphosphatidic acid, into the media in NPC1-deficient cells
treated with CD (70-72). Furthermore, TRPML1, a lysosomal ion channel that has been implicated
in lysosomal exocytosis, autophagy, and vesicular trafficking (151-153), is required for CDmediated correction of lysosomal cholesterol accumulation in NPC1-deificent cells (72). Relocalization of lysosomes to the PM in a TPRML1-dependent matter could also provide a
mechanism by which CD increases trafficking of lysosomal cholesterol to the PM. However, these
studies did not directly quantify movement of bulk or lysosome-derived cholesterol out of the cells.
Our data do not support a model in which lysosomal cholesterol is directly released from
the cell in exosomes. Although exosomes are rich in total cholesterol, d7-cholesterol that
originated from the lysosome could not be detected in isolated EVs. It is possible that U2OSSRAshNPC1 cells do not secrete robust amounts of EVs relative to previously studied cell lines.
However, even pharmacologic stimulation of lysosomal exocytosis with ionomycin did not
increase release of lysosomal cholesterol into the media. On the other hand, in the presence of CD,
we observed d7-cholesterol movement from the PM to extracellular lipoproteins that was balanced
by delivery of lipoprotein cholesterol to the cells. These actions are consistent with a large body
of literature on the cholesterol solubilization properties of CD (154). While our tracing shows that
lysosomal cholesterol accumulates in the media following CD treatment, the mechanism is one of
exchange and not net efflux, and it is inconsequential with respect to overall cholesterol trafficking
to the ER. The exchange mechanism is consistent with observations, in vivo, that CD treatment
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does not decrease total cellular cholesterol or increase cellular cholesterol clearance (149). Taken
together, these data indicate that CD facilitates cholesterol exchange but does not support net efflux
to CD as a functional pathway.
Arrival and re-esterification of lysosomal cholesterol at the ER is the signature of CDmediated restoration of cholesterol homeostatic responses. It was recently reported that, in normal
cells, lysosomal cholesterol transits to the PM before trafficking to the ER (75). Our finding that
treatment with CD in LPDM, which lacks suitable extracellular cholesterol acceptors, leads to
significant PM accumulation of lysosomal d7-cholesterol supports a similar lysosome to PM
itinerary for movement of cholesterol in NPC1-deficient cells. Increase in CD-stimulated
esterification of d7-cholesterol in LPDM compared with full media likely reflects enrichment of
d7-cholesterol within the overall PM pool, providing more d7 substrate for esterification (d16cholesteryl esters), despite the absence of changes in overall esterification (d9-cholesteryl esters).
For this study, we directly monitored movement of lysosomal cholesterol cargo after CD
treatment. Prior studies have relied on filipin staining to quantify residual lysosomal cholesterol or
radiolabeled oleate to monitor total cholesterol esterification. The former is uninformative with
respect to the post-lysosomal trafficking of cholesterol, and the latter is indirect, since it quantifies
all cholesterol esterification, rather than esterification of molecules originating from the lysosome.
Moreover, these approaches are confounded by the asynchronous export of cholesterol from the
lysosome. By contrast, our stable isotopic approach allowed for specific loading of the lysosomal
compartment with labeled cargo and synchronous release of labeled cholesterol through the use of
a reversible LAL inhibitor. Using sensitive identification of deuterated products by mass
spectrometry and selective enzymatic modification approaches (e.g., treatment with cholesterol
oxidase), we followed the post-lysosomal trafficking of the pool of cholesterol that accumulates
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aberrantly in lysosomes in NPC1. These techniques provide powerful tools with which to more
precisely delineate the itinerary of cholesterol and to investigate mechanisms that underlie its postlysosomal trafficking.

6.5 Methods
6.5.1 Cells and media
U2OS-SRA and U2OS-SRAshNPC1 cells were a gift from the Maxfield Laboratory (93).
U2OS-SRAshNPC1 cells were transduced with a lentiviral vector for expression of TMEM192-HARFP as described (155). Cells were cultured in McCoy’s medium containing 10% FBS, 1.2 g/L
sodium bicarbonate, and 1 mg/mL G418. LPDM contained lipoprotein-depleted FBS instead of
regular serum. Media depleted of EVs was prepared as described (156). Unless otherwise
specified, experiments were performed using a standard protocol: On day 1, 2 x 105 cells were
plated in 6-well dishes and grown overnight. On day 2, growth media was replaced with medium
containing 10 µM lalistat-1, an inhibitor of LAL (Tocris Bioscience), with 25 µg/mL acLDL or
acLDL reconstituted with d7-cholesteryl ester (d7-acLDL), and cells were incubated for an
additional 18 h. For re-esterification experiments, 36 µg/mL d9-oleate complexed to BSA was
included during this period. On day 3, cells were washed twice with PBS and then incubated in
fresh growth media containing 500 µM CD (Janssen Pharmaceuticals) or vehicle (H2O) for 6 h.
Reconstituted acLDL was prepared as described (97). Lipoproteins were obtained from Alfa Aesar
or Kalen Biomedical. Human ApoA1 was obtained from Millipore Sigma.
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6.5.2 Lysosomal Isolation
U2OS-SRAshNPC1 cells expressing TMEM192-HA-RFP were plated at 12 x 105 in 10cm
dishes, loaded with d7-acLDL and treated with CD according to the standard protocol. Lysosomes
were isolated as described (155) using PierceTM Anti-HA Magnetic Beads (Thermo Fisher) and
were eluted from the beads with a 5-minute incubation in 50 mM NaOH. Eluate was neutralized
immediately with 100 mM Tris pH 6.8. Cholesterol and cholesteryl ester content was measured in
cell lysate, post-nuclear supernatant, or elution fractions by LC-MS/MS. For western blot analysis,
lysosomal protein was eluted from beads in RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS,
0.5% sodium deoxycholate, 1X Protease Complete [Roche]), separated on 4-12% Bis-Tris gels,
transferred to nitrocellulose membranes, and analyzed for protein markers of lysosomes (LAMP1,
HEXA), ER (calreticulin), PM (Na/K ATPase), mitochondria (COXIV), and nucleus (Histone H3).
See Supplemental Table S1 for antibody sources and dilutions.

6.5.3 Extraction of cholesterol and cholesteryl esters from isolated fractions, cell
homogenates, and media
To extract lipids, a portion of the fraction, cell homogenate, or media was added to a
1:1:1:0.5 mixture of chloroform:methanol:water:5M NaCl in glass tubes along with internal
standards for cholesterol and cholesteryl ester. Mixtures were vortexed, centrifuged at 1000 x g
for 5 minutes, and chloroform phase was transferred to a 1.2 mL glass tube, dried under N2, and
resuspended in 1:1 methanol:chloroform. 20% of this solution was transferred to a new tube for
derivatization of cholesterols with 0.05 M nicotinic acid, 0.05 M 4-(dimethylamino)pyridine, and
0.05 M 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide for 1 h at 55°C. Lipids were analyzed by
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LC-MS/MS. Another portion of the fraction or homogenate was used for determination of protein
concentration using bicinchoninic acid assay (BCA, Pierce). Conditioned media was collected and
centrifuged at 550 x g to remove debris, and frozen prior to extraction. Lysosomal fractions, EVs,
and lipoprotein fractions were thawed and then added directly to extraction mixture. Cells were
recovered in PBS by scraping, and centrifuged at 2500 x g for 10 minutes at 4°C, then frozen at 20°C. Pellets were thawed and homogenized with a 25-gauge needle in PBS before extraction.

6.5.4 PM cholesterol and cellular cholesteryl esters
To quantify PM cholesterol and cholesteryl ester, cells were washed 3 times with 1% BSA
in tris-buffered saline (140 mM NaCl, 3 mM KCl, 25 mM Tris Base, pH 7.4), washed twice with
PBS, then fixed for 10 minutes in 1% glutaraldehyde. Cells were washed twice more with PBS,
then incubated in McCoy’s medium containing 2 units/mL cholesterol oxidase and 0.1 units/mL
sphingomyelinase for 30 minutes at 37°C to convert PM cholesterol to cholestenone. Cells were
washed again, then incubated in 9:1 methanol:chloroform supplemented with internal standards
for cholestenone and cholesteryl ester for 30 minutes to extract cellular lipids. Lipid extract was
transferred to 1.2 mL glass tubes, dried under nitrogen, and resuspended in 1:1
methanol:chloroform. 20% of this solution was transferred to a new tube for derivatization of
cholestenones with 2:1 5 mg/mL O-benzylhydroxylamine hydrochloride: formic acid for 1 h at
55°C, followed by LC-MS/MS analyses. Protein concentration of cellular homogenate prepared in
parallel was determined using BCA assay. For lipoprotein-dependent efflux assays, U2OSSRAshNPC1 were treated in LPDM or LPDM supplemented 25 µg/mL LDL or 25 µg/mL HDL and
harvested as described above, except that cells were plated at 4 x 104 in 24-well dishes.
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6.5.5 Extracellular Vesicle (EV) isolations
For EV isolations, 12 x 105 cells were plated in each of 5 plates (10 cm) per condition,
loaded with 10 µg/mL d7-acLDL in the presence of 10 µM lalistat, and incubated overnight to
load the lysosomal compartment. Cells were washed twice with PBS, then incubated in fresh media
(depleted of EVs) with or without 500 µM CD for 6 h. EVs were isolated from conditioned media
by differential ultracentrifugation as described (156). Cholesterol content was quantified in media,
EVs, and media following depletion of EVs by LC-MS/MS. EV proteins were separated on 4-12%
Bis-Tris precast gels, transferred to PVDF membranes and probed for nuclear (Lamin B1) and EV
(CD63) markers.

6.5.6 SiRNA and shRNA Knockdowns
For transient knockdowns of SR-B1, U2OS-SRAshNPC1 cells were incubated with 25 µg/mL
d7-acLDL and 10 µM lalistat in 2.1 mL media that also contained 0.5 mL OptiMEM/RNAiMax/siRNA. A set of cells were harvested to evaluate protein knockdown by western
blot and baseline d7-cholesteryl oleate content by LC-MS/MS. Cells were then incubated in
complete media with or without 500 µM CD for 6 h, and media was collected for analysis of d7cholesterol content. For stable knockdown of ABCA1, or ABCG1, shRNA plasmids were obtained
from Origene and used to produce lentivirus in HEK 293T cells according to the TransIT®-Lenti
protocol using TransIT®-Lenti transfection reagent and Mission Lentiviral Packaging Mix.
U2OS-SRAshNPC1 cells were transduced with viral supernatants (obtained 48-72 h after
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transfection), expanded, and the top 10% GFP expressing cells were isolated by flow cytometry.
Protein knockdown was evaluated by western blot.

6.5.7 Lipoprotein Isolation
U2OS-SRAshNPC1 cells were plated and treated according to the standard protocol.
Conditioned media was removed from cells and spun at 550 x g to remove debris. Cleared media
was transferred to a 1.4 mL polycarbonate tube and the density was adjusted to 1.21 g/mL with
KBr. 150 µL of 0.9% NaCl was added to the top of the suspension. After centrifugation for 18 h
at 259,000 x g at 4°C, the top 200 µL were removed as fraction 1 (F1), the second 200 µL were
removed as fraction 2 (F2), and the remaining volume as fraction 3 (F3). Cholesterol content was
measured for whole media and fractionated media by LC-MS/MS. Proteins were analyzed on
NuPage 3-12% Bis/Tris gels using NativePage Running Buffer (100V x 30 minutes, 150V x 30
minutes, and 200V until the dye front reached the bottom). Gels were fixed and stained using
Sypro Ruby according to manufacturer’s protocol (Thermo Fisher).

6.5.8 Fluorescent Lipoprotein Uptake
U2OS-SRAshNPC1 cells were plated at 4 x 104 cells per well of 24 well dishes. After
overnight growth, cells were pre-incubated with 10 µM dynasore hydrate (DYN, Millipore Sigma)
or vehicle (DMSO) in complete media for 30 minutes. Media was then replaced with LPDM with
or without DYN, with or without 25 µg/mL dil-lipoprotein (dil-LDL or dil-HDL, Kalen
Biomedical), and with or without 500 µM CD. After 6 h, cells were washed then lysed in RIPA
buffer with protease complete for 30 minutes at 4°C. Lysate was spun at 16,000 x g for 10 minutes
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to remove debris. Lysate fluorescence was quantified using a TECAN scanner (ex/em: 550/580nm)
in a black flat bottom 96-well plate. Percent uptake was calculated as the ratio of cell associated
fluorescence relative to the fluorescence in the media at baseline.

6.5.9 Lipoprotein Cholesterol Exchange Assay
U2OS-SRAshNPC1 cells were plated and treated as for fluorescent lipoprotein uptake, except
that lipoproteins were labeled with d7-cholesterol instead of dil. After CD treatment, cellular
cholesterol was recovered as described above. Percent exchange was calculated as the ratio of cellassociated d7-cholesterol relative to the d7-cholesterol in the media at baseline. To prepare
lipoproteins with isotope-labeled cholesterol, d7-cholesterol was dried under nitrogen and then
incubated with LDL or HDL at a ratio of 15 µg d7-cholesterol to 100 µg protein at a final protein
concentration of 2 mg/mL. After overnight incubation at 4°C, lipoprotein mixtures were
centrifuged at 10,000 x g for 10 minutes at 4°C. 90% of the supernatant was recovered and diluted
to 25 µg/mL in LPDM for administration to cells.

6.5.10 Mass Spectrometry
LC-MS/MS analysis was conducted using a Shimadzu HPLC system coupled to a TSQ
Quantum Ultra Plus mass spectrometer (ThermoFisher Scientific) operating in positive mode and
using selected reaction monitoring. Chromatography for cholesterol and cholestenone was
performed on an Eclipse XDB-C18 column (3.0x100mm, Agilent) at 50°C with 1% formic acid
in isopropanol:methanol (1:1) as the mobile phase, a flow rate of 0.4mL/min, and a run time of 4.5
minutes. Chromatography for cholesteryl esters utilized a BetaSilTM C18 column (100x2.1mm,
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ThermoFisher Scientific) at 50°C, with 97% 10 mM ammonium acetate in isopropanol:methanol
(1:1) and 3% 10 mM ammonium acetate in acetonitrile:H2O (3:7) as the mobile phase, a flow rate
of 0.4 mL/min, and a run time of 11 minutes. Collision energies for cholesterol, cholestenone, and
cholesteryl ester were 22, 30, and 14 V respectively. Monitored transitions are reported in
Supplemental Table S2. Additional assay parameters are reported in Supplemental Table S3. Data
was analyzed using Xcalibur software. Calibration curves were constructed by plotting peak ratios
of standard/internal standard versus analyte concentration.

6.5.11 Supplemental Information
Supplementary material is available at JLR online.
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Chapter 7 – Conclusion
7.1 Main findings
Cholesterol is an essential mammalian lipid and cellular distribution of LDL-derived
cholesterol is required for normal cell function. However, existing approaches for the study of
post-lysosomal cholesterol trafficking are limited; the cholesterol-interacting proteins, itineraries,
and precise trafficking routes remain poorly characterized. The work presented here addresses this
constraint by developing novel cholesterol probes and strategies for specifically targeting the
lysosomal cholesterol pool. These strategies are applied to provide new mechanistic insight into
NPC therapeutics.
Prior to this work, trans-sterol was the only described diazirine alkyne cholesterol probe
in the literature. The ester linkage in the side chain and absence of established cholesterol binding
proteins NPC1 and NPC2 from the specifically labeled proteome raised concerns that trans-sterol
may be a poor cholesterol mimic. In Chapter 2, trans-sterol and a panel of novel diazirine alkyne
probes were evaluated for their ability to mimic cholesterol. Of these probes, only LKM38 was
able to sustain growth of auxotrophic cells, appropriately regulate SREBP-2-dependent gene
expression, and label NPC1 and NPC2. Further, LKM38 localizes to the lysosome when
introduced in ester form in lipoprotein particles. LKM38 traffics to the PM, with kinetics similar
to deuterated cholesterol, and to the ER, with greater efficiency than deuterated cholesterol.
LKM38 represents a major advance in diazirine alkyne cholesterol probes. Moreover, this work
outlines a battery of characterization assays that will be useful for evaluating cholesterol probes in
the future.
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The work in Chapter 2 is extended in Chapter 3 to identify MQ182 as a second, promising
diazirine alkyne cholesterol probe. While the diazirine of LKM38 positioned on the sterol ring
system, the diazirine of MQ182 is in the side chain. By using probes with crosslinking groups in
different positions, the labeled proteomes of MQ182 and LKM38 could potentially complement
each other enabling access to a wider cholesterol interactome. Additional diazirine alkyne probes,
particularly those with crosslinking functionality in the form of a TBD group (which crosslinks to
a wider range of amino acids) could further expand the accessible proteome. By evaluating
diazirine- and alkyne- only cholesterol derivatives, a structure-activity relationship has been
established to help guide the design of future probes.
Using the methods outlined by Hulce et al. (81), the diazirine alkyne probes characterized
in this thesis could be used to identify overlapping, and potentially more authentic, cholesterol
interactomes. These studies could uncover new cholesterol-binding candidate proteins, and
comparisons of the proteomes could help to develop interesting hypothesis about specific proteinsterol interactions. In an effort to address the current gap in knowledge surrounding post-lysosomal
cholesterol trafficking, we aimed to develop a strategy for the identification of the post-lysosomal
cholesterol trafficking proteome. In Chapter 4, I describe the optimization of a method for loading
cholesterol probe to the lysosome and monitoring egress out of the compartment by collecting
time-resolved interactomes and provide proof-of-concept data for the approach. This work lays the
foundation for future analysis of both normal and mutant cholesterol trafficking.
The limited tools available for the study of cholesterol trafficking have also hampered the
development of therapeutics for NPC disease, a condition of impaired post-lysosomal cholesterol
trafficking. NPC1-independent lysosomal cholesterol release has been observed (35, 157).
Activation of such pathways could serve as potential points for therapeutic intervention. Studies,
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such as those described in Chapter 4, could be powerful tools for the identification of NPC1independent routes.
Monitoring the re-distribution of lysosome-derived deuterated cholesterol using
biochemical trafficking assays serves as another approach for gaining insight into the mechanism
of post-lysosomal cholesterol trafficking. These methods were described and utilized in Chapters
2, 5, and 6. In Chapter 5, I used this approach to evaluate the effect of Alexidine, a novel
therapeutic identified by our collaborators, on the redistribution of lysosome-derived cholesterol.
I found that alexidine promotes esterification of the lysosomal cholesterol pool suggesting
alexidine increases lysosome-ER cholesterol transfer. This is potentially mediated by an increase
in lysosome-localized NPC1 as we also observe that alexidine increases expression of the mature,
glycosylated protein. Increasing the amount of mature NPC1 also underlies the mechanism of
HDAC inhibitors and arimoclomol, drugs that have shown promise in cell culture and the latter of
which is currently in clinical trials. While alexidine is unsuitable for human treatment, our
discoveries provide proof-of-concept for an innovative NPC drug-discovery screening platform
and uncover a new modulator of post-lysosomal cholesterol trafficking.
In Chapter 6, the isotopic cholesterol labeling strategy was further utilized to study CD, a
promising NPC therapeutic. This investigation helps to resolve seemingly contradictory reports
that CD induces exocytic release of lysosomal cholesterol while also increasing cholesterol
delivery to the ER, as indicated by increased esterification and normalization of SREBP-2-target
gene expression. By tracking the lysosomal cholesterol pool, we find that cholesterol does leave
the cell, but does so in exchange for lipoprotein-derived cholesterol at the PM, and that lysosomal
cholesterol cannot be found associated with EVs. Our data supports a mechanism by which CD
induces an intracellular redistribution of cholesterol to correct cholesterol homeostasis. These
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findings will help guide the continued investigation of the CD mechanism which could potentially
help guide the design of CD mimetics.

7.2 Future Directions
Diazirine alkyne probes are powerful tools and have been used for binding studies, to map
binding sites, to identify interactomes, and to determine subcellular distribution. The better the
tools we have, the better we will be able to study authentic cholesterol biology. LKM38 has been
extensively characterized and has been shown to be an authentic cholesterol mimic. MQ182 shows
great promise but will need to be evaluated for its ability to bind other classes of cholesterolbinding proteins (i.e., NPC2, Caveolin, CRAC/CARC proteins). Further, MQ238 performed well
in auxotrophy and gene expression assays but was not found to bind to NPC1. MQ238 should be
further investigated in regard to trafficking and binding to other cholesterol-interacting proteins as
well as to determine if this probe is viable. Future probe design should be guided by the findings
in Chapter 3.
Using the probes and the proteomic method described in Chapters 2-4, the post-lysosomal
cholesterol trafficking interactome can begin to be uncovered. This approach will be useful for the
study of normal, NPC1-independent, and drug-induced post-lysosomal cholesterol trafficking
pathways. Candidate proteins identified in these proteomic screens can be genetically deleted or
knocked down in order to isolate the candidate’s specific role in the trafficking pathway. By using
multiple probes, interactomes can be overlaid to generate a deeper picture of the protein network.
Following the lysosomal cholesterol pool using isotopic labeling approaches serves as a
useful technique for expanding our understanding of post-lysosomal cholesterol trafficking. The
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role of cholesterol trafficking proteins like the STARD and ORP family members in the
redistribution of lysosomal cholesterol trafficking could be clarified using this approach. This
technique will also serve as an important assay for evaluating emerging NPC therapeutics.
MCOLN1 is a gene that codes for the lysosomal ion channel TRPML1, a protein that has
been implicated in lysosomal exocytosis, vesicular trafficking, and autophagosome biogenesis
(151-153, 158). It was recently found to be required for CD-mediated cholesterol release in NPC1deficient cells (72). While our trafficking data suggests that the MCOLN1-depedence for CD
cholesterol clearance is not due to the lysosomal exocytosis function, potential vesicular trafficking
and autophagy functions warrant further investigation. Re-localization of LAMP1-positive
vesicles to the PM after CD treatment has been observed and could explain the increased lysosomePM trafficking we observed in our studies. The MCOLN1-dependency of this re-localization
should be investigated. In addition, pharmacological activation of autophagy through AMPK
inhibition has been shown to decrease lysosomal cholesterol storage in NPC1-deificent cells (69),
and several autophagy activators are already used to treat human disease (159). These pathways
serve as potential targets for the further development of NPC therapeutics.
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Appendix
Appendix A: Cellular component GO analysis
Terms associated with block/unique, block/enriched, shared, no-block/enriched, and noblock/unique are listed below. The number of proteins in the Homo sapiens reference set (REF)
and the input data set (#) are listed. P-value (P) and % of the input data set associated with the term
(%) are also calculated. Terms are sorted by P-value. Shaded terms were selected for Table 4.1.

Block/unique:
GO cellular component complete
extracellular organelle (GO:0043230)
extracellular vesicle (GO:1903561)
vesicle (GO:0031982)
extracellular exosome (GO:0070062)
membrane-bounded organelle (GO:0043227)
extracellular space (GO:0005615)
lysosome (GO:0005764)
organelle (GO:0043226)
lytic vacuole (GO:0000323)
vacuole (GO:0005773)
intracellular membrane-bounded organelle (GO:0043231)
lysosomal lumen (GO:0043202)
endomembrane system (GO:0012505)
extracellular region (GO:0005576)
intracellular organelle (GO:0043229)
cytoplasm (GO:0005737)
cytosolic ribosome (GO:0022626)
intracellular (GO:0005622)
ribonucleoprotein complex (GO:1990904)
intracellular vesicle (GO:0097708)
cytoplasmic vesicle (GO:0031410)
vacuolar lumen (GO:0005775)
lysosomal membrane (GO:0005765)
lytic vacuole membrane (GO:0098852)
membrane (GO:0016020)
organelle membrane (GO:0031090)
vacuolar membrane (GO:0005774)
ribosome (GO:0005840)
cytosolic large ribosomal subunit (GO:0022625)
bounding membrane of organelle (GO:0098588)
endoplasmic reticulum (GO:0005783)
ribosomal subunit (GO:0044391)
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REF
2124
2119
3889
2098
12661
3358
702
13794
702
805
10959
96
4585
4391
12761
11544
111
14571
710
2396
2393
172
372
372
9898
3576
430
245
61
2117
1447
195

#
34
34
44
33
67
36
18
68
18
18
60
8
38
37
64
61
8
67
14
25
25
8
10
10
53
29
10
8
5
21
17
7

P
1.82E-13
2.54E-13
3.99E-13
7.98E-13
4.17E-10
1.67E-09
2.77E-09
2.94E-09
3.17E-09
1.98E-08
2.61E-07
2.92E-07
3.17E-07
3.68E-07
3.69E-07
3.95E-07
6.05E-07
9.55E-07
7.26E-06
7.48E-06
7.69E-06
1.19E-05
3.75E-05
3.91E-05
5.53E-05
7.65E-05
1.20E-04
1.23E-04
1.72E-04
1.82E-04
2.26E-04
2.75E-04

%
49%
49%
64%
48%
97%
52%
26%
99%
26%
26%
87%
12%
55%
54%
93%
88%
12%
97%
20%
36%
36%
12%
14%
14%
77%
42%
14%
12%
7%
30%
25%
10%

membrane-enclosed lumen (GO:0031974)
intracellular organelle lumen (GO:0070013)
organelle lumen (GO:0043233)
cytosol (GO:0005829)
whole membrane (GO:0098805)
Golgi apparatus (GO:0005794)
endocytic vesicle lumen (GO:0071682)
large ribosomal subunit (GO:0015934)
blood microparticle (GO:0072562)
high-density lipoprotein particle (GO:0034364)
endosome (GO:0005768)
platelet alpha granule (GO:0031091)
plasma lipoprotein particle (GO:0034358)
lipoprotein particle (GO:1990777)
coated vesicle membrane (GO:0030662)
intermediate-density lipoprotein particle (GO:0034363)
protein-lipid complex (GO:0032994)
secretory granule (GO:0030141)
coated vesicle (GO:0030135)
endoplasmic reticulum lumen (GO:0005788)
clathrin-coated vesicle membrane (GO:0030665)
cellular anatomical entity (GO:0110165)
perinuclear region of cytoplasm (GO:0048471)
vesicle lumen (GO:0031983)
endosome membrane (GO:0010008)
chylomicron (GO:0042627)
late endosome membrane (GO:0031902)
low-density lipoprotein particle (GO:0034362)
platelet alpha granule lumen (GO:0031093)
cellular_component (GO:0005575)
secretory vesicle (GO:0099503)
organelle envelope (GO:0031967)
polysome (GO:0005844)
late endosome (GO:0005770)
envelope (GO:0031975)
clathrin-coated endocytic vesicle membrane (GO:0030669)
protein-containing complex (GO:0032991)
very-low-density lipoprotein particle (GO:0034361)
lipid droplet (GO:0005811)
triglyceride-rich plasma lipoprotein particle (GO:0034385)
nuclear membrane (GO:0031965)
Golgi membrane (GO:0000139)
clathrin-coated endocytic vesicle (GO:0045334)
endocytic vesicle membrane (GO:0030666)
clathrin-coated vesicle (GO:0030136)
spliceosomal complex (GO:0005681)
U2-type spliceosomal complex (GO:0005684)
secretory granule lumen (GO:0034774)
cytoplasmic vesicle membrane (GO:0030659)
cytoplasmic vesicle lumen (GO:0060205)
endocytic vesicle (GO:0030139)
membrane raft (GO:0045121)
membrane microdomain (GO:0098857)
nuclear envelope (GO:0005635)
vesicle membrane (GO:0012506)
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5887
5887
5887
5228
1715
1602
20
121
143
28
950
91
38
38
179
7
41
846
298
310
114
18739
735
326
493
14
138
15
67
18929
1016
1223
74
273
1223
76
5560
22
82
22
303
761
94
194
192
194
94
320
787
324
327
328
329
479
809

37
37
37
34
17
16
3
5
5
3
11
4
3
3
5
2
3
10
6
6
4
69
9
6
7
2
4
2
3
69
10
11
3
5
11
3
30
2
3
2
5
8
3
4
4
4
3
5
8
5
5
5
5
6
8

5.77E-04
5.94E-04
6.12E-04
9.23E-04
1.72E-03
2.77E-03
2.92E-03
2.93E-03
6.12E-03
6.75E-03
1.23E-02
1.25E-02
1.43E-02
1.46E-02
1.47E-02
1.57E-02
1.65E-02
1.81E-02
1.89E-02
2.27E-02
2.31E-02
2.44E-02
2.53E-02
2.73E-02
4.19E-02
4.26E-02
4.28E-02
4.65E-02
5.17E-02
5.27E-02
5.61E-02
6.34E-02
6.38E-02
6.42E-02
6.44E-02
6.47E-02
6.88E-02
7.65E-02
7.74E-02
7.75E-02
9.17E-02
9.52E-02
1.02E-01
1.02E-01
1.03E-01
1.03E-01
1.04E-01
1.05E-01
1.06E-01
1.08E-01
1.11E-01
1.11E-01
1.11E-01
1.17E-01
1.17E-01

54%
54%
54%
49%
25%
23%
4%
7%
7%
4%
16%
6%
4%
4%
7%
3%
4%
14%
9%
9%
6%
100%
13%
9%
10%
3%
6%
3%
4%
100%
14%
16%
4%
7%
16%
4%
43%
3%
4%
3%
7%
12%
4%
6%
6%
6%
4%
7%
12%
7%
7%
7%
7%
9%
12%

membrane region (GO:0098589)
perinuclear endoplasmic reticulum lumen (GO:0099020)
mature chylomicron (GO:0034359)
chylomicron remnant (GO:0034360)
Sec62/Sec63 complex (GO:0031207)
neuronal cell body (GO:0043025)
nucleus (GO:0005634)
NF-kappaB complex (GO:0071159)
endoplasmic reticulum Sec complex (GO:0031205)
nuclear periphery (GO:0034399)
cytosolic small ribosomal subunit (GO:0022627)
U2-type precatalytic spliceosome (GO:0071005)
discoidal high-density lipoprotein particle (GO:0034365)
myosin II filament (GO:0097513)
endoplasmic reticulum-endosome membrane contact site (GO:0140284)
precatalytic spliceosome (GO:0071011)
cell body (GO:0044297)
primary lysosome (GO:0005766)
azurophil granule (GO:0042582)
GAIT complex (GO:0097452)
phosphopyruvate hydratase complex (GO:0000015)
integral component of lysosomal membrane (GO:1905103)
neurofibrillary tangle (GO:0097418)
integral component of Golgi membrane (GO:0030173)
intrinsic component of vacuolar membrane (GO:0031310)
integral component of vacuolar membrane (GO:0031166)
somatodendritic compartment (GO:0036477)
intrinsic component of Golgi membrane (GO:0031228)
host cell (GO:0043657)
host cellular component (GO:0018995)
small ribosomal subunit (GO:0015935)
endoplasmic reticulum membrane (GO:0005789)
chromaffin granule (GO:0042583)
nuclear outer membrane-endoplasmic reticulum membrane network
(GO:0042175)
spherical high-density lipoprotein particle (GO:0034366)
extrinsic component of external side of plasma membrane (GO:0031232)
catalytic step 2 spliceosome (GO:0071013)
nuclear pore outer ring (GO:0031080)
haptoglobin-hemoglobin complex (GO:0031838)
azurophil granule lumen (GO:0035578)
nuclear pore (GO:0005643)
coated membrane (GO:0048475)
membrane coat (GO:0030117)
hemoglobin complex (GO:0005833)
mitochondrial proton-transporting ATP synthase complex, coupling factor
F(o) (GO:0000276)
myofibril (GO:0030016)
dendritic spine head (GO:0044327)
contractile fiber (GO:0043292)
proton-transporting ATP synthase complex, coupling factor F(o)
(GO:0045263)
COPI vesicle coat (GO:0030126)
focal adhesion (GO:0005925)
collagen-containing extracellular matrix (GO:0062023)
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342
1
1
1
1
523
7540
2
2
133
47
50
3
3
3
52
592
154
154
4
4
4
5
66
6
6
863
71
75
75
77
1097
8

5
1
1
1
1
6
36
1
1
3
2
2
1
1
1
2
6
3
3
1
1
1
1
2
1
1
7
2
2
2
2
8
1

1.26E-01
1.41E-01
1.42E-01
1.44E-01
1.46E-01
1.64E-01
1.65E-01
2.02E-01
2.04E-01
2.07E-01
2.28E-01
2.53E-01
2.54E-01
2.56E-01
2.59E-01
2.59E-01
2.60E-01
2.78E-01
2.81E-01
2.96E-01
2.99E-01
3.02E-01
3.52E-01
3.75E-01
3.99E-01
4.03E-01
4.09E-01
4.13E-01
4.49E-01
4.53E-01
4.63E-01
4.64E-01
4.82E-01

7%
1%
1%
1%
1%
9%
52%
1%
1%
4%
3%
3%
1%
1%
1%
3%
9%
4%
4%
1%
1%
1%
1%
3%
1%
1%
10%
3%
3%
3%
3%
12%
1%

1119
9
9
86
10
10
90
91
93
93
11

8
1
1
2
1
1
2
2
2
2
1

5.01E-01
5.22E-01
5.26E-01
5.42E-01
5.59E-01
5.64E-01
5.74E-01
5.80E-01
5.85E-01
5.90E-01
5.91E-01

12%
1%
1%
3%
1%
1%
3%
3%
3%
3%
1%

11
228
12
239

1
3
1
3

5.95E-01
6.01E-01
6.20E-01
6.55E-01

1%
4%
1%
4%

13
13
409
410

1
1
4
4

6.57E-01
6.62E-01
6.71E-01
6.71E-01

1%
1%
6%
6%

nuclear nucleosome (GO:0000788)
cell-substrate junction (GO:0030055)

14
416

1
4

6.83E-01
6.91E-01

1%
6%

REF
96
172
2124
2119
2098
702
702
805
3358
1016
3889
105
105
4391
846
410
154
154
538
4585
58

#
5
5
9
9
9
6
6
6
9
6
9
3
3
9
5
4
3
3
4
8
2

P
2.10E-06
1.78E-05
2.06E-05
2.52E-05
3.08E-05
1.64E-04
1.92E-04
3.19E-04
6.21E-04
9.80E-04
1.80E-03
3.26E-03
3.53E-03
4.00E-03
5.43E-03
5.51E-03
7.20E-03
7.62E-03
1.32E-02
4.29E-02
4.35E-02

%
45%
45%
82%
82%
82%
55%
55%
55%
82%
55%
82%
27%
27%
82%
45%
36%
27%
27%
36%
73%
18%

REF
5787
5940
3576
2117
809
4585
1602
9898
787
1715
133
303
2124
2098
2119
1447
2396
2393
430
18

#
25
25
21
15
9
19
11
26
8
11
4
5
11
11
11
9
11
11
5
2

P
3.24E-07
3.94E-07
4.38E-07
2.08E-05
4.47E-04
4.89E-04
2.09E-03
2.45E-03
2.51E-03
2.79E-03
7.55E-03
1.15E-02
1.35E-02
1.39E-02
1.41E-02
1.69E-02
3.29E-02
3.45E-02
3.63E-02
3.69E-02

%
83%
83%
70%
50%
30%
63%
37%
87%
27%
37%
13%
17%
37%
37%
37%
30%
37%
37%
17%
7%

Block/enriched
GO cellular component complete
lysosomal lumen (GO:0043202)
vacuolar lumen (GO:0005775)
extracellular organelle (GO:0043230)
extracellular vesicle (GO:1903561)
extracellular exosome (GO:0070062)
lysosome (GO:0005764)
lytic vacuole (GO:0000323)
vacuole (GO:0005773)
extracellular space (GO:0005615)
secretory vesicle (GO:0099503)
vesicle (GO:0031982)
pigment granule (GO:0048770)
melanosome (GO:0042470)
extracellular region (GO:0005576)
secretory granule (GO:0030141)
collagen-containing extracellular matrix (GO:0062023)
primary lysosome (GO:0005766)
azurophil granule (GO:0042582)
extracellular matrix (GO:0031012)
endomembrane system (GO:0012505)
azurophil granule membrane (GO:0035577)

Shared
GO cellular component complete
integral component of membrane (GO:0016021)
intrinsic component of membrane (GO:0031224)
organelle membrane (GO:0031090)
bounding membrane of organelle (GO:0098588)
vesicle membrane (GO:0012506)
endomembrane system (GO:0012505)
Golgi apparatus (GO:0005794)
membrane (GO:0016020)
cytoplasmic vesicle membrane (GO:0030659)
whole membrane (GO:0098805)
sarcolemma (GO:0042383)
secretory granule membrane (GO:0030667)
extracellular organelle (GO:0043230)
extracellular exosome (GO:0070062)
extracellular vesicle (GO:1903561)
endoplasmic reticulum (GO:0005783)
intracellular vesicle (GO:0097708)
cytoplasmic vesicle (GO:0031410)
vacuolar membrane (GO:0005774)
COPI-coated vesicle membrane (GO:0030663)
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lysosome (GO:0005764)
pigment granule (GO:0048770)
lytic vacuole (GO:0000323)
vesicle (GO:0031982)
melanosome (GO:0042470)
secretory vesicle (GO:0099503)
Golgi membrane (GO:0000139)

702
105
702
3889
105
1016
761

6
3
6
14
3
7
6

3.70E-02
3.73E-02
3.87E-02
3.87E-02
3.88E-02
4.01E-02
4.81E-02

20%
10%
20%
47%
10%
23%
20%

REF
5940
5787
3576
1097

#
41
40
33
20

P
3.45E-17
2.18E-16
1.01E-14
4.02E-12

%
95%
93%
77%
47%

1119
4585
9898
2117
1715
1447
410
171
163
1318
1602
5
6
379
12661
493

20
32
42
17
13
12
7
5
5
11
12
2
2
6
37
6

4.65E-12
1.08E-10
1.34E-10
9.53E-05
4.33E-03
4.39E-03
4.43E-03
4.44E-03
4.62E-03
7.72E-03
8.69E-03
1.07E-02
1.34E-02
1.38E-02
4.42E-02
4.77E-02

47%
74%
98%
40%
30%
28%
16%
12%
12%
26%
28%
5%
5%
14%
86%
14%

REF
3576
5940
5787

#
176
203
201

P
2.45E-78
4.11E-71
4.27E-71

%
74%
85%
84%

1119
1097
9898
4585
1447
410
2117
379
171
163
394

108
106
231
169
85
48
93
45
30
29
35

7.12E-67
1.57E-65
4.50E-62
1.82E-55
6.65E-35
2.97E-30
2.80E-29
1.57E-28
7.27E-23
3.04E-22
4.46E-18

45%
45%
97%
71%
36%
20%
39%
19%
13%
12%
15%

No-block, enriched
GO cellular component complete
intrinsic component of membrane (GO:0031224)
integral component of membrane (GO:0016021)
organelle membrane (GO:0031090)
endoplasmic reticulum membrane (GO:0005789)
nuclear outer membrane-endoplasmic reticulum membrane network
(GO:0042175)
endomembrane system (GO:0012505)
membrane (GO:0016020)
bounding membrane of organelle (GO:0098588)
whole membrane (GO:0098805)
endoplasmic reticulum (GO:0005783)
intrinsic component of organelle membrane (GO:0031300)
intrinsic component of endoplasmic reticulum membrane (GO:0031227)
integral component of endoplasmic reticulum membrane (GO:0030176)
membrane protein complex (GO:0098796)
Golgi apparatus (GO:0005794)
GPI-anchor transamidase complex (GO:0042765)
signal peptidase complex (GO:0005787)
integral component of organelle membrane (GO:0031301)
membrane-bounded organelle (GO:0043227)
endosome membrane (GO:0010008)

No-block/unique
GO cellular component complete
organelle membrane (GO:0031090)
intrinsic component of membrane (GO:0031224)
integral component of membrane (GO:0016021)
nuclear outer membrane-endoplasmic reticulum membrane network
(GO:0042175)
endoplasmic reticulum membrane (GO:0005789)
membrane (GO:0016020)
endomembrane system (GO:0012505)
endoplasmic reticulum (GO:0005783)
intrinsic component of organelle membrane (GO:0031300)
bounding membrane of organelle (GO:0098588)
integral component of organelle membrane (GO:0031301)
intrinsic component of endoplasmic reticulum membrane (GO:0031227)
integral component of endoplasmic reticulum membrane (GO:0030176)
organelle subcompartment (GO:0031984)
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membrane-bounded organelle (GO:0043227)
Golgi membrane (GO:0000139)
Golgi apparatus (GO:0005794)
Golgi subcompartment (GO:0098791)
whole membrane (GO:0098805)
organelle (GO:0043226)
organelle envelope (GO:0031967)
envelope (GO:0031975)
vesicle (GO:0031982)
membrane protein complex (GO:0098796)
intracellular membrane-bounded organelle (GO:0043231)
cytoplasmic vesicle (GO:0031410)
intracellular vesicle (GO:0097708)
Golgi cisterna (GO:0031985)
cytoplasm (GO:0005737)
Golgi stack (GO:0005795)
cellular anatomical entity (GO:0110165)
endoplasmic reticulum tubular network (GO:0071782)
nuclear envelope (GO:0005635)
coated vesicle (GO:0030135)
vesicle membrane (GO:0012506)
transport vesicle (GO:0030133)
endoplasmic reticulum subcompartment (GO:0098827)
nuclear inner membrane (GO:0005637)
trans-Golgi network (GO:0005802)
cytoplasmic vesicle membrane (GO:0030659)
cellular_component (GO:0005575)
endoplasmic reticulum-Golgi intermediate compartment membrane
(GO:0033116)
organelle inner membrane (GO:0019866)
COPII-coated ER to Golgi transport vesicle (GO:0030134)
vacuolar membrane (GO:0005774)
Golgi-associated vesicle (GO:0005798)
endoplasmic reticulum-Golgi intermediate compartment (GO:0005793)
endocytic vesicle (GO:0030139)
intracellular organelle (GO:0043229)
lysosomal membrane (GO:0005765)
lytic vacuole membrane (GO:0098852)
nuclear membrane (GO:0031965)
pigment granule (GO:0048770)
melanosome (GO:0042470)
rough endoplasmic reticulum (GO:0005791)
integral component of Golgi membrane (GO:0030173)
endoplasmic reticulum tubular network membrane (GO:0098826)
Golgi cisterna membrane (GO:0032580)
integral component of nuclear inner membrane (GO:0005639)
intrinsic component of Golgi membrane (GO:0031228)
intrinsic component of nuclear inner membrane (GO:0031229)
endocytic vesicle membrane (GO:0030666)
SNARE complex (GO:0031201)
mitochondrial membrane (GO:0031966)
phagocytic vesicle membrane (GO:0030670)
endosome (GO:0005768)
phagocytic vesicle (GO:0045335)
vacuole (GO:0005773)
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12661
761
1602
367
1715
13794
1223
1223
3889
1318
10959
2393
2396
116
11544
150
18739
25
479
298
809
419
29
62
246
787
18929

208
45
62
29
60
208
47
47
90
46
174
64
64
14
178
15
236
8
24
19
31
22
8
10
17
30
236

8.05E-18
3.75E-17
1.50E-15
1.30E-13
4.55E-13
5.46E-12
2.84E-11
2.98E-11
3.57E-10
1.21E-09
4.77E-09
4.78E-09
4.82E-09
1.67E-08
3.01E-08
3.89E-08
1.25E-07
1.51E-07
1.67E-07
2.05E-07
3.25E-07
3.34E-07
3.50E-07
3.99E-07
4.01E-07
5.90E-07
7.47E-07

87%
19%
26%
12%
25%
87%
20%
20%
38%
19%
73%
27%
27%
6%
75%
6%
99%
3%
10%
8%
13%
9%
3%
4%
7%
13%
99%

73
550
98
430
186
133
327
12761
372
372
303
105
105
86
66
5
93
16
71
16
194
52
726
76
950
134
805

10
24
11
21
14
12
17
182
18
18
16
10
10
9
8
4
9
5
8
5
12
7
24
8
28
10
25

1.44E-06
1.58E-06
1.81E-06
1.87E-06
2.63E-06
3.70E-06
1.53E-05
1.71E-05
1.77E-05
1.80E-05
2.49E-05
2.52E-05
2.56E-05
4.29E-05
6.00E-05
6.20E-05
7.31E-05
9.33E-05
9.41E-05
9.48E-05
1.19E-04
1.26E-04
1.27E-04
1.37E-04
1.54E-04
1.56E-04
2.12E-04

4%
10%
5%
9%
6%
5%
7%
76%
8%
8%
7%
4%
4%
4%
3%
2%
4%
2%
3%
2%
5%
3%
10%
3%
12%
4%
11%

mitochondrial envelope (GO:0005740)
coated vesicle membrane (GO:0030662)
endosome membrane (GO:0010008)
integral component of plasma membrane (GO:0005887)
extracellular exosome (GO:0070062)
outer membrane (GO:0019867)
extracellular vesicle (GO:1903561)
extracellular organelle (GO:0043230)
lysosome (GO:0005764)
lytic vacuole (GO:0000323)
intrinsic component of plasma membrane (GO:0031226)
azurophil granule membrane (GO:0035577)
ER to Golgi transport vesicle membrane (GO:0012507)
organelle outer membrane (GO:0031968)
cis-Golgi network (GO:0005801)
Derlin-1 retrotranslocation complex (GO:0036513)
synaptic vesicle (GO:0008021)
secretory granule membrane (GO:0030667)
cortical endoplasmic reticulum (GO:0032541)
Golgi trans cisterna (GO:0000138)
transport vesicle membrane (GO:0030658)
late endosome (GO:0005770)
exocytic vesicle (GO:0070382)
Golgi-associated vesicle membrane (GO:0030660)
COPI-coated vesicle (GO:0030137)
lipid droplet (GO:0005811)
rough endoplasmic reticulum membrane (GO:0030867)
primary lysosome (GO:0005766)
azurophil granule (GO:0042582)
recycling endosome membrane (GO:0055038)
mitochondrion (GO:0005739)
cell (GO:0005623)
secretory vesicle (GO:0099503)
trans-Golgi network membrane (GO:0032588)
focal adhesion (GO:0005925)
perinuclear region of cytoplasm (GO:0048471)
intracellular (GO:0005622)
cell-substrate junction (GO:0030055)
autophagosome membrane (GO:0000421)
recycling endosome (GO:0055037)
synapse (GO:0045202)
mitochondrial outer membrane (GO:0005741)
mitochondrial inner membrane (GO:0005743)
cation-transporting ATPase complex (GO:0090533)
clathrin-coated vesicle (GO:0030136)
intrinsic component of synaptic vesicle membrane (GO:0098563)
pore complex (GO:0046930)
endoplasmic reticulum quality control compartment (GO:0044322)
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768
179
493
1643
2098
211
2119
2124
702
702
1719
58
62
209
69
8
213
303
9
9
221
273
230
113
28
82
29
154
154
86
1641
1117
1016
95
409
735
14571
416
38
182
1379
185
488
19
192
49
23
23

24
11
18
38
45
11
45
45
21
21
38
6
6
10
6
3
10
12
3
3
10
11
10
7
4
6
4
8
8
6
34
26
24
6
13
19
188
13
4
8
29
8
14
3
8
4
3
3

2.87E-04
2.90E-04
5.29E-04
7.76E-04
8.07E-04
1.10E-03
1.27E-03
1.29E-03
1.65E-03
1.67E-03
1.82E-03
1.87E-03
2.60E-03
4.30E-03
4.38E-03
4.73E-03
4.81E-03
5.24E-03
5.93E-03
5.99E-03
6.05E-03
7.81E-03
8.03E-03
8.29E-03
8.58E-03
8.95E-03
9.22E-03
9.23E-03
9.32E-03
1.07E-02
1.16E-02
1.22E-02
1.32E-02
1.69E-02
1.74E-02
1.83E-02
1.87E-02
1.97E-02
2.06E-02
2.32E-02
2.40E-02
2.52E-02
2.70E-02
2.93E-02
3.08E-02
4.62E-02
4.64E-02
4.68E-02

10%
5%
8%
16%
19%
5%
19%
19%
9%
9%
16%
3%
3%
4%
3%
1%
4%
5%
1%
1%
4%
5%
4%
3%
2%
3%
2%
3%
3%
3%
14%
11%
10%
3%
5%
8%
79%
5%
2%
3%
12%
3%
6%
1%
3%
2%
1%
1%

Appendix B: A step-wise protocol for acLDL reconstitution
A protocol for the reconstitution of acLDL with the cholesteryl ester click probe (LKM38 oleate),
and for the quantification of LKM38 oleate recovered in acLDL particles by LC-MS/MS. LDL
can be substituted for acLDL, and alternative cholestryl oleates or linoleates can replace LKM38
oleate, depending on the application. If potato starch pellets are already prepared, acLDL
reconstitution and analysis requires 4 days. Reconstituted acLDL should be stored protected from
light at 4°C and should be used within 1 week of preparation. Reagents and materials required for
this protocol are listed in Table A.1 and Table A.2, respectively.
Adapted from: Krieger, M. 1986. Reconstitution of the hydrophobic core of low-density
lipoprotein. Methods Enzymol 128: 608-613.
Preparation of potato starch pellets (~ 1week)
1. Coat the inside of 15, 13x100 mm glass tubes with Sigma-cote. Drain excess. Let tubes dry
overnight, upside-down.1
2. Weigh out 400 mg potato starch in small glass beaker, add 1.6 mL water and stir bar. Stir
until homogenous
3. While stirring, transfer 100 µL slurry to each siliconized tube
4. Allow to dry for several days, as the pellet dries it will pull away from tube. Dry pellets
can be prepared and stored, covered at room temperature for months-years before use
Lipoprotein dialysis (day 1-2)
5. Prepare 8L of dialysis buffer (1 mM EDTA, 0.1 mM EGTA, pH to 7.0 with HCl)
Use 2 x 4 L plastic beakers. To reach pH 7, ~175 µL of 12 N HCl / 4 L is required
6. Float 2 empty Slide-A-Lyzer cassettes using buoys in prepared dialysis buffer ~ 30 sec to
hydrate.
7. Remove cassette from buffer. Without touching the dialysis membrane, use chemwhipe to
wick away excess buffer. Use 5 mL syringe with 16-gauge needle to collect 2.5 mL acLDL
(~3 mg). Slowly load acLDL to dialysis cassette, remove excess air, float in 1 L dialysis
buffer. Repeat with remaining acLDL and second dialysis cassette.
8. Incubate stirring at 4°C protected from light for 4 h
9. Discard buffer, replace with fresh 1 L/beaker buffer, continue stirring at 4°C, 4 h
10. Discard buffer, replace with fresh 1 L/beaker buffer, continue stirring at 4°C, O/N
11. Discard buffer, replace with fresh 1 L/beaker buffer, continue stirring at 4°C, 4 h
12. Using 5 mL syringe with 16-gauge needle, transfer dialyzed acLDL to a 15 mL conical,
pool acLDL from both cassettes. Proceed immediately with lyophilization.
1

5 tubes are required / batch of acLDL reconstituted with LKM38 oleate for proteomics

[157]

Liophilization2 (day 2-3)
13. Transfer dialyzed lipoprotein to siliconized glass tube with prepared potato starch pellet.
Divide ~5 mL of dialyzed lipoprotein amongst 5 tubes. Flick to mix.
14. Freeze the lipoprotein/potato starch mixture in thin layer on sides of tube: pour LN2 into
shallow tray/ice bucket. While rotating at ~45 degree angle, dip the tube in the LN2 for ~5
sec. Continue rotating. Dip again. Lipoprotein/potato starch will begin to freeze. Repeat
until all liquid has frozen
15. Cover tube with parafilm, immediately make a few pin holes in the parafilm
16. Store tube on dry ice until other 4 tubes have been prepared
17. Attach lid of vacuum flask to cooled/evacuated lyophilizer. Place 5 prepared tubes in
vacuum flask. Attach to lid. Open vacuum. Cover flask in foil. Allow to lyophilize
overnight3
Lipoprotein reconstitution (day 3-4)
18. Remove tubes containing lyophilized lipoprotein from lyophilizer
19. Wrap each tube in foil to protect from light
20. Add 4 mL heptane to each of the 5 tubes
21. Mix gently by vortex4
22. In a swinging bucket centrifuge, spin for 5 minutes at 500 g, 4°C
23. Carefully remove heptane with glass Pasteur pipette
24. Repeat steps 20-23 twice more. On last round, discarded heptane should be clear
25. Add 1.5 mg LKM38 oleate (200 µL of 1.5 mg/200 µL solution) to each tube
26. Cap tubes with parafilm. Incubate at -20°C for 1 h
27. Remove parafilm. Evaporate benzene under nitrogen dryer (~10 min)
28. Resuspend each pellet in 1 mL 10 mM sterile tricine pH 8.4. Cover with parafilm. Incubate
overnight at 4°C
Lipoprotein recovery (day 4)
29. Remove parafilm. In a swinging bucket centrifuge, spin for 10 minutes at 440 g, 4°C
30. Transfer supernatant to 2 mL Eppendorf tubes (split ~5 mL between 3 tubes, ~1.5 mL/tube)
31. Centrifuge 10,000 g 10 minutes at 4°C
32. Transfer supernatants to fresh tubes
33. Centrifuge 10,000 g 10 minutes at 4°C
34. Transfer supernatants to a single 5 mL Eppendorf tube or 15 mL conical. Gently pipette up
and down to mix

2

Turn on lyophilizer >1 h before use so that it has time to reach temperature and vacuum
Okay to lyophilize longer, over-weekend does not reduce yield
4
On Vortexgenie this is considered a “shake” and is setting 2/10
3
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35. Assay protein concentration by BCA.5
Quantification of LKM38 oleate by LC-MS/MS – Day 4
36. Prepare standard curve in 1.2 mL glass MS tubes:
a. Add 100 ng internal standard (IS) to 3 tubes
IS: d17-LKM38 oleate, prepare and store at 0.1 mg/mL in 9:1 methanol chloroform.
100 ng is 100 µL of a 100X dilution.
b. Add 100, 250, or 500 ng LKM38 oleate
LKM38 oleate: prepare and store at 1 ng/µL in 9:1 methanol chloroform
c. Set aside, protected from light, until step 38
37. Dilute 2 µL LKM38 oleate acLDL in 198 µL 9:1 methanol chloroform. Vortex vigorously
1 min. Prepare in triplicate
38. Transfer 25 µL of LKM38 oleate acLDL from each prepared dilution to a glass culture
tube containing 1:1 water chloroform (1 mL each). Add 100 ng IS to each tube. Cap. Vortex
vigorously 5 min
39. In swinging bucket centrifuge, spin for 5 min, 1000 g 4°C
40. Using a glass Pasteur pipette, transfer chloroform (lower layer) to 1.2 mL glass MS tube.6
41. Dry collected chloroform (and standard curve preparations) under N2 for 30 minutes or
until dry
42. Resuspend in 100 µL 9:1 methanol chloroform
43. Determine LKM38 oleate:IS ratio for each sample by LC-MS/MS
44. Plot “Ratio to IS” vs. “ng standard” and fit with linear regression. Use m (slope) and b (yintercept) values to determine mass of LKM38 oleate in reconstituted LDL
d. y = ratio to IS
e. x = ng LKM38 oleate
f. y = mx+b à (y-b)/m=x
45. Calculate yield: LKM38 oleate in (1.5 mg*5 = 7.5 mg) / LKM38-recovered7

5

Protein concentration should be 0.8-1.2 mg/mL, with a yield of 4-5 mg protein
To avoid collecting aqueous phase, blow out air through pastuer pipette while lowering the tip into the chloroform
layer. Collect as much of the chloroform layer as possible without collecting aqueous phase. Okay to leave some
chloroform behind.
7
LKM38 oleate recovery ranges from 50-80%
6
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Table A.1: reagents for acLDL reconstitution
Reagent
Sigmacote®
Starch from Potato
EDTA
EGTA
HCl
Human acLDL
Heptane
Benzene
LKM38 oleate

Vendor and product
number
Millipore Sigma, SL2
Millipore Sigma, S2004
American Bio,
AB00500
Millipore Sigma, E4378
Kalen Biomedical,
770201
Millipore Sigma, 34873
Millipore Sigma,
270709
Doug Covey Lab

Storage/shelf life

Notes

4°C
RT
RT

Save excess for reuse

RT
RT, corrosive
4°C, protected from
light, use within 3
months
RT, flammable
RT, flammable
-20°C, glass capped
tube, parafilmed,
protect from light

D17-LKM38 oleate
(Internal Standard)

Doug Covey Lab

Tricine

Millipore Sigma, T0377

-20°C, glass capped
tube, parafilmed,
protect from light
RT

Pierce BCA protein
assay kit
chloroform
methanol

ThermoFisher, 23225

RT
RT, flammable
RT, flammable
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Prepare at 0.5M in H2O
8 mL / 4 L buffer
Prepare at 0.5M in H2O
0.8 mL / 4 L buffer
5mg

Also known as LKM39
Prepare at 1.5 mg/200 µL benzene
for reconstitution
Prepare at 1 ng/µL in 9:1 methanol
chloroform for standard curve
prep
Prepare at 100 ng/µL in 9:1
methanol chloroform
Prepare at 10 mM in MQ H2O, pH
to 8.4. (for 50 mL use ~0.25 mL 1
N NaOH)
Sterile filter (Steriflip®, 0.22 µm
Millipore, SCGP00525)
Prepare BSA standards in 10 mM
sterile tricine

Table A.2: Materials and equipment for acLDL reconstitution
Description
13x100mm FisherBrandTM Borosilicate
Glass Tubes with Plain End
Small glass beaker
Stir plate
Stir bar
pH meter
Clean 4 L plastic beaker
Clean 1 L plastic beaker
Slide-A-LyzerTM Dialysis Cassettes, 10
MWCO
Slide-A-LyzerTM Bouys
5 mL syringe
16-guage needle
Shallow pan for LN2
LN2
Parafilm
Aluminum foil
Vacuum flask: 600 mL Fast-Freeze Flask
Bottom and Lid with elbow attachment
Lyophilizer
FisherBrandTM Disposable Borosilicate
Glass Pasteur Pipets
10x0.1 mL sterile glass serological
pipettes
Vortex
Cooled swinging bucket centrifuge
N2 dryer
Table-top centrifuge
Glass culture tube
1.2 mL glass MS tube with lids

Notes
FisherScientific 14-961-27
2-5 mL
For potato starch and dialysis buffer prep need at RT. For dialysis
need at 4°C
For potato starch, to fit in small glass beaker
For dialysis, ~2”x0.25”
For preparing dialysis buffer
For dialysis
ThermoFisher, 66380. 3mL is ideal for proteomics-sized experiments.
Other sizes are available.
ThermoFisher, 66430. Two needed per prep. Can be reused.
Need 2
Need 2

Labconco 7542800 & 7544400
FreeZone -105 C 4.5L Cascade Benchtop Freeze Dry System
Pulls vacuum to <0.1 mBar
Collector reaches -105°C
For Sigmacote and heptane handling FisherScientific 13-678-20B
For heptane handling
Milipore Sigma, CLS7077-10N
Vortexgenie
To spin glass tubes and culture tubes at 440 g, 500 g, and 1,000 g
15 mL conical compatible for preparing LDL
1.2 mL MS tube compatible for MS prep
To spin Eppendorf tubes at 10,000 g
Kimble, 45066A-16100
Wheaton 07-0000-1200
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Appendix C: A stepwise protocol for lysosome-targeted
probe-based proteomics
A protocol for in situ labeling of proteins with diazirine alkyne probe, LKM38 oleate, after
lysosomal loading, and for the isolation of labeled proteins for mass spectrometry-based
proteomics. Labeling requires 3 days. Protein isolation requires 1 day. Reagents and materials
required for this protocol are listed in Table A.4 and Table A.5, respectively.
Adapted from: Hulce, J. J., A. B. Cognetta, M. J. Niphakis, S. E. Tully, and B. F. Cravatt. 2013.
Proteome-wide mapping of cholesterol-interacting proteins in mammalian cells. Nat Methods 10:
259-264.
Labeling (3 days)
1. Plate U2OS-SRAshNPC1 cells 2E6 in NuncTM dishes in 10 mL/plate culture medium, 4
plates/condition, grow overnight in cell incubator
2. Treat cells
a. Prepare culture medium with 18 µg/mL LKM38 oleate reconstituted in acLDL +
10 µM lalistat
b. Wash cells 1X with PBS
c. Add 8 mL/plate of prepared media to cells, incubate 18 h in cell incubator
3. Washout
a. Wash cells 2X with PBS.
b. Add 8 mL/ plate culture medium +/- 500 µM CD (H2O as vehicle)
c. Incubate 1, 3, or 6 h in cell incubator
4. Crosslink8,9,10
a. Wash cells 2X with PBS, aspirate
b. Place 4 NuncTM dishes on foil-covered ice block, remove NuncTM dish lid
c. Place dishes on ice block within 3 cm of stratalinker bulbs (see Figure A.1)
d. Crosslink in Stratalinker for 5 min
e. Using residual PBS, scrape cells, transfer to 15 mL conical
f. Spin 2,500 g 4°C to pellet cells. Aspirate supernatant and freeze pellet at -20°C
8

Install bulbs and test UV output using UV meter for 3 minutes prior to use. Place meter at the base of the stratalinker
so that the sensor is in the middle of the chamber. By 3 minutes, UV output should reach 9-9.5 µW/cm2.
9
To ensure consistent crosslinking, bulbs need to be changed between consecutive exposures. Bulb sets and
arrangements are detailed in Table A.3 and Figure 4.4
10
4 plates can be exposed at a time. For 0 h timepoint, expose all 4 plates at once, use bulb set 1. For subsequent
timepoints, expose 2 plates/condition (ie: 2 CD treated and 2 vehicle treated) at once, use bulb set 2. Expose the
remaining 2 plates/condition in a second exposure using bulb set 3.
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Enrichment – 1 day
5. Thaw cell pellets on ice in 300 µL PBS
6. Lyse by sonication: 20 pulses (duty cycle: 40%, output control: 4), rest 10 sec on ice, repeat
3 times
7. Assay protein concentration by BCA11
8. Dilute each lysate to 4 mg/mL with PBS, transfer to 2 mL Eppendorf tube
9. Add CuSO4, TBTA, PC-Biotin-Azide, then TCEP sequentially to first tube, mixing
between additions. Repeat for remaining tubes (final concentrations are 1 mM, 100 µM,
500 µM, 1 mM respectively)
10. Shake 1,100 rpm on thermomixer for 30 minutes at 37°C protected from light
11. Add equal volume methanol and quarter volume chloroform to clicked lysate. Vortex 1
minutes on high12
12. Centrifuge 1,500 g, 20min, 4°C13
13. Aspirate upper aqueous layer, add 600 µL methanol, vortex to break up pellet, centrifuge
16000 g, 10 min, 4°C
14. Carefully aspirate supernatant
15. Repeat step 13 and 14 twice more
16. After final wash, allow pellet to air dry 5 minutes RT
17. Resuspend pellet in 1 mL 25 mM ammonium bicarbonate / 6 M urea, add 280 µL 10%
SDS, vortex to dissolve pellet14
18. Heat 65°C 10 min
19. Remove aliquot (10 µl) to assay protein concentration by BCA, perform BCA assay in
parallel to steps 20 and 2115
20. Add 10 µL 1 M DTT to each sample, heat at 65°C for 8 min16
21. Cool samples 1 minute on ice
22. Add 80 µL 0.5 M iodoacetamide, mix, incubate 30 minutes at room temperature protected
from light17
11

Use standards in PBS, for this volume, protein concentration is ~8mg/mL. To be within range of BCA standards,
dilute 5X. Set thermomixer to 37°C for step 10.
12
Volume is ~800 µL post-click… for 800 µL use 800 µL methanol and 200 µL chloroform
13
Set thermomixer to 37°C for steps 17 and 19, prepare 25 mM ammonium bicarbonate / 6 M urea for step 16, prepare
DTT for step 20, prepare Iodoacetamide for step 22
14
If pellet remains after SDS addition, use wetted 23 g needle to break it up. Total Volume = 1.280mL; 25mM
ammonium bicarbonate, 6 M urea, 2.2% SDS (ABUS). Prepare ABUS buffer in parallel to sample prep for volume
correction in step 24 (add DTT and iodoacetamide accordingly)
15
Use standards in ABUS. Protein concentration 1.5-2.5 mg/mL. Dilute 2X
16
Total Volume = 1.280 mL; 25 mM ammonium bicarbonate, 6 M urea, 2.2% SDS, 7.8 mM DTT
17
Total Volume = 1.360 mL; 23 mM ammonium bicarbonate, 6 M urea, 2.1% SDS, 7.3 mM DTT, 29.4 mM
iodoacetamide.Wash streptavidin beads 3x5minutes in 0.4% SDS in PBS. Spin at 2500 g to separate beads from
wash buffer. Do not allow beads to dry. After final spin, resuspend beads in 0.4% SDS to original volume to create
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23. Transfer 13.6 µL (1% of total) of mixture to Eppendorf tube as the “Input” sample. Flash
freeze and tore at -20°C.
24. Dilute remaining protein to 1.5 mg/mL with ABUS+DTT+Iodoacetamide buffer and
transfer to 15 mL conical
25. Add 4 volumes PBS to dilute lysate to 300 µg/mL protein, 0.4% SDS
26. Transfer 400 µL washed, 50% bead slurry to each tube
27. Incubate 4 h rotating end-over-end at room temperature protected from light18
28. Spin 2,500 g 1 minute 4°C to collect beads, aspirate supernatant leaving ~0.5 mL
29. Add 10 mL 1% SDS, rotate 5 minutes room temperature protected from light
30. Spin 2,500 g 1 minute 4°C to collect beads, aspirate supernatant leaving ~0.5 mL
31. Add 10 mL PBS, rotate 5 minutes room temperature protected from light
32. Spin 2,500 g 1 minute 4°C to collect beads, aspirate supernatant leaving ~0.5 mL
33. Repeat steps 31 and 32 twice
34. After last wash, transfer beads in remaining 0.5 mL PBS to a PeirceTM Spin Column in a
1.7 mL Eppendorf tube
35. Remove PBS from beads by microfuge-ing ~10 sec. Do not allow beads to dry. Discard
PBS
36. Plug spin column and add 100 µL 1% SDS in PBS
37. Irradiate 1 h room temperature shaking 1,100 rpm on thermomixer (see Figure A.2)
38. Irradiate 1 h 37°C shaking 1,100 rpm on thermomixer
39. Transfer spin column to clean Eppendorf to collect elution: remove plug, microfuge ~30
sec (or until beads are dry) to collect eluted protein19
40. Assay protein recovery by BCA20
41. Flash freeze elution fractions and store at -20°C
Ship overnight on dry ice

a 50% bead slurry (for 400 µL bead slurry at start, resuspend in 200 µL 0.4% SDS after final wash, total volume
will be 400 µL)
18
Set thermomixer to 25°C for step 37
19
Total Volume = variable, 0.12-0.16 mL; 1% SDS in PBS
20
Use 1% SDS in PBS BCA standards. To conserve sample, assay in singlet (1x10 µL)

[164]

Table A.3: UV output of individual bulbs used for crosslinking in stratalinker.
UV output was determined for one bulb at a time in the 1 position in UV stratalinker with UV meter on a 5 cm tip box
spacer. UV meter was placed against the back wall of the stratalinker directly under position 1. Bulb positions are
illustrated in Figure 4.4. Bulb set 1 is used for 0 h irradiation. Bulb set 2 is used for first exposure for 1, 3, and 6 h.
Bulb set 3 is used for second exposure for 1, 3, and 6 h.
Bulb Set
1
Position
1
2
3
4
5

Bulb ID
E6
D1
C2
C3
A1
Average
Total

2
µW/cm2
2.96
3.25
3.22
3.02
2.4
2.97
14.85

Bulb ID
E4
D3
E3
E2
A4
Average
Total

3
µW/cm2
2.97
3.25
3.2
3.02
2.4
2.97
14.84
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Bulb ID
C1
D2
E5
D4
B5
Average
Total

µW/cm2
3
3.14
3.1
3.08
2.56
2.98
14.88

Avg. 2 & 3
µW/cm2
2.99
3.20
3.15
3.05
2.48
Average
2.97
Total
14.86

Table A.4: Reagents for probe-based proteomics
Reagent

Vendor and product
number

Storage/shelf life

Notes

Culture medium

4°C

LKM38 oleate
reconstituted in acLDL
Lalistat

4°C, protect from light

10% FBS in McCoys medium
with G418 and sodium
bicarbonate
see “Culturing U2OS Cells”
protocol
See “LDL Reconstitution”
protocol
Prepare at 10 mM in DMSO,
aliquot and freeze
Aka Kleptose HPB parenteral
Prepare at 25 mM in H2O, sterile
filter (Steriflip®, 0.22 µm
Millipore, SCGP00525)
Prepare BSA standards in 10 mM
sterile tricine
Prepare fresh on enrichment day at
50 mM in H2O
Prepare fresh on enrichment day at
5 mM in DMSO
Prepare at 50 mM in DMSO,
dilute to 25 mM in H2O for click
reaction
Prepare fresh on enrichment day at
50 mM in H2O

Tocris Bioscience, 6098

-20°C in DMSO

CD
(Hydroxpropyl-Bcyclodextrin)

Janssen Pharmaceutical
E0165

4°C as solution in H2O

Pierce BCA protein
assay kit
CuSO4

ThermoFisher, 23225

RT

Millipore Sigma,
451657
Millipore Sigma,
678937
Click Chemistry Tools,
1119

RT, solid

Millipore Sigma,
C4706

4°C, solid

TBTA
PC-Biotin-Azide
TCEP
methanol
chloroform
Ammonium
Bicarbonate
Urea

Millipore Sigma,
A6141
GE Healthcare, 171319-01

-20°C, solid
-20°C in DMSO,
protect from light

RT, flammable
RT, flammable
RT, store 25mM
solution on bench
RT, solid

10% SDS

Millipore Sigma,
L3771

RT, solution

DTT

GOLDBIO, DTT10

-20°C, solid, desiccate

Iodoacetamide

Millipore Sigma,
A3221-10VL
ThermoFisher, 20361

4°C, solid

PierceTM high capacity
streptavidin beads

4°C

[166]

Prepare at 25mM in H2O
Prepare fresh on enrichment day at
6 M in 25 mM ammonium
bicarbonate
Lab stock is 20%
10% SDS: dilute 20% 2X in H2O
0.4% SDS: dilute 20% solution
50X in PBS
1% SDS: dilute 20% solution 20X
in PBS
Prepare fresh on enrichment day at
1 M in H2O
Prepare fresh on enrichment day at
0.5 M in H2O
Wash before use (step 22)

Table A.5: Materials and Equipment for probe-based proteomics
Description
Incubator
Cell Counter
NuncTM Rectangular Dishes
PBS
250 mL sterile container
Foil covered ice block
Stratalinker
Stratalinker bulb sets
UV meter
15mL Conicals
Sonicator
BCA standards
2 mL Eppendorf tubes
Thermomixer
Vortex
Cooled swinging bucket
centrifuge
Tabletop centrifuge for
Eppendorf tube
LN2
Rotators
Microfuge
PierceTM spin columns – screw
cap
Handheld UV

Notes
For cell culture, 37°C, 5% CO2
Invitrogen Countess, protocol 38A9 (see “Culturing U2OS Cells” protocol)
ThermoFisher 267060
Corning 430281
For preparation of treatment media
For keeping cells cold during crosslink
Large western container filled with ice, covered in foil
Stratagene, UV Stratalinker 1800
EIKO CE F8T5/BL TCLP compliant
Use specified bulb arrangement
Sper Scientific UVA/B Light Meter 850009
Falcon 352097
For collection of cells and affinity enrichment
Branson Sonifier 150 102C
In PBS – step 7
In ABUS – step 18
In 1% SDS, PBS – step 39
For protein precipitation
Eppendorf Thermomixer C with 1.5 mL rack for click (37°C), resolubilization
(65°C), and UV elution (25/37°C)
Vortexgenie
For spins at 2,500 g for cell pelleting and bead collection, 15mL tubes
To spin 2 mL epp tubes at 1,500 and 16,000 g
Small volume needed to flash freeze input and elution fractions
Must accommodate 15 mL conical tubes. Rotating samples must be protected
from light. Critical for bead enrichment and washing steps
Spectrafuge mini. Required for quick spins and handling of spin columns
ThermoFisher, 69705
BLAK-RAY LAMP Model UVL-21, UV-366 nm, 115 V, 60 hz, 0.1 amp
August 1995
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Figure A.1: UV crosslinking assembly for Stratalinker.
Arrange spacers to position top surface of ice block (where dishes will be) within 3 cm of the UV bulbs. To assemble
this arrangement, the ice block with dishes atop are placed in the stratalinker on top of the western spacer before
raising up the ice block with tip block spacers.

Figure A.2: UV elution assembly.
Thermomixer surface is covered with foil to protect material from UV exposure. Spin column in a 1.2 mL Eppendorf
tube is placed in mixer rack. Use tape to secure Eppendorf lid (or cut off). UV light is positioned above the tube on
the thermomixer using the box support. Distance between lamp and top of spin column is approximately 1.8 cm.
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